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ABSTRACT
Rheumatoid arthritis (RA) is a chronic inflammatory condition with poorly understood 
pathophysiology and increased cardiovascular risk. The mechanisms for increased 
cardiovascular risk are not fully known, however one novel mechanism explored in this thesis 
is autonomic nervous system (ANS) dysfunction. The thesis comprises of: a systematic 
literature review; two case-control studies (n=30 RA patients, n=34 controls; a longitudinal 
case-study (n=1 RA patient); a cohort study (n=112 RA patients); and a randomised placebo-
controlled crossover study (n=10 healthy controls). The work presented in this thesis 
demonstrates that ANS dysfunction is prevalent in ~60 % of RA patients and characterised by 
heightened sympathetic outflow to the peripheral vasculature (determined by muscle 
sympathetic nerve activity using microneurography), depressed baroreflex control of heart 
rate (determined using the modified Oxford technique), depressed heart rate variability and 
heightened vascular responses to stressors (cold pressor test and mental stress). Inflammation 
was associated with ANS dysfunction, and may well contribute to the increased 
cardiovascular risk seen in RA. Further studies are required to: confirm these findings;
determine whether therapeutic strategies to restore ANS function improve prognosis in RA;
and further explore the precise mechanisms by which inflammatory cytokines may influence 
ANS function in health and disease.
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1CHAPTER 1 Introduction and Purpose
2Rheumatoid arthritis (RA) is a chronic inflammatory condition predominantly 
affecting the synovial joints. Other body systems are also affected and it has been recognised 
that RA carries a significant cardiovascular mortality – estimated at around 50 %. Current 
understanding is that local inflammation within the synovial joints may lead to systemic 
inflammatory responses that may affect other body organs and contribute to morbidity and 
mortality risks. Disease modifying anti-rheumatoid drugs and biologic agents are effective in 
controlling inflammation in RA patients and there is evidence to suggest improved 
cardiovascular risk and mortality that parallels reductions in inflammation. Extensive work in 
RA has not yet been able to identify the underlying mechanisms linking inflammation with 
increased cardiovascular risk and novel mechanisms are being sought. One such novel 
mechanism that is explored in this thesis is the role of the autonomic nervous system (ANS). 
The ANS plays a key role in maintaining homeostasis and in particular blood pressure (BP) 
and heart rate (HR) regulation, through the parasympathetic and sympathetic nervous systems 
and a number of neural reflexes including the arterial baroreflex. There is a wealth of 
evidence to show that ANS dysfunction, in a pattern of increased sympathetic activity, 
reduced parasympathetic activity and reduced baroreflex sensitivity (BRS), is associated with 
cardiovascular diseases and predicts increased cardiovascular risk and mortality. Recent work 
from animal studies have demonstrated reciprocal links between inflammatory molecules and 
alterations in ANS function which raise the possibility that inflammation may play a role in 
promoting cardiovascular diseases and increasing mortality risk. Indeed there is evidence that 
cardiovascular disease such as hypertension, coronary artery disease and chronic heart failure 
are characterised by low-grade inflammation and that the degree of inflammation relates to 
cardiovascular and mortality risk. The precise mechanisms by which inflammation can lead to 
3ANS function are not known. It remains to be shown whether increased concentrations of 
circulating pro-inflammatory molecules lead to ANS dysfunction in humans.
The central hypothesis in this thesis is that elevated circulating pro-inflammatory 
cytokines are associated with ANS dysfunction (heightened sympathetic activity, reduced 
BRS, impaired cardiovascular reactivity) in RA patients. Thesis aims and hypotheses are 
summarised in Table 1.1.
Chapter 2 provides a literature review covering RA (pathophysiology, immunology, 
clinical features and management); the immune system; the normal function of the ANS 
including methods of assessment; autonomic dysfunction and immune interactions. Chapter 3
is a systematic literature review, which aims to (i) determine whether ANS dysfunction is 
present in RA,  (i) determine the pattern of ANS dysfunction, and (iii) determine whether any 
associations exist between inflammation and ANS dysfunction in RA patients. Chapter 4
outlines the methodology employed in the experimental chapters. There are five experimental 
chapters (Chapters 5-9) and a synthesis (Chapter 10).
Chapter 5 is a case control study assessing muscle sympathetic nerve activity (MSNA) 
and BRS in RA patients compared to age-, sex-and body mass index (BMI)-matched 
hypertensive and normotensive controls. This study is unique and novel as it is the first time 
MSNA has been recorded directly in RA patients, and the first time BRS has been assessed 
using the Modified Oxford Technique (MOT, sequential infusions of sodium nitroprusside
[SNP] and phenylephrine [PE] one minute apart) in RA patients.
Chapter 6 is a case control study assessing heart rate variability (HRV, marker of 
parasympathetic activity) and cardiovascular reactivity (responses to cold pressor test, CPT
4and paced auditory serial arithmetic task, PASAT mental stress test) in RA patients compared 
to age-, sex-and BMI-matched hypertensive and normotensive controls.
Chapter 7 is a case report of an RA patient who was assessed prior to, 2 weeks and 3 
weeks following anti-inflammatory therapy with tumour necrosis factor-alpha (TNF-α) 
inhibitor. ANS assessment included MSNA, BRS, HRV and cardiovascular reactivity 
(responses to mental stress). The hypothesis was that inhibition of the pro-inflammatory 
cytokine TNF-α would reduce inflammation and restore ANS function (i.e. reduce MSNA, 
increase HRV and BRS, and normalise cardiovascular reactivity).
Chapter 8 is a cohort study of RA patients assessing for associations between 
inflammatory cytokines (pro- and anti-inflammatory) and the corrected QT interval (QTc, a 
proxy marker of ANS function and strong predictor of cardiovascular risk and mortality).
Chapter 9 is a randomised placebo-controlled single-blinded cross-over study 
assessing the acute effects of intravenous hydrocortisone (HCN, pharmacological preparation 
of cortisol) on BRS, HRV and cardiovascular reactivity in healthy humans. The study 
explores important mechanistic links between the hypothalamic-pituitary-adrenal (HPA) axis 
and the ANS, which are co-activated in acute stress. The study aims to provide insights into 
autonomic changes during acute stress, which is associated with increased cardiovascular risk 
and mortality. 
The final chapter involve a synthesis and discussion (Chapter 10) summarising the 
conclusions that can be drawn from the experimental chapters, including limitations and 
future directions to further advance knowledge and understanding in the field.
1Table 1.1 Summary of the aims and hypotheses of the thesis
Chapter Hypotheses Aims
3 In patients with RA, elevated concentrations of circulating 
inflammatory cytokines are associated with autonomic 
dysregulation (heightened sympathetic activity, reduced 
parasympathetic activity, reduced BRS and impaired 
cardiovascular responses to stressors).
A systematic literature review on ANS function in RA was 
performed to: 
 investigate whether there is sufficient evidence to 
determine if patients with RA have altered ANS function; 
 determine the prevalence and nature of any autonomic 
dysregulation in patients with RA; 
 elucidate whether there is a causal relationship between 
systemic inflammation and ANS dysfunction in RA.
5 Central sympathetic outflow (MSNA) is elevated in RA 
compared to normotensive controls.
Cardiovagal and sympathetic BRS is reduced in RA compared 
to normotensive controls.
An observational, case-control study in RA patients (with and 
without hypertension) and controls (with and without 
hypertension) was undertaken to measure baseline serum 
inflammatory cytokine concentrations, MSNA and BRS.
2Elevated circulating concentrations of inflammatory cytokines 
are associated with increased MSNA and reduced BRS.
6 Reduced HRV is associated with increased inflammatory 
cytokine concentration.
Cardiovascular reactivity to CPT and mental stress are 
impaired in RA compared to controls, with greater 
impairments seen in hypertensive RA patients.
Cardiovascular responses to CPT and mental stress are 
associated with serum inflammatory cytokine concentrations.
An observational, case-control study in patients with RA (with 
and without hypertension) and controls (with and without 
hypertension) was undertaken to measure baseline serum 
inflammatory cytokine concentrations, HRV and 
cardiovascular responses to CPT and PASAT mental stress.
7 In RA, TNF-α inhibition:
 reduces sympathetic outflow (MSNA);
 increases sensitivity of the baroreflex control of the heart;
 increases HRV;
 normalises cardiovascular responses to mental stress.
A longitudinal, case study in RA patients was undertaken to 
measure baseline serum inflammatory cytokine 
concentrations, MSNA, BRS, HRV and cardiovascular 
responses to mental stress before and after TNF-α inhibition.
38 In patients with RA, elevated concentrations of circulating 
inflammatory cytokines are associated with increased QTc 
interval.
Associations between cytokines and QTc interval are affected 
by the QT correction method used.
An observational cohort study was undertaken to measure 
baseline serum inflammatory cytokine concentrations, QT 
interval and relevant clinical parameters.
9 During acute stress, surges in serum cortisol elicit deleterious 
changes in ANS function that may predispose an individual to 
adverse cardiac events. 
HCN:
 Reduces cBRS;
 Reduces HRV;
 Increases BP variability; and 
 Exaggerates cardiovascular responses to the CPT and 
PASAT mental stress test.
A randomized placebo-controlled single-blinded cross over 
study was performed in healthy male volunteers assessing 
cBRS, HRV, BP variability and cardiovascular reactivity to a 
CPT and PASAT mental stress test 3 hours after bolus 
infusion of HCN or placebo.
1CHAPTER 2 Background literature review
22.1 Rheumatoid arthritis (RA)
Rheumatoid (adjective, Greek “rheuma” meaning “that which flows” and “-oid” 
meaning “to see”) arthritis (noun, Greek meaning “inflammation of a joint”) is a chronic 
inflammatory condition characterised by synovial destruction resulting in joint pain, stiffness 
and swelling. Its name, first proposed by the English Physician A.B Garrod (1819-1907) may 
reflect the flow of fluid into the inflamed joint or indeed the relapsing/remitting nature of the 
condition. RA affects patients in a heterogeneous fashion ranging from mild disease to severe 
advanced disease with marked joint deformity and disability (Figure 2.1). At a given moment 
a typical RA patient may be in a state ranging from low or high disease activity (remission 
and flare, respectively).
Figure 2.1 Image demonstrating severe joint deformity in a patient with RA.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M., Inc.; ©2005. Rheumatoid arthritis; 
[updated 22 January 2014; cited September 15 2015]. Available from: 
http://www.nlm.nih.gov/medlineplus/ency/article/000431.htm
32.1.1 Epidemiology
RA affects approximately 0.8 % of the United Kingdom adult population (1), 0.1-0.5 
% of the European population (2, 3) and 0.24 % worldwide (4). RA predominantly affects 
women (2:1 preponderance) (2, 4) with a higher prevalence in women over 60 years (1).
2.1.2 Pathophysiology
Although the precise pathophysiology remains poorly understood, RA is considered 
an autoimmune condition thought to be triggered by environmental and lifestyle factors in 
individuals with a genetic predisposition (5, 6). Hormonal factors, infectious agents and 
smoking have all been implicated in the development of RA. Autoantibodies bind to and 
destroy synovial cells within the affected joint leading to activation of the immune system 
resulting in localised and systemic inflammation. The immune basis of RA is discussed in 
more detail in section 2.2.3.
2.1.3 Clinical features and diagnosis
RA predominantly affects the small joints of the hands and wrist although other joints 
may also be affected including the elbows, shoulders, knees, ankles and spine. Symptoms 
include joint pain, stiffness and swelling which can limit mobility and cause mild to severe 
disability (4). Clinical examination may reveal tender, swollen joints with reduced range of 
movement as well as associated muscle wasting and signs of deformity (e.g. ulnar deviation, 
swan-neck deformity of the fingers, Figure 2.1). In some patients other organs aside from the 
joints may also be affected giving rise to extra-articular manifestations and their associated 
signs and symptoms (7) (Table 2.1).
4Table 2.1 Extra-articular manifestations of RA (7)
Manifestation Clinical features
Cardiovascular
Pericarditis, pericardial effusion, myocarditis, endocarditis, congestive cardiac 
failure, myocardial infarction, hypertension, arterial stiffness
Chest pain, breathlessness, leg swelling
Pulmonary
Pulmonary fibrosis, bronchiolitis obliterans, pleural effusions, pulmonary nodules
Breathlessness, haemoptysis, cough
Skin
Rheumatoid nodules, skin rash, pyoderma gangrenosa, vasculitis
Pain, lumps, rash
Ocular
Keratoconjunctivitis sicca, scleritis, episcleritis, xerostomia, retinal vasculitis
Visual disturbance, eye redness, soreness, discharge, 
dry eyes
Oral
Sjogren’s syndrome
Dry mouth
5Gastrointestinal
Mesenteric vasculitis, drug induced gastritis/gastric ulcer
Abdominal pain, intestinal bleeding, perforation, 
haematemesis
Renal
Glomerulonephritis, vasculitis, amyloidosis
Anuria, oliguria, polyuria, haematuria, breathlessness, 
swelling
Neurological
Neuropathy, carpal tunnel syndrome, cervical myelopathy
Limb weakness, pain, limited mobility/function
Haematological
Anaemia (drug induced, chronic disease, nutritional, gastrointestinal bleeding, 
bone marrow suppression, ineffective erythropoeisis, Felty’s syndrome*), 
neutropenia, thrombocytopenia, thrombocytosis, lymphadenopathy, splenomegaly, 
hepatomegaly, haematological malignancy
Breathlessness, chest pain, fatigue, bleeding, 
thrombosis, susceptibility to infections
* Felty’s syndrome is a combination of RA, splenomegaly and neutropenia.
6The diagnosis of RA is based upon a combination of clinical (history, examination), 
laboratory and radiographic features (5). The diagnosis of RA can often be difficult to 
establish as there is no specific test to diagnose RA and often there is an overlap of features 
with other rheumatological conditions. The American College of Rheumatology (ACR) 
provide guidelines to help with the classification and diagnosis of RA (8) (Table 2.2). For the 
classification of RA a patient needs to satisfy at least 4 of the 7 criteria, while criteria 1 to 4 
must have been present for at least 6 weeks. Using the ACR 1987 criteria allows distinction of 
RA from other conditions with a sensitivity and specificity of 94 % and 89 %, respectively
(8).
Laboratory investigations are important for the diagnosis of RA, as well as monitoring 
disease activity and response to treatment (5). Autoantibodies including serum rheumatoid 
factor (RF, antibodies directed against the Fc portion of immunoglobulin G) and anti-cyclic 
citrullinated peptide (anti-CCP) may be present in 60-80 % and 65 % of RA patients, 
respectively (9). The presence of RF and anti-CCP autoantibodies aids in the diagnosis of RA, 
while providing prognostic information indicating more severe disease (9, 10). Laboratory 
markers of inflammation include high sensitivity C-reactive protein (hs-CRP, a non specific 
inflammatory marker) and erythrocyte sedimentation rate (ESR). While plain radiographs of 
the joints have been traditionally used to diagnose RA, newer modalities have emerged 
including ultrasound, computed tomography and magnetic resonance imaging which can help 
with the diagnosis (5).
7Table 2.2 The ACR 1987 revised criteria for the classification of RA (8)
Criterion Definition
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement
2. Arthritis of 3 or more 
joint areas
At least 3 joint areas* simultaneously have had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. 
3. Arthritis of hand joints At least 1 area* swollen in a wrist, MCP, or PIP joint
4. Symmetric arthritis Simultaneous involvement of the same joint areas* on both sides 
of the body† 
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions observed by a physician
6. Serum rheumatoid 
factor
Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the results has been positive in <5 % of 
normal control subjects
7. Radiographic changes Radiographic changes typical of RA on postero-anterior hand and 
wrist radiographs, which must include erosions or unequivocal 
bony decalcification localized in or most marked adjacent to the 
involved joints (osteoarthritis changes alone do not qualify)
* The 14 possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints. † Bilateral 
involvement of PIPs, MCPs, or MTPs is acceptable without absolute symmetry. MCP = metacarpal joint, MTP = 
metatarsal joint, PIP = proximal interphalangeal joint
82.1.4 Management and prognosis
The management of RA requires a holistic multidisciplinary approach (e.g. doctors, 
nurses, physiotherapists, occupational therapists, and psychologists) and may involve 
pharmacological agents (e.g. analgesia, disease modifying drugs and biological agents, Table 
2.3), non-pharmacological interventions (e.g. aids to improve mobility and disability, lifestyle 
changes), regular assessment of disease activity and invasive interventions (e.g. orthopaedic 
surgery, spinal cord nerve stimulator implant). In the United Kingdom (UK) guidelines exist 
to help aid clinicians in the management of patient with RA (Table 2.4) (11-13).
Assessment of disease activity is crucial in the management of RA, in order to help 
guide choice of treatment and monitor response to treatment (5). Traditionally, a count of the 
number of swollen or tender joints on clinical examination was used to assess disease 
severity. One of the earliest scores used was the Ritchie articular index. Developed in the 
1960s, the Ritchie articular index is a composite score based on the number of swollen joints 
(out of 52 joints) and degree of tenderness (14). The Thompson index, developed in the 
1980s, is also based on number of swollen and tender joints (of 38 joints) but weighted 
according to the surface area of the particular joint (15). The disease activity score 28 
(DAS28) is now the most widely accepted measure of disease activity and is a based on a 
composite of the number of tender or swollen joints (of 28 joints based on clinical 
examination), the serum ESR (DAS28-ESR) or CRP concentration (DAS28-CRP), and a 
visual analogue scale (VAS) (16, 17). For the VAS, the patient is asked to make a “global 
assessment of health” by marking how they feel their disease has been affecting them (usually 
over the prior week) on a simple scale ranging from 0 (bad) to 10 (good) (16). The composite 
score provides an assessment of disease activity including disease remission (<2.6), low (2.6-
3.2), moderate (3.2-5.1) and high (>5.1) disease activity. In addition, there are a number of 
9useful questionnaires including the Health Assessment Questionnaire (HAQ) also known as 
the Stanford HAQ, which provides an assessment of a patient’s functional status/disability 
(i.e. the impact of RA on the patient’s ability to carry out normal daily activities) (18). The 
ACR improvement criteria have been developed for use in clinical trials to help standardise 
outcome measures with various treatments (5) but are also useful for clinicians as a measure 
of response to treatment. Falls in number of affected joints, global health assessments, and 
laboratory markers of inflammation are included as a composite score e.g. ACR 20, ACR 50, 
ACR 70 indicate 20, 50 and 70 % improvements, respectively.
Patients with RA have a considerably worse prognosis compared to the general 
population. They have an approximately doubled risk of mortality and 10-year shortening of 
life span (19). Cardiovascular disease accounts for up to 50 % of the mortality in RA, with a 
doubled risk of myocardial infarction (MI) and sudden cardiac death (20-23). While 
traditional cardiovascular risk factors are present in RA (21, 24-33), they do not wholly 
account for the substantially increased risk seen and hence novel mechanisms are being 
sought (34-38). One potential mechanism to be explored is ANS dysfunction and its 
interaction with the immune system.
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Table 2.3 Pharmacological agents used in the treatment of RA
Agent Structure/mechanisms
Analgesics
Paracetamol COX inhibitor
Weak opioids Mu-opioid (e.g. codeine), mu-opioid and monoaminergic 
(e.g. tramadol)
Strong opioids Mu-opioid (e.g. morphine, fentanyl)
Antidepressants Tricyclic antidepressant (e.g. amitriptyline), selective 
serotonin re-uptake inhibitors (e.g. fluoxetine), serotonin-
epinephrine reuptake inhibitors (e.g. venlafaxine)
Anticonvulsants GABA structural analogue (e.g. gabapentin), 
iminodibenzyl derivative (e.g. carbamazepine)
Anti-inflammatory
Non-steroidal anti-inflammatory 
drugs
Non-selective COX inhibitor (e.g. ibuprofen), selective 
COX-2 inhibitor (e.g. celecoxib), salicylate (e.g. aspirin)
Steroids Oral glucocorticoid (e.g. prednisolone), intra-muscular 
glucocorticoids (e.g. methylprednisolone)
Disease modifying anti-rheumatic drugs
Methotrexate Inhibits dihydrofolate reductase (enzyme required for 
DNA, RNA and protein synthesis)
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Hydroxychloroquine Anti-malarial
Sulphasalazine Mechanism not fully understood but thought to have anti-
inflammatory effects due to its metabolites (5-
aminosalicylic acid and sulfapyridine)
Leflunomide Inhibits pyrimidine synthesis (required for DNA and 
RNA synthesis)
Azathioprine Inhibits purine synthesis (required for DNA and RNA 
synthesis)
Cyclosporin Inhibits calcineurin reducing activity of T-lymphocytes
Mycophenolate Inhibits B- and T-lymphocyte proliferation
Penicillamine Inhibits T-lymphocyte, macrophage function
Gold Unknown mechanism
Biologic agents
TNF-α inhibitors
Adalimumab Human monoclonal antibody
Certolizumab pegol Pegylated humanised Fab’ fragment of an anti-TNF-α 
monoclonal antibody
Etanercept TNF-α receptor-Fc fusion
Golimumab Human monoclonal antibody
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Infliximab Chimeric monoclonal antibody
Interleukin-6 inhibitor
Toclizumab Humanised monoclonal antibody
Interleukin-1 inhibitor
Anakinra Interleukin-1 receptor antagonist
CD20 inhibitor cell depleting agent
Rituximab Chimeric monoclonal antibody
CD80 and CD86 inhibitor
Abatacept CTLA4-Ig fusion protein
COX = cyclo-oxygenase, CTLA4-Ig = Cytotoxic T-lymphocyte-associated antigen 4 and the Fc fragment of 
Immunoglobulin subclass G1, DNA = de-oxyribonucleic acid, GABA = gamma-aminobutyric acid, RNA = 
ribonucleic acid, TNF = tumour necrosis factor.
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Table 2.4 Summary of NICE recommendations for management of symptoms in RA (adapted
from (12))
General recommendations
Step 1 Offer oral analgesics if pain control is inadequate
Step 2 Offer an oral NSAID or COX-2 inhibitor at the lowest effective dose for the shortest 
time with a proton pump inhibitor
Step 3 If NSAIDs or COX-2 inhibitors are not providing adequate control of symptoms then 
consider disease modifying or biological drugs
For patients with newly diagnosed active disease 
Offer combination therapy with disease modifying drugs as first line treatment ideally within 
3 months of onset of persistent symptoms (Methotrexate and at least one other, plus short 
course of glucocorticoids)
If combination therapy not possible then use monotherapy and escalate dose to achieve 
effective response
Offer short-term oral, intramuscular or intra-articular glucocorticoids to rapidly improve 
symptoms
For patients with recent onset disease (within last 2 years)
If sustained and satisfactory disease control achieved then attempt to cautiously reduce dose
For patients with established disease (more than 2 years)
If the disease is stable cautiously reduce dose of disease modifying or biological drugs but 
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return promptly to disease controlling dose at the first sign of a flare
When introducing new drugs to improve disease control consider decreasing or stopping pre-
existing drugs once the disease is controlled
If doses of disease modifying or biological drugs are being decreased then arrange a prompt
review
Glucocorticoids
Offer short-term glucocorticoid treatment to control flare-ups
Continue long term treatment with glucocorticoids only after discussing with the patient the 
long term complications and after offering all other treatment options (including biological 
drugs)
COX = cyclo-oxygenase, NICE = national institute for health and clinical excellence, NSAID = non steroidal 
anti-inflammatory drug, 
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2.2 Immune system 
2.2.1 Basic overview
The immune system is an important system involved in protection against pathogens 
(noun, Greek “pathos” meaning “suffering, disease”). The first line of defence against 
pathogens involves barriers such as the skin and surface mucus; the innate (adjective, Latin 
“innatus” meaning “inborn”) and the adaptive (also called the acquired) immune system form 
the next lines of defence (39). Immune cells of the innate system may recognise molecules 
within the pathogen resulting in activation. Phagocytes (noun, Greek “phago” meaning “to eat 
or devour” and Greek “kytos” meaning “hollow receptacle” used in biology to describe a 
“cell”) such as neutrophils, monocytes and macrophages devour pathogens (Figure 2.2), 
natural killer cells destroy damaged host cells, while basophils, mast cells and eosinophils 
release inflammatory mediators. Inflammatory mediators include cytokines (noun, Greek 
“kinesis” meaning “movement”), acute phase proteins and complement that act to promote 
migration of inflammatory and immune cells, fluid and blood to the site of the pathogen. The 
inflammatory response results in the clinical features known in Latin as dolor (“pain”), calor 
(“heat”), rubor (“redness”), tumor (“swelling”) and functio laesa (“loss of function”).
The adaptive immune response can be activated directly by the innate response, but 
also when antigen-presenting cells recognise pathogens or antigens (noun, Green “anti” 
meaning “against, opposite” and “gen” meaning “thing that produces” commonly known in 
biology as a “substance that produces an antibody”) within the pathogen. Consequently, 
antigen-specific B-lymphocytes are stimulated to produce antibodies that act to destroy 
pathogens, as well as activating macrophages to destroy infected host cells. Additionally, 
antigen-specific T-lymphocytes are stimulated to produce T-killer cells that destroy infected 
host cells and T-helper cells which help mediate innate and adaptive immune responses.
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Figure 2.2 Neutrophil engulfing anthrax bacteria, taken with a Leo 1550 scanning electron
microscope. Scale bar is 5 micrometers. "Neutrophil with anthrax copy" by Volker 
Brinkmann - (November 2005).
"Neutrophil engulfing Bacillus anthracis". PLoS Pathogens 1 (3): Cover page. DOI:10.1371. Retrieved on 2009-
01-04. Licensed under CC BY 2.5 via Wikimedia Commons -
https://commons.wikimedia.org/wiki/File:Neutrophil_with_anthrax_copy.jpg#/media/File:Neutrophil_with_anth
rax_copy.jpg
2.2.2 Cytokines
Cytokines are peptides that are released by immune cells to help with modulation of 
the immune response (39, 40). Cytokines can have pro- or anti-inflammatory properties or 
both; endothelial functions; or platelet actions. Examples of cytokines include interleukins 
(IL), TNF, interferon (IFN), cell adhesion molecules and fibrinogen. While cytokines have an 
essential role in modulation of the immune response during acute inflammation, dysregulation 
can have deleterious consequences such as in sepsis and chronic inflammatory conditions 
including RA.
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2.2.3 Immunological basis of RA
RA is considered an auto-immune condition (6). Autoantibodies attach to synovial 
cells within synovial joints causing destruction and activation of the immune system. 
Localised inflammation ensues which may lead to systemic inflammatory responses. While 
acute inflammatory responses are protective, chronic inflammation leads to deleterious 
consequences (41). 
The adaptive immune system is thought to play an important role in the early 
pathogenesis of RA, however both adaptive and innate immune systems are co-activated 
resulting in a milieu of inflammatory molecules within the synovial joint (6, 42-44). The 
inflammatory process is regulated by a host of feedback mechanisms and a complex 
interaction between various structures within the inflamed joint including fibroblasts, 
synoviocytes, chondrocytes, osteoclasts, macrophages, neutrophils, mast cells, plasma cells 
and T cells (T helper-1, Th1 and T helper-2, Th2). 
Cytokines are key regulators of the inflammatory response in RA (6). The most 
important cytokines include IL-6, TNF-α, IL-1, IL-17, IFN and IL-10 (Table 2.5). IL-6 has 
both pro- and anti-inflammatory actions and activates the production of the acute phase 
molecule CRP from liver cells (40). IL-1 (alpha and beta, IL-1α and IL-1β), IL-17, TNF-α and 
IFN have pro-inflammatory actions whilst IL-10 has anti-inflammatory properties and hence 
helps to regulate the inflammatory response (45). Th1 cells secrete the cytokines IL-2, IFN-γ
and inhibit Th2 cell activity. Th2 cells secrete the cytokines IL-4, IL-5 and IL-6 while 
inhibiting Th1 cell activity. Th1 cell activity is mainly related to cell-mediated or innate 
immunity (i.e. activation of macrophages or cytotoxic T cells) whilst Th2 cell activity is 
largely related to humoral or acquired immune responses (i.e. production of antibodies by B 
cells) (39). In RA, Th1 cell (43, 44) and Th17 cell (42) activity predominates within the 
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inflamed synovium (39). The immune-pathophysiology of RA is complex and not fully 
understood, however the development of immune targeted therapies which specifically target 
and inhibit cytokines (IL-6, TNF-α, IL-1) and B cell activity has helped improve 
understanding (6). The efficacy of TNF-α inhibitors as demonstrated in randomised clinical 
trials supports the deleterious role of TNF-α in the pathogenesis of RA (46-48).
It has been long known in clinical practice that RA patients are a heterogenous group 
with differing disease patterns, severity and responses to treatments (1, 5). Indeed, these 
targeted immune modifying agents (biological therapy) have varying efficacy suggesting non-
uniform pathological mechanisms in RA (49, 50). It remains unclear why certain patients 
appear to have more severe disease activity and more pronounced systemic inflammatory 
responses. Recent developments suggest that the ANS may play a fundamental part in 
immune regulation (51) and hence ANS dysfunction may lead to immune dysregulation. 
Furthermore accumulating animal data has shown that inflammatory cytokines exert 
deleterious effects on key cardiovascular regulatory sites of the ANS (52-61), which suggests 
a perpetual cycle of inflammation leading to ANS dysfunction and further inflammation.  
Given that inflammation and ANS dysfunction are recognised pathological features of 
numerous cardiovascular diseases including hypertension, atherosclerosis and chronic heart 
failure (51, 62-71), ANS-immune dysregulation may well contribute to the increased 
cardiovascular risk in RA. Further work is required to ascertain underlying mechanisms that 
drive immune-dysregulation in order for appropriate therapies to be developed and targeted to 
individual patients.
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Table 2.5 Key cytokines in the pathophysiology of RA
Cytokine Important actions
TNF-α Produced by macrophages, natural killer cells, T cells, B cells and mast cells.
Pro-inflammatory actions. Activates leucocytes, endothelial cells and synovial 
fibroblasts. Stimulates production of cytokines, adhesion molecules and matrix 
enzymes. Inhibits T cell. Activates osteoclasts. Bone resorption.
IL-1α, IL-
1β
Produced by macrophages.
Pro-inflammatory actions. Activates leucocytes, endothelial cells and synovial 
fibroblasts. Stimulates production of matrix enzymes from chondrocytes. 
Activates osteoclasts. Increases glucose metabolism. 
IL-6 Produced by Th2 cells, macrophages.
Pro- and anti-inflammatory actions. Activates leucocytes and osteoclasts. 
Stimulates an acute-phase response with production of CRP in hepatocytes. 
Regulates lipid metabolism. Mediates fever, chronic anaemia.
IL-17 Produced Th17 cells
Activates synovial fibroblasts, chondrocytes and osteoclasts.
IL-10 Produced by monocytes, macrophages, Th1 cells
Anti-inflammatory actions. Inhibits synthesis and actions of TNF-α, IL-1β, IL-
6. Stimulates B cell maturation and antibody production.
CRP = C-reactive protein, IL = interleukin, Th = T helper, TNF = tumour necrosis factor.
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2.3 Autonomic nervous system (ANS)
2.3.1 The sympathetic and parasympathetic nervous systems
The autonomic (adjective, Greek “auto” meaning “self” and “nomos” meaning “law”) 
nervous system is the part of the nervous system that regulates physiological processes 
without conscious control (72). The term “autonomic nervous system” was first coined by the 
English Physiologist John N. Langley (73). He divided the ANS into three components: 
sympathetic (adjective, Greek “sympathos” meaning “affected by feelings”), parasympathetic 
(adjective, Greek “para” meaning “alongside”) and enteric nervous systems. The ANS is now 
recognised as a complex network comprising central structures (within the brain and spinal 
cord), ascending and descending pathways and peripheral nerves (afferent and efferent) that 
exert their effects on “end-organs” or “effector organs”. The purpose of the ANS is to 
maintain homeostasis (noun, Greek “homio-” meaning “like, resembling, of the same kind” 
and “stasis” meaning “standing still”) within the body (e.g. body temperature, BP, brain 
blood flow). The term “homeostasis” was coined by the American Physiologist Walter B. 
Canon, whereby he proposed that the brain coordinates the body systems to maintain a set of 
goal values for internal variables (74). Perturbations in these values, whether by internal or 
external factors arouse internal nervous and hormonal systems to re-establish homeostasis.
Canon also proposed that the sympathetic nervous system was responsible for the 
“fight-or-flight” response (74) (peripheral vasodilation, increased HR and BP, increase 
respiration, mobilisation of glucose into the blood, cutaneous vasoconstriction). During 
periods of stress (physical or emotional) the sympathetic nervous system is activated to 
prepare the body to respond to the particular stress and maintain homeostasis. The 
sympathetic nervous system consists of pre-ganglionic neurons found within the lateral grey 
column of the spinal cord, the majority within the intermediolateral (IML) cell column 
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(Figure 2.3), which synapse within ganglia at various sites (paravertebral: cervical, thoracic, 
lumbar, sacral; prevertebral: celiac, aorticorenal, superior mesenteric and inferior mesenteric; 
chromograffin cells within the adrenal medulla) and post-ganglionic neurones project to 
end/effector organs. The myocardium and peripheral vasculature are innervated by 
sympathetic nerves and can be activated directly or indirectly, increasing cardiac contractility 
and peripheral vasoconstriction resulting in a rise in arterial BP. The principle post-ganglionic 
neurotransmitter of the sympathetic nervous system is nor-epinephrine (noun, Greek “epi” 
meaning “upon” and “nephros” meaning “kidney”1, also known as noradrenaline), with 
acetylcholine (Ach) as the principle pre-ganglionic neurotransmitter. Noradrenaline exerts its 
effects by binding to β-adrenoreceptors in the heart and α-adrenoreceptors in the peripheral 
vasculature. Other important co-transmitters include adrenaline (epinephrine), adenosine 
triphosphate, neuropeptide-Y (NPY), somatostatin and opioid peptides. 
The parasympathetic nervous system is responsible for a number of processes that 
promote “rest and digest” (75). Activation of the parasympathetic nervous system facilitates 
numerous activities including digestion (stimulation of gastric acid section and gut smooth 
muscle contraction), salivation, lacrimation, sexual arousal, urination and defecation. The 
parasympathetic nervous system works alongside the sympathetic nervous system to maintain 
homeostasis. In contrast to the sympathetic nervous system the pre-ganglionic cell bodies of 
the parasympathetic nervous system are found within two sites: the brain stem and sacral
spinal cord (72) (Figure 2.3). Important central parasympathetic structures include the dorsal 
nucleus of the vagus nerve (numerous activities including HR regulation, gastrointestinal 
motility, thermoregulation), the nucleus ambiguus (HR regulation), the periaqueductal gray 
(pain modulation) and parabrachial nucleus. Pre-ganglionic neurones project and synapse 
1 so called as the adrenal glands sit upon the kidneys.
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within parasympathetic ganglia located within the effector organs. Post-ganglionic neurones 
are typically very short (1-2 mm in length). The vagus (noun, Latin “vagus” meaning 
“wandering”1) nerve innervates the heart, lung and visceral organs, and constitutes 
approximately 75 % of all parasympathetic fibres2. Acetylcholine (noun, “acetyl” refers to the 
methyl group single-bonded to a carbonyl, “choline” derived from “cholera” Greek “khole” 
meaning “bile”) is the principle neurotransmitter of the parasympathetic nervous system but 
nitric oxide (NO) can also be used (76). Important co-transmitters include vasoactive 
intestinal peptide (77), calcitonin gene-related peptide (78), somatostatin (79) and opioid 
peptides (80).
2.3.2 Integrative control of the cardiovascular system
The ANS plays a critical role in the regulation of HR and arterial BP through a 
number of reflex neural circuits (72, 81, 82). A multitude of inputs from sensory afferents 
including arterial baroreceptors, cardiopulmonary receptors, peripheral and central 
chemoreceptors as well as somatic and visceral receptors (including nociceptors) synapse 
within the medulla oblongata in the brain stem, and particularly the nucleus of the solitary 
tract (NTS). The specific pattern of autonomic response that arises as a consequence of the 
activity of these neural inputs is also dependent upon modulatory inputs from other brainstem 
regions, the hypothalamus, higher neural structures (e.g. amygdala, cerebral cortex) and 
circumventricular organs (e.g. area postrema, arcuate [infundibular] nucleus, subfornical 
nucleus). The circumventricular organs are found within the brain but lack a brain blood 
barrier. It is thought that circulating molecules (e.g. hormones) (81, 83) can modulate ANS 
1 so called due to its wandering course from the brainstem to the neck, chest and abdomen
2 the term “vagal” and parasympathetic are used interchangeably
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Figure 2.3 Simplified schematic representation of the ANS
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This figure is a simplified representation of parasympathetic (blue) and sympathetic (red) activation within the 
ANS, with regulatory (green) pathways. Central nerve fibres project from the PVN in the hypothalamus to the 
nucleus ambiguus and dorsal motor nucleus of the vagus within the medulla. Pre-ganglionic parasympathetic 
fibres project from the nucleus ambiguus and the dorsal motor nucleus of the vagus to synapse with 
parasympathetic ganglion (closed circles) within the heart. Post-ganglionic parasympathetic nerves project from 
these ganglia to the SA node to modulate HR. Pre-ganglionic parasympathetic fibres (i.e. the vagus nerve) 
project from the dorsal motor nucleus of the vagus to other effector organs (open circles). Additionally pre-
ganglionic parasympathetic fibres project from the sacral spine to the gastrointestinal and genitourinary tract. 
Central nerve fibres project from the PVN to nuclei within the medulla (RVLM, RVMM, NTS and caudate raphe 
nuclei) and pons (A5 cells). Further descending nerve fibres project to the spinal cord (IML). From there pre-
ganglionic sympathetic fibres project to and synapse with sympathetic ganglion. The IML cell column contains
the most sympathetic ganglia although present in other regions (e.g. coeliac, mesenteric ganglia). Post-ganglionic 
sympathetic fibres project to cardiomyocytes within the heart, and smooth muscle cells within the peripheral 
vasculature to allow modulation of BP through changes in cardiac contractility and peripheral 
vasoconstriction/dilation. The PVN additionally receives input (from the hippocampus, cerebral cortex, 
trigeminal pars caudalis, amygdala and other hypothalamic structures) to allow modulation of sympathetic and 
parasympathetic activity. Additionally there are reflex feedback mechanisms that regulate autonomic activity 
(e.g. carotid and cardiopulmonary baroreceptors, peripheral and central chemoreceptors). Ach, NA and A 
neurotransmitters are shown. Interconnections between nuclei within the medulla, or between the medulla and 
pons are not shown. A = adrenaline, Ach = acetylcholine, BP = blood pressure, HR = heart rate, IML = 
intermediolateral, NA = noradrenaline, NTS = nucleus of the solitary tract, PVN = paraventricular nucleus, 
RVLM = rostral ventrolateral medulla, RVMM = rostral ventromedial medulla, SA = sino-atrial.
function by binding to receptors within the circumventricular organs, which project to 
centralANS sites such as the hypothalamus, or to autonomic motor neurons in the spine or 
brainstem (84). Important mediators include angiotensin II, natriuretic peptides and leptin 
(83). Collectively, these integrated responses represent the main cardiovascular reflex 
pathways, i.e. arterial baroreflex, cardiopulmonary reflex, chemoreflex, diving reflex, 
oculocardiac reflex, startle reflex, somatic nociception and centrally evoked “defence 
responses” (81, 82, 85). 
The hypothalamus, brain stem and limbic structures (including the amygdala, 
hippocampus, cerebral cortex) are important central structures implicated in the regulation of 
ANS activity (Figure 2.3) (72, 81). The paraventricular nucleus (PVN), within the
hypothalamus receives projections from hypothalamic, brain stem and limbic structures and 
additionally receives sympathetic and parasympathetic afferent signals from the trigeminal 
pars caudalis (sympathetic) and the NTS (parasympathetic). Consequently, the PVN is an 
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important ANS site as it forms connections with both the sympathetic and parasympathetic 
pathways. Other important central sympathetic structures include the caudal and rostral 
ventrolateral medulla (RVLM, BP and HR regulation), the pontine and medullary raphe 
(serotonin mediated control of circadian rhythms) and the lateral hypothalamus (numerous 
activities including arousal, thermoregulation, gastrointestinal motility, pain modulation, 
respiration, micturition). The RVLM within the medulla is a key cardiovascular regulatory 
site, receiving inputs from the hypothalamus and caudal ventrolateral medulla (CVLM) 
nucleus, while projecting sympathetic pre-ganglionic neurones to the IML cell column 
allowing sympathetic modulation of the heart and peripheral vasculature (i.e. via arterial 
baroreflex as discussed in next section). 
The heart is innervated by the vagus nerve at the sinus node and within the 
myocardium (86). Parasympathetic activation and withdrawal results in a fall and rise in HR, 
respectively. The myocardium and peripheral vasculature are innervated by sympathetic 
nerves and can be activated directly or indirectly (via noradrenaline or adrenaline acting upon 
β-adrenoreceptors in the heart and α-adrenoreceptors in the peripheral vasculature), increasing 
cardiac contractility and peripheral vasoconstriction resulting in a rise in arterial BP. 
However, this may be an over simplification as responses to efferent impulses are not always 
uniform. For example Folkow et al. demonstrated that in cats, electrical stimulation of the 
hypothalamus resulted in differential responses in different vascular beds as well as within the 
same vascular bed (87). 
HR and BP can be influenced by a number of pathways involving reflex (e.g. arterial 
baroreflex, chemoreflex, diving reflex) and non-reflex (skeletal muscle afferent, respiratory 
sinus arrhythmia) mechanisms (72, 81, 82, 88, 89). The main components of these reflexes 
include sensors, afferent pathways, central integration, efferent pathways and effector organs. 
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Depending on the circumstances there may be reciprocal or non-reciprocal effects on the 
sympathetic and parasympathetic components of the responses (85), e.g. activation of the 
arterial baroreceptors results in a reflex parasympathetic activation and sympathetic inhibition 
resulting in bradycardia and hypotension. Conversely activation of the diving reflex in 
conscious rabbits results in vagally mediated bradycardia, peripheral vasoconstriction and 
sympathetically-mediated ventricular arrhythmogenesis (90).
Whilst one can consider each reflex as separate and distinct, in reality there are usually 
complex interactions between each of these reflexes depending on the clinical situation (e.g. 
stress, exercise, arrhythmias) (91). For example during ventricular tachycardia (VT) there are 
conflicting reflex actions. The fall in arterial BP during VT unloads the arterial baroreceptors 
causing sympatho-excitation, whilst elevations in cardiac filling pressures load the 
cardiopulmonary baroreceptors resulting in sympatho-inhibition (92). The net outcome is a 
sympathetic excitation suggesting that arterial baroreceptors have a predominant effect (45, 
92, 93). 
2.3.3 The arterial baroreflex 
The arterial baroreflex modulates the ANS to buffer beat-to-beat fluctuations in BP 
(94) (Figure 2.4). Baroreceptors (mechanosensitive afferent nerve endings) within the carotid 
artery or aortic arch (aortic baroreceptors) respond to vessel wall distension which coincide 
with changes in BP, and when activated transmit afferent signals to the NTS (82). Excitatory 
neurons project from the NTS to the nucleus ambiguus within the medulla, which transmits 
signals to the heart via efferent parasympathetic fibres. Vagal pre-ganglionic neurones project 
to and synapse in the parasympathetic ganglia near the heart, and post-ganglionic fibres 
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project to the sino-atrial node (82) and myocardium (95). In addition, excitatory neurons from 
the NTS project to the CVLM, from which inhibitory (GABAergic) neurones project to the 
RVLM. Pre-ganglionic sympathetic neurones project from the RVLM to the sympathetic 
ganglion within the IML cell column with further post-ganglionic nerve projections to the 
effector organs (heart, peripheral vasculature). Therefore, baroreceptor activation results in 
parasympathetic activation and sympathetic inhibition, resulting in bradycardia and 
hypotension (91, 96, 97).
Much of our understanding of the contribution of central neural circuits to arterial 
baroreflex regulation has been derived from animal studies. Kollai and Koizumi (1979) 
demonstrated that in anaesthetised dogs baroreflex activation (achieved by injecting 
intravenous noradrenaline) resulted in an immediate increase in cardiac vagal nerve activity 
with a fall in cardiac sympathetic nerve activity that coincided with a fall in HR (97). A recent 
human study by Macefield and Henderson (2010) confirmed some of the findings in previous 
animal studies (98). Functional magnetic resonance imaging of the brain was performed with 
simultaneous MSNA (peroneal nerve) recordings in healthy humans. They were able to 
demonstrate that during spontaneous falls in BP there was a fall in NTS activity, decreased 
CVLM activity and increased RVLM activity. During spontaneous rises in BP the opposite 
was observed. 
In summary, a fall in BP unloads the baroreflex causing parasympathetic inhibition at 
the sinus node resulting in a reflex tachycardia, and sympathetic activation of the heart and 
peripheral vasculature resulting in increased cardiac contractility and peripheral 
vasoconstriction. By contrast a rise in BP activates the baroreflex causing parasympathetic 
activation at the sinus node, and sympathetic inhibition at the heart and peripheral vasculature. 
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Figure 2.4 Schematic representation of the arterial baroreflex (81, 82)
This figure demonstrates the arterial baroreflex. Baroreceptors (carotid and cardiopulmonary receptors) are activated in response to increased BP. Afferent signals 
project to the NTS, which stimulate parasympathetic activation via the nucleus ambiguuus resulting in slowing of the HR. Sympathetic inhibition occurs via the 
CVLM, RVLM and ILM cell column resulting in reduced sympathetic outflow to the heart and vasculature causing a fall in BP (reduced cardiac contractility, 
peripheral vasodilation). Ach, NA and A neurotransmitters are shown. A = adrenaline, Ach = acetylcholine, BP = blood pressure, CVLM = caudal ventrolateral 
medulla, HR = heart rate, ILM = intermediolateral, NA = noradrenaline, NTS = nucleus of the solitary tract, RVLM = rostral ventrolateral medulla.
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BRS, also known as baroreflex gain, can be determined and used as a measure of the 
autonomic control of the cardiovascular system. Baroreflex gain is defined as the change in 
autonomic effector responses (e.g. change in HR or sympathetic outflow) for a given change 
in arterial BP (82). A reduced BRS indicates impairment in the ability to buffer changes in 
BP. Cardiovagal (or cardiac) BRS (cBRS) is a measure of vagally-mediated HR responses to 
BP changes whilst sympathetic BRS is a measure of sympathetic nerve activity changes in the 
peripheral vasculature (81, 82).
2.4 ANS dysfunction
For the body to maintain homeostasis an intact ANS is essential. The consequences of 
altered sympathetic and parasympathetic activity, manifest as impairments in BRS and 
cardiovascular reactivity will be outlined in this section. Abnormalities in the QT interval, a 
proxy marker of autonomic function, and the role of stress and the HPA axis will also be 
discussed. Evidence regarding the relationships between ANS dysfunction and inflammation 
will be extensively covered in the relevant sub-sections.
2.4.1 Pathophysiological consequences of sympathetic dysfunction
Failure of the sympathetic nervous system to activate appropriately can lead to 
deleterious consequences. For example, neuro-cardiogenic syncope is thought to be partly due 
to failure of sympathetic activation and failure to maintain BP and brain perfusion (99). 
Conditions such as diabetes or pure autonomic failure can result in debilitating symptoms of 
postural dizziness and fainting (100, 101). 
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Heightened sympathetic outflow is a pathogenic feature of numerous cardiovascular 
conditions including hypertension (62), chronic heart failure (63), cardiac arrhythmias (102)
and ischaemic heart disease (64) as well as non-cardiovascular diseases including diabetes 
mellitus (103), chronic kidney disease (104), obesity (105), metabolic syndrome (106), 
obstructive sleep apnoea (107), chronic obstructive pulmonary disease (108), pulmonary 
hypertension (109), depression (110), pre-eclampsia (111) and ulcerative colitis (112). 
Heightened sympathetic activity has been shown to predict mortality in chronic heart failure 
(113). Cohn et al. (1984) observed that plasma noradrenaline concentration was an 
independent predictor of mortality in patients with moderate to severe heart failure, in a dose-
dependent manner. The increased mortality risk increased associated with sympathetic 
activation may be partially explained by arrhythmogenesis (114). In anaesthetised cats, 
sympathetic stimulation reduced the threshold for cesium chloride-induced VT, whilst β-
adrenergic blockade prevented sustained VT (115). There is also evidence to suggest that 
chronic sympathetic over-activity may contribute to the pathogenesis and progression of 
hypertension (62, 116-119), although not universally agreed upon (120). In patients with 
essential hypertension MSNA (62, 119), plasma noradrenaline levels (121, 122) and 
noradrenaline spillover from the heart and kidneys (123) are reported to be elevated. Smith et 
al. (2004) found that central sympathetic activity was higher in borderline hypertensives (BP 
130/85 – 139/89 mmHg), early stage essential hypertensives (BP 140/90 – 159/99 mmHg) 
with and without left ventricular hypertrophy compared to normotensives and late stage 
hypertensive patients (BP ≥ 160/100 mmHg)(119). They also showed that central sympathetic 
activity was higher in white coat hypertensives compared to normotensive individuals. This 
data adds to earlier animal evidence suggesting that sympathetic nerve activity may be a 
causal factor in the development of hypertension. In spontaneously hypertensive rats increases 
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in sympathetic nerve activity (124), plasma noradrenaline (125) and vascular resistance (126)
are seen prior to the development of hypertension. In chronic heart failure, sympathetic 
activation is thought to be a compensatory mechanism to increase cardiac contractility 
(cardiac sympathetic activity) and increase circulating volume via peripheral vasoconstriction 
and co-activation of the renin-angiotensin-aldosterone system (127). However, chronic 
sympathetic activation places more strain on a failing heart and serves to accelerate the 
progression of heart failure and can reduce survival (127). The efficacy of β-adrenergic 
blockade in improving symptoms and mortality in chronic heart failure patients is well 
established (128-133) and may well relate to the reduction in sympathetic activity (134, 135).
Chronic elevations in BP are known to cause structural and functional remodelling of 
the heart and vasculature leading to left ventricular hypertrophy (136, 137), vascular smooth 
cell hypertrophy and hyperplasia (138-140), increased arterial wall stiffness (141, 142) and 
endothelial dysfunction (143-145). These changes may lead to diastolic dysfunction (146, 
147), chronic heart failure (148, 149) and can accelerate the process of atherosclerosis (139, 
150). However there is also evidence to suggest that chronic elevations in sympathetic nerve 
activity may have similar deleterious effects to the vasculature, independent of BP. Bevan 
(1984) demonstrated that chronic sympathetic activation without a rise in BP caused vascular 
smooth muscle hypertrophy and proliferation (151). These changes were attenuated by 
sympathetic denervation (151, 152). 
While the deleterious consequences of heightened SNA have been described, the 
precise mechanisms driving sympathetic over-activity remain to be fully elucidated. Once 
underlying mechanisms are identified then appropriate therapeutic interventions can be 
employed on a patient-specific basis. 
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2.4.2 Sympathetic-immune interactions
There are a multitude of pathways that may result in heightened sympathetic activity 
(e.g. NO pathways, angiotensin II, respiratory sympathetic coupling etc.), however given the 
focus of my thesis I will provide an overview of potential mechanisms whereby sympathetic-
immune interactions may elevate SNA.
Accumulating evidence suggests the presence of bi-directional links between 
sympathetic activity and inflammation. Niijima et al. (1991) were the first to report that 
intravenous administration of recombinant human IL-1β increased splenic, adrenal and renal 
sympathetic nerve activity in anaesthetised rats (153). Haefeli et al. (1993) were the first to 
provide evidence that pro-inflammatory cytokines can cause sympathetic activation in 
humans (154). Infusion of recombinant IL-1β into humans with malignant melanoma 
increased HR and systolic BP, and decreased hand vein compliance (suggestive of 
vasoconstriction). The vasoconstriction was sympathetically mediated as it was reversed with 
local administration of the α-antagonist phentolamine. Subsequent animal studies have 
demonstrated that cytokines can increase sympathetic activity (52-61). Peripheral 
administration of TNF-α (58, 61) and IL-1β (54, 55, 153), and central administration of TNF-
α (57, 59), IL-1β (53-57, 60) and IL-6 (52) increase sympathetic nerve activity. These studies 
support the concept that circulating inflammatory cytokines can increase sympathetic activity 
via centrally mediated mechanisms, although how this occurs is not known. Pro-inflammatory 
cytokines are lipophobic and too large to pass the blood brain barrier (155). One potential 
explanation is that circulating cytokines exert their central effects via the circumventricular 
organs, which lack a blood brain barrier. These organs are important and key regulating sites 
whereby hormones can modulate autonomic responses e.g. angiotensin, leptin (83). Helwig et 
al. (2008) administered IL-6 centrally in rats whilst making direct splenic sympathetic nerve 
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recordings (52). They found that splenic sympathetic activity increased in a dose responsive 
manner. Interestingly using fluorescent immunohistochemistry they demonstrated that 
following central infusion IL-6 was distributed within the periventricular areas of the 
ventricular system and not within the brain parenchyma. Wei et al. (2013) localised the site of 
action to the subfornical organ (SFO) (58), a forebrain circumventricular organ. In their 
experiment intra-carotid administration of TNF-α and IL-1β in rats increased HR, mean BP 
and renal sympathetic nerve activity. These changes were significantly reduced in rats with 
SFO lesions. Immunofluorescent staining localised a dense distribution of TNF-α and IL-1 
receptors within the SFO. Other potential explanations include disruption of the blood-brain 
barrier (as occurs in bacterial meningitis); blood-brain barrier transporters; activation of 
cytokine receptors on afferent nerve fibres; or via activation of microglia (inflammatory cells 
within the brain), which release chemokines that attract immune cells to the brain parenchyma 
(155, 156). Cytokines may potentially enter the brain via the blood-cerebrospinal fluid barrier. 
Recent experiments have shown that concentrations of IL-1β within the cerebrospinal fluid of 
RA patients appear to be elevated (157, 158).
It has long been known that immune organs such as the spleen and bone marrow have 
sympathetic innervation (159-161). Furthermore, immune cells have been shown to express α-
and β-adrenergic receptors on their cell surface. Therefore the immune system has the 
potential to be modulated by the sympathetic nervous system. There is a growing body of 
evidence showing that catecholamines can affect the release of cytokines by increasing Th2 
responses (humoral) and inhibiting Th1 responses (cellular immunity). Catecholamines inhibit 
IL-1 (162, 163), IL-2 (164), IFN-γ (165, 166), TNF-α (167-171) and promote release of IL-10 
(170, 172-175), IL-6 (168, 176), transforming growth factor-β (177) and IL-8 (163, 178). 
During acute inflammation there is activation of the HPA axis and sympathetic nervous 
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system (179), which help equip the body to deal with invading pathogens. From the 
aforementioned studies it appears that a degree of sympathetic activation may be protective. 
Current understanding is that sympathetic activation results in a shift from Th1 activity 
(cellular) to Th2 activity (humoral), resulting in a more specific immune response that limits 
the inflammatory response to local and specific targets (159). Therefore sympathetic 
activation may protect the host from the deleterious effects of systemic inflammation. A 
recent animal study supports this. Martelli et al. measured the inflammatory responses to 
lipopolysaccharide (LPS) in rats and demonstrated that dissecting the splanchnic nerve 
(thereby reducing splenic nerve activity) increased the plasma TNF-α responses five-fold 
(180).
Chronic sympathetic activation however may have pro-inflammatory effects. Studies 
have consistently shown that conditions associated with chronic sympathetic activation such 
as hypertension and chronic heart failure are characterised by low-grade inflammation (51, 
65-71) although whether this is a cause or effect remains a matter of debate. In animal studies 
chronic β-adrenergic stimulation with isoproterenol (non selective β-adrenergic agonist) 
increased plasma concentrations of IL-1β and IL-6 and tissue IL-1β within the pituitary, 
hypothalamus, hippocampus (181) and increased tissue IL-1β, IL-6 and TNF-α within the 
myocardium (182). A number of studies have assessed the effects of sympathetic inhibition 
on inflammation in heart failure and hypertension (183). β-blockers have been shown to 
reduce concentrations of IL-6 (184-186), TNF-α (184-187), IL-1 (187) and IL-18 (188) (a 
pro-inflammatory cytokine) whilst increasing IL-10 (188) in chronic heart failure. In one 
study, renal sympathetic denervation was found to reduce circulating concentrations of IL-6 
and hs-CRP in hypertensive patients after 6 months (189). In another study sympathetic 
blockade with clonidine was found to reduce MSNA and disease activity in patients with 
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active chronic inflammatory bowel disease however unfortunately the authors did not assess 
inflammatory cytokines or CRP (112). While these studies suggest that chronic sympathetic 
activity may have pro-inflammatory effects the exact mechanisms are not known. 
The results of these experiments have major implications for RA. It is possible that 
chronic inflammation as seen in RA may lead to chronic elevations in sympathetic nerve 
activity leading to deleterious cardiovascular consequences thereby increasing cardiovascular 
risk and mortality. It is also possible that chronic sympathetic activation in RA may 
perpetuate inflammation resulting in a “vicious cycle” of sympathetic activation and chronic 
inflammation. The ANS may therefore be a potential therapeutic target in RA in order to 
control inflammation and reduce cardiovascular risk. Evidence to date however suggests that 
a degree of sympathetic activation is needed in order to control inflammatory responses, and 
therefore reduced sympathetic activity may potentially trigger the onset of RA or exacerbate 
flares. Chronic sympathetic activation may also cause a down regulation of β2-adrenergic 
receptors rendering the individual less equipped to deal with acute flares. The relationship 
between the sympathetic nervous system and inflammation in RA is potentially complex and 
requires further exploration, to try and gain insights into the pathophysiology of the disease 
and improve understanding of the increased cardiovascular risk so that therapeutic targets can 
be developed and effective treatments employed.
A major aim of my thesis is to determine whether elevated sympathetic nerve activity 
is a pathogenic feature of RA and to explore the relationship between sympathetic activity and 
inflammation. To achieve this I have performed a systematic literature review (Chapter 4), a 
case-control study assessing MSNA in RA patients, as compared to healthy and hypertensive 
controls (Chapter 6) and a case study of an RA patient where MSNA was measured before 
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and three months following anti-TNF-α therapy (Chapter 8). To my knowledge these are the 
first MSNA recordings in RA human subjects.
2.4.3 Parasympathetic dysfunction
Inappropriate cardiac parasympathetic stimulation can result in deleterious 
consequences. The excessive increases in parasympathetic activation that occur in neuro-
cardiogenic syncope results in an inappropriate slowing of the HR causing a reduction in 
cardiac output, BP and brain perfusion that can lead to fainting episodes (99). Conversely, 
low cardiac parasympathetic activity appears to be associated with worse prognosis. Large 
epidemiological studies have demonstrated an inverse relationship between resting HR and 
survival in the general population (190) and in patients with cardiovascular diseases (191-
194). Elevated HR predisposes to obesity and diabetes (195); conditions associated with 
increased cardiovascular risk. A mechanism for such elevations in HR could be low cardiac 
parasympathetic activity, although this was not directly tested. HRV, a proxy measure of 
parasympathetic activity based on statistical analysis of HR fluctuations (196, 197), has been 
found to be reduced in coronary artery disease (198), heart failure (199), diabetes (200), 
stroke (201, 202) and epilepsy (203).  Lower HRV is an independent predictor of death 
following MI (204-206) and in patients with chronic heart failure (207-210) and chronic renal 
failure (211). Athletes have a lower resting HR (212, 213) which may be attributed to 
increased vagal tone as a consequence of exercise training (214). In healthy, individuals 
exercise training increased resting vagal tone and lowered resting HR (215). This has also 
been noted in older sedentary individuals (216-218) and patients with chronic heart failure 
(219-222). The cardiovascular benefits of exercise are well documented (223-225) and 
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include reductions in BP (226, 227) improved endothelial function (228, 229) and reduced all-
cause and cardiovascular mortality in patients with coronary heart disease (230) and chronic 
heart failure (231). The mechanisms by which exercise improves cardial vagal tone are not 
fully known (232) but seem to include NO dependent pathways (228).
These studies strongly support the notion that vagal activity has a protective effect 
against cardiovascular diseases, although the precise mechanisms have not been fully 
established (233). Suggested mechanisms include antagonising deleterious effects of 
sympathetic activation (234), inhibiting arrhythmogenesis (235), increasing NO (236) (228), 
reducing oxidative stress (237) and intracellular calcium (238), improving mitochondrial 
function (239), and exerting anti-inflammatory effects through the anti-inflammatory pathway
(240).
2.4.4 Parasympathetic-immune interactions
Tracey and colleagues stimulated a new understanding of the immune system with the 
discovery that neural reflex circuits are able to mediate an inflammatory response via 
nicotinic Ach receptors; a concept that has been described as the cholinergic anti-
inflammatory pathway (241-243). In 1984, Blalock put forward the concept that “the immune 
system may act as a sensory organ” (244). Approximately two decades later Borovikova and 
associates were able to show that stimulation of the parasympathetic nervous system could 
attenuate systemic inflammatory responses (241). Ach attenuated the release of inflammatory 
cytokines (TNF, IL-1β, IL-6 and IL-18) and high mobility group box 1 (a pro-inflammatory 
nuclear protein with autocrine and paracrine properties (245)) in LPS-stimulated human 
macrophage cultures (241, 246). Additionally they showed that in rats, electrical stimulation 
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of the vagus nerve inhibited TNF synthesis within the liver, reduced the peak concentration of 
serum TNF and prevented the development of shock (hypotension) (241). Interestingly IL-10 
concentrations were not affected by Ach suggesting that the anti-inflammatory properties of 
vagal stimulation could not be attributed to the anti-inflammatory effects of IL-10. Bernik et 
al. (2002) showed that an intact vagus nerve was required for the anti-inflammatory pathway 
(247). Injection of a pharmacological vagal stimulator into the brains of rats 
(intracerebroventricular) suppressed endotoxin-induced release of TNF, however this did not
occur in vagotomised rats. Huston et al. (2006) demonstrated that the spleen played a vital 
role (248) as splenectomy abolished the anti-inflammatory effects of vagal stimulation in their 
mice model of sepsis. Further work has clarified that Ach acts via the nicotinic Ach receptor
α7 subunit (α7nAChR), a ligand gated ion channel (243). 
The cholinergic anti-inflammatory pathway has been challenged for a number of 
reasons (180, 249, 250). Firstly it has been demonstrated that there is no evidence for vagal 
innervation of the spleen and no synapse between vagal and sympathetic neurons exist within 
the spleen (179, 249). Secondly, in experimental rat models of sepsis vagotomy had no effect 
on inflammatory responses (180, 247, 251, 252). The most current proposal for the 
cholinergic anti-inflammatory reflex involves a vagal afferent arc that relays signals to the 
brain, which stimulates a complex efferent arc involving vagal efferent neurones with Ach
interacting with the α7nAChR expressed on cytokine producing macrophages within the 
spleen. Activation of this reflex results in attenuated inflammatory responses. How the neural 
circuit is completed without the vagal innervation of the spleen is not known, but is postulated 
to result via an interaction with splenic sympathetic neurones (253) or via alternative neural 
transmission involving Ach-producing T cells (254).
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Although the precise pathway remains to be fully elucidated, vagal nerve stimulation 
has been shown to reduce inflammatory responses in animal experiments (255-258). Vagal 
nerve stimulation improved local inflammation (ankle swelling, histological joint 
inflammation) as well as reduced systemic pro-inflammatory cytokine (IL-1α, IL-1β, IL-2, 
IL-6, IFN-γ and TNF) production in a rat model of collagen-induced arthritis (255). In a 
mouse model of arthritis vagotomy exacerbated arthritis whilst oral nicotine ameliorated it 
(258). Cholinergic agonists have been found to reduce clinical signs of arthritis, synovial 
inflammation, serum cytokine concentrations and bone erosions in animal models of RA 
(256-258). 
Assessing the vagal nerve in humans is problematic primarily due to its anatomical 
inaccessibility and hence human studies tend to rely on HRV as a proxy (196). A number of 
studies in healthy individuals (259, 260); the general population (261, 262); populations with 
increased cardiovascular risk (263-265); and populations with cardiovascular diseases (266-
270) have demonstrated inverse relationships between HRV parameters and inflammatory 
markers. E.g. in inflammatory bowel disease more active disease is associated with higher HR 
and lower HRV parameters (271). These studies support the hypothesis that increased vagal 
tone may attenuate inflammation, however the observational nature of these studies carries a 
major limitation.
Marsland et al. (2007) simulated inflammatory responses in healthy volunteers using 
LPS and found an inverse relationship between LPS-induced production of IL-6 and high 
frequency power (HF, frequency domain HRV index of parasympathetic activity), which 
remained after controlling for age, sex, gender and BP (272). Similar trends were seen 
between HF power and TNF-α and IL-1β. They also found significant inverse relationships 
between rMSSD (a time domain HRV index of parasympathetic activity) and TNF-α and a 
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trend for IL-6. In an animal study infusion of TNF-α caused a depression in HRV with a 
similar response to that seen in LPS-induced sepsis, suggesting a causal relationship (273).
A few studies in RA patients support the results of animal studies suggesting that 
vagal nerve stimulation may reduce inflammation. Fibrocyte-like synoviocytes obtained from 
the synovium of RA patients were pretreated with Ach, nicotine or AR-R1770 (α7nAChR 
activator) reduced the production of IL-6 and IL-8 (258, 274, 275). These studies in animals 
and humans led to a trial of vagal stimulation in human RA patients (276, 277). One Bosnian 
RA patient with severe disease underwent surgical implantation of a vagal stimulator (276). 
Following 8 weeks of vagal nerve stimulation complete remission of his disease was achieved 
with reduction of C-reactive protein to normal, and reduced number of swollen, tender joints. 
Further studies of vagal stimulation are underway in RA and although initial reports suggest 
they are safe to use, outcome data regarding their efficacy is still awaited (277).
Given this background the major aims of my thesis are to establish whether reduced 
parasympathetic activity is a feature of RA, and if so to determine whether there is a 
relationship between parasympathetic activity and inflammation in RA. To achieve this aim I 
have performed a systematic literature review (Chapter 4) and a case-control study comparing 
parasympathetic activity (using HRV) amongst RA patients to healthy and hypertensive 
controls (Chapter 7). In the case report I have assessed parasympathetic activity before and 
after 12 weeks of anti-TNF-α therapy (Chapter 8). 
2.4.5 Impaired baroreflex sensitivity (BRS)
Impairments in BRS have been demonstrated in numerous cardiovascular conditions 
(278) including hypertension (279, 280), heart failure (281-283), coronary artery disease 
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(284) as well as normal aging (279, 285-289) and has prognostic implications. Reduced BRS 
is predictive of decreased survival following MI (206, 284) and in patients with heart failure 
(290-293) and hypertension (294). Impaired BRS was an independent predictor of new onset 
hypertension in the elderly (295) and predicted increased BP in healthy adults (296) and 
patients with type 1 diabetes mellitus (297).
One possible explanation for the increased mortality risk in individuals with reduced 
BRS is increased risk of cardiac arrhythmia (206, 298, 299). Landolina et al. (1997) assessed 
cBRS in 24 patients with sustained monomorphic VT and a healed MI (298). They divided 
patients into those who tolerated the VT well and those who were syncopal or if systolic BP 
fell <90 mmHg with clinical signs of shock. They found that cBRS was significantly lower in 
patients who developed haemodynamic compromise or fainted compared to those who 
tolerated VT well. The arterial baroreflex is a key mechanism in the regulation of beat-to-beat 
BP, allowing appropriate parasympathetic and sympathetic tone to the heart and peripheral 
vasculature. Impairments in BRS may result in heightened cardiac sympathetic tone and 
parasympathetic withdrawal, which can promote arrhythmias (102, 114, 235). Additionally 
reduced BRS may impair the individual’s ability to buffer changes in BP and lead to 
worsening haemodynamic compromise.
Impairments in BRS may be a consequence of disruption within sites along the reflex 
arc (300). For example, carotid arterial stiffness or impaired distensibility (287, 288) and 
abnormalities within the carotid baroreceptor will impair the ability to sense BP changes 
(301); damage within the baroreceptor afferents may disrupt the transmission of afferent 
signals (302); and lesions within the NTS (303, 304) or related central areas (305, 306) may 
impair processing of afferent signals and/or transmission of efferent signals. Finally impaired 
baroreflex function can be due to abnormalities within vagal or sympathetic efferents (e.g. 
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denervation, demyelination or nerve damage) (302) or within effector organs (e.g. sinoatrial 
disease, myocardial or arterial stiffness, endothelial dysfunction). Circulating molecules or 
hormones may also potentially affect baroreflex function (307-312). Angiotensin (307, 311, 
313), melatonin (309), leptin (308), oestrogen (310) and glucocorticoids (312) have all been 
found to modulate BRS.
2.4.6 BRS and inflammation
In contrast to sympathetic and parasympathetic immune interactions, there is a paucity 
of literature available assessing interactions between BRS and inflammation. Takagishi and 
colleagues (2010) provided the strongest evidence for a relationship between inflammation 
and baroreflex function (314). They found that injection of IL-6 into the NTS reduced cBRS 
in rats. Prior studies have shown associations between inflammation and reductions in cBRS 
in humans (315) and experimental models of sepsis (316, 317). Annane et al. (1999) assessed 
critically ill patients with septic shock and found that hypotension was accompanied with 
reductions in HRV and cBRS (315). Vaysettes-Courchay et al. (2005) showed that the 
hypotension induced by sepsis was not a result of baroreflex dysfunction (317). LPS induced 
septic shock resulted in hypotension, tachycardia and increased sympathetic nerve activity 
which was similar in rats with intact or denervated baroreceptors. In a study of healthy 
humans inoculated with the influenza vaccine cBRS remained unchanged (318), although 
inflammatory markers were not assessed. There is some evidence that improvements in BRS 
may attenuate inflammatory responses (319, 320). In a canine model of heart failure, 8 weeks 
of vagal stimulation increased cBRS and attenuated increases in serum CRP (320). In an 
experimental model of LPS-induced sepsis (319) mice were pre-treated with Ketanserin (5-
hydroxytryptamine receptor antagonist), an antihypertensive agent known to increase BRS in 
43
rats (321). Ketanserin reduced serum TNF-α and IL-1β concentrations and increased IL-10 
concentrations, whilst improved survival independent of BP and HR (319). In mice with 
sinoaortic denervation Ketanserin had little effect on reducing shock. In a second experiment 
Ketanserin prevented the sepsis-induced baroreflex impairment in rats treated with LPS-
induced shock and improved survival.
The relationship between BRS and inflammation warrants further investigation. In RA 
chronic elevations in IL-6 may potentially contribute to reductions in BRS, and partly explain 
the increased cardiovascular risk and mortality seen in RA. It remains to be seen whether 
reduced BRS is a pathogenic feature of RA or whether attenuated BRS may exacerbate 
inflammation. A major aim of my thesis is to establish whether BRS is altered in RA, and if 
so to determine whether there is a relationship between BRS and inflammation. To achieve 
this I have performed a systematic literature review (Chapter 4) and a case-control study 
assessing cardiac and sympathetic BRS in RA patients compared to healthy and hypertensive 
controls (Chapter 6). In the case report I have also assessed the effects of anti-TNF-α therapy 
on cardiac and sympathetic BRS (Chapter 8).
2.4.7 Cardiovascular reactivity
Cardiovascular reactivity may be defined as a measure of physiological responses 
observed in an individual after a physical or mental stressor (322). It is usually reported as a 
change in a given variable before and after the stressor, or individuals may be grouped into 
low and high responders (322). Examples of cardiovascular variables include HR, BP and 
MSNA. Physical stressors include the CPT (immersion of a limb into cold water), isometric 
handgrip or exercise. Mental stressors include various laboratory-based tasks such as paced 
44
auditory serial arithmetic task, the Stroop test and stressful interviews. The CPT and mental 
stress tasks can be used to measure sympathetic function (323). Increases in BP, HR and 
MSNA comprise a normal response to the CPT (324, 325). Mental stress tests also increase 
BP and HR although sympathetic responses are variable (326-328). Impairments in 
cardiovascular response can indicate autonomic failure (e.g. in patients with orthostatic 
hypotension CPT responses are impaired due to sympathetic efferent failure (11)), whilst 
increased cardiovascular reactivity has prognostic implications. Increased cardiovascular 
reactivity can predict the development of hypertension (329-338) and may predict future 
cardiovascular events in selected populations (339) although not necessarily in the general 
population (329). Mental stress responses may also predict the development of cardiovascular 
disease. In a study of 756 men, systolic BP responses to mental stress at baseline were 
independently related to carotid intima-media thickness measured 7 years later (340). This has 
important implications as carotid intima-media thickness correlates to both systemic (341)
and coronary atherosclerosis (342), as well as increased incidence and prevalence of MI and 
stroke (343-345). There are a number of possible mechanisms that may contribute to an 
abnormal response. These include: sympathetic and/or parasympathetic dysfunction, impaired 
BRS, endothelial dysfunction (346), increased arterial stiffness, altered α- and/or β-adrenergic 
sensitivity, oxidative stress and HPA axis dysfunction. It is also possible that the immune 
system may have a modulatory effect on cardiovascular responses.
2.4.8 Cardiovascular reactivity and inflammation
Reciprocal links between inflammation and cardiovascular responses to stressors have 
been identified. Acute stressors induce an inflammatory response (347-354), while 
inflammation appears to have a modulatory effect on cardiovascular reactivity. The rise in 
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inflammatory cytokines (IL-6, IL-1β and TNF-α) in sepsis is thought to play a key role in the 
development of hypotension through vascular hyporeactivity although the precise 
mechanisms are not fully known. In animal models of sepsis IL-1β induces vascular 
hyporeactivity via NO-dependent (355) and NO-independent (355-358) mechanisms. Bucher 
et al. (2003) found that increased tissue concentrations of IL-1β and TNF-α were associated 
with down-regulation of α-1 receptor messenger ribonucleic acid (mRNA) concentrations 
within mesangial renal cells (357). The sepsis-induced down-regulation of α-1 receptors was 
unaffected by nitric oxide synthase (NOS) inhibition suggesting NO-independent 
mechanisms.  Liang et al. (2014) found that IL-1β reduced the vascular reactivity of rabbit 
superior mesenteric arteries to phenylephrine (an α-1 adrenergic receptor agonist) (358). 
Administration of IL-1 receptor antagonist partly reversed the LPS-induced decrease in 
vascular reactivity. IL-1β has also been shown to up-regulate the expression of NO receptors 
on vascular smooth muscles (355), and downregulate endothelin (359), vasopressin (356) and 
angiotensin (360). CRP also appears to be involved in the modulation of vascular reactivity
(361-363). In a study of 60 males with coronary artery disease, elevated concentrations of 
serum CRP were independently associated with impaired vascular responses to acetycholine
(362). Further evidence from Clapp et al. (2005) suggests that CRP appears to exert a direct 
effect on vascular function (361). In an in-vitro experiment human CRP applied to human 
internal mammary arteries induced hyporeactivity to phenylephrine. Taken together these 
studies suggest that in an acute sepsis paradigm, increased serum concentrations of 
inflammatory cytokines (IL-6, IL-1β, TNF-α) may promote vascular hyporeactivity through a 
number of mechanisms. However it remains to be known whether these effects would be seen 
in chronic inflammatory diseases such as RA. 
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In summary, cardiovascular reactivity has important prognostic implications and can 
predict the development of hypertension. Studies to date suggest there are reciprocal 
mechanistic links between cardiovascular reactivity and inflammation. The pattern of 
cardiovascular responses to CPT and mental stress in RA patients need to be established and 
relationships between inflammation and cardiovascular reactivity explored. A major aim of 
my thesis is to determine whether cardiovascular reactivity is impaired in patients with RA, 
and to determine whether there is a relationship between inflammation and cardiovascular 
responses to CPT and mental stress. To achieve this I have performed a case-control study
assessing cardiovascular reactivity to CPT and mental stress in RA patients with and without 
hypertension compared to healthy and hypertensive controls (Chapter 7). I have also assessed 
the effects of anti-TNF-α therapy on cardiovascular responses to mental stress in a case study 
(Chapter 8).
2.4.9 QTc interval and inflammation
The QT interval is the time from the onset of ventricular depolarisation (beginning of 
the Q wave on an electrocardiogram, ECG) to the end of ventricular repolarisation (end of the 
T wave). The QT interval varies with HR and hence several formulas have been developed to 
provide a HR-corrected QT measure (QTc) (e.g. Bazett’s formula = QT/√RR, Framingham 
Heart Study formula = QT + 0.154 x [1-RR]). The normal QTc interval is 390-450 ms in 
males and 390-460 ms in females (364). Prolongation of QTc predicts all-cause mortality in 
the general population (365, 366) and a number of conditions (367-373) including RA (35).
QTc interval prolongation increases the risk of developing arrhythmias including Torsade de 
Pointes which if left untreated may result in fatal ventricular arrhythmias (374). 
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QTc interval measurement is a simple, non-invasive and highly specific diagnostic 
tool for the detection of cardiac autonomic neuropathy (375). Studies have demonstrated 
associations between QT or QTc prolongation and autonomic dysfunction (376): reduced 
HRV (377); reduced parasympathetic activity (376, 378-380); and heightened sympathetic 
activity (381-383). These features of autonomic dysfunction are associated with increased 
cardiovascular and mortality risk (113, 206, 384, 385). QTc interval prolongation has been 
shown to be associated with inflammation in the general population (386, 387), in cardiac 
disease (388) and inflammatory arthritis (35, 377). Accumulating evidence from clinical 
studies suggests that inflammation may be driving QTc prolongation (35, 377, 386, 388-390)
although the precise mechanisms are not fully known. In one animal experiment, TNF-α was 
found to prolong the cardiomyocyte action potential by inhibiting the human ether-a-go-go 
related gene (HERG) potassium channel, currently known as KCNH2 (390). The disruption in 
HERG protein function (either congenital or acquired) is thought to be a primary mechanism 
for long QT syndrome (391, 392). Few studies have assessed cytokines or inflammatory 
markers in association with QTc interval. Yue et al. (2007) found that prolonged QTc interval 
was associated with increased CRP and fibrinogen in patients with coronary artery disease 
(388). However, the authors found no association between QTc interval and ICAM-1, E-
selectin or von Willebrand factor (a marker of endothelial function). Senel et al. (2011) found 
that 6 months treatment with infliximab (TNF-α inhibitor therapy) reduced QTc interval in 
patients with ankylosing spondylitis (389). In another study Vadetanib, a vascular endothelial 
growth factor receptor-2 (VEGFR-2) inhibitor was incidentally found to cause prolongation of 
QTc interval in patients treated for ovarian cancer (393). In one study of healthy young men 
prolonged QTc interval was associated with CRP (386). These studies suggest that 
inflammatory pathways may be implicated in the development of autonomic dysfunction and 
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prolongation of QTc interval, although further work is required to fully characterise which 
pathways are affected.
One major aim of my thesis is to determine whether serum concentrations of 
inflammatory cytokines can predict QTc interval prolongation in patients with RA. To 
achieve this I have performed an observational cohort study of RA patients to assess for 
associations between inflammatory cytokines and QTc interval (Chapter 9). 
2.4.10 Stress, the HPA axis and autonomic function
Heightened stress is a known cardiovascular risk factor and is associated with an 
increased mortality (394, 395). In response to stress both the HPA axis and the ANS are 
activated; however the precise interaction between these systems is not fully understood. At 
periods of stress, corticotrophin releasing hormone (CRH) is released from the hypothalamus 
and acts upon the pituitary to stimulate adrenocorticotrophin hormone (ACTH) which acts on 
the adrenal glands to stimulate the release of glucocorticoids. Cortisol, the principle 
glucocorticoid in humans has numerous effects: mobilisation of glucose, fatty acids and 
amino acids; anti-inflammatory; and reducing bone formation. Chronic cortisol excess, as 
occurs in Cushing’s syndrome, has deleterious consequences including hypertension (396), 
left ventricular hypertrophy, arteriosclerosis and up to four-fold increased mortality (397). 
However, the cardiovascular consequences of acute rises in cortisol are not fully understood. 
Acute glucocorticoids have been reported to have differential effects on BP, HR and 
sympathetic nerve activity (398-401). In healthy subjects, acute HCN has been shown to 
increase resting HR, without affecting BP or MSNA (398) whereas in other studies a fall in 
BP and MSNA were observed (399). In an early study, acute glucocorticoid treatment in 
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healthy subjects increased cardiac output and reduced peripheral vascular resistance, whilst 
maintaining arterial BP (402).  In one study of Pima Indians, cortisol inhibition with 
metapyrone had no effect on MSNA, however subsequent replacement with HCN reduced 
MSNA (400). In a study of obese and lean individuals, acute dexamethasone had no effect on 
HR, BP or MSNA (401). The variability in these studies may be explained by differences in 
glucocorticoid type, doses administered and time between administration and testing. 
Altered baroreflex function may partly explain the observed changes in HR and BP 
associated with rises in cortisol. BRS has been reported to fall (403, 404) during acute mental 
stress, an effect that may be due to the central actions of cortisol (403). Animal studies 
support the hypothesis that glucocorticoids can elicit centrally mediated alterations in BRS 
(405-407). In rats, administration of glucocorticoids into the RVLM (406) and NTS (407)
rapidly alters activity of baroreceptive neurons and depresses baroreflex control of HR. A 
cortisol-induced fall in BRS may be an important mechanism whereby acute stress increases 
cardiovascular risk (408). To the author’s knowledge only one study has assessed the effects 
of acute glucocorticoids on BRS (409). Cottin et al. (2015) showed that one-week of oral 
prednisolone increased HR but did not affect cBRS in healthy volunteers. However the 
investigators only assessed one parameter of spontaneous BRS, which may have been 
inadequate given that indices of BRS do not always correlate (410). It still remains to be 
established whether acute surges in cortisol can reduce BRS and hence provide a substrate for 
arrhythmogenesis and increased cardiovascular risk. 
A major aim of my thesis is to investigate the haemodynamic and autonomic 
consequences of acute surges in cortisol in healthy humans. A single-blinded cross-over 
randomized control study was performed to assess the acute effects of HCN bolus infusion on 
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haemodynamic and autonomic parameters including BRS, HRV and cardiovascular reactivity 
(Chapter 10).
2.4.11 Autonomic dysfunction in RA
In summary RA is a chronic inflammatory condition with increased cardiovascular 
mortality that is not fully explained by the presence of traditional risk factors. While it has 
been established that autonomic dysfunction is a pathogenic feature of cardiovascular disease 
and is associated with increased cardiovascular and mortality risk, whether autonomic
dysfunction is present in RA requires further study. Experimental data supports strong links 
between inflammation, autonomic dysfunction and cardiovascular disease. Inflammatory 
cytokines have been shown to increase sympathetic activity and reduce BRS and HRV in 
animals although whether this occurs in humans is not presently known. Furthermore 
accumulating evidence suggests that the ANS may have a modulatory effect on inflammatory 
responses. Given the potential for therapeutic interventions that target the ANS it is important 
to establish the presence and nature of ANS dysfunction in RA and relationships with 
inflammation. Additionally, biological agents that specifically target and block inflammatory 
cytokines (e.g. TNF-α and IL-6 inhibitors) have been shown to improve disease control in RA 
(411) as well as improve mortality (412) and cardiovascular risk (413). The effects of 
cytokine inhibition on ANS function need to be determined to provide important mechanistic 
insights into the pathophysiology of RA, improve our current understanding of autonomic-
immune interactions and to potentially pave the way for their use in cardiovascular 
conditions.
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2.5 Assessment of the ANS
There are various clinical and research techniques that can be used to assess ANS 
function (Table 2.6); each with their relative merits and limitations (89, 196, 323, 414-427).
Clinical cardiovascular reflex tests (CCTs, e.g. HR or BP responses to orthostasis) 
allow for simple, quick and non-invasive detection of autonomic dysfunction with the 
additional benefit of grading severity (415). These reflex tests however are unable to diagnose 
the cause of autonomic dysfunction and hence should be interpreted within the clinical 
context. 
HRV is a useful, non-invasive research tool that provides an indirect assessment of 
cardiac ANS function (196). Cyclical fluctuations in resting HR are caused by cardiac 
parasympathetic and sympathetic influences and modulated by baroreflex mechanisms. 
Statistically derived indices of HRV can indicate the contribution of these parasympathetic 
and sympathetic influences (422, 428), although the physiological interpretation of HRV 
metrics is an issue of debate (429). Despite guidelines for HRV assessment and interpretation 
(Task Force of the European Society and the North American Society of Pacing and 
Electrophysiology 1996) there is variability in methodology and a lack of normative data 
(196), which needs to be considered when comparing results between studies. 
Plasma or urinary catecholamines provide an estimate of global sympathetic activity 
but cannot delineate regional variations in sympathetic activity. Measured levels of 
catecholamines reflect metabolism and clearance, as well as resting sympathetic tone or 
release and are affected by numerous confounding factors (including medications, diurnal
variation and concomitant diseases) that can make interpretation difficult (323, 422). Other 
blood biomarkers of sympathetic activity (e.g. NPY) have similar limitations (417, 425). 
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Noradrenaline spillover studies, unlike plasma or urinary measurement, can assess organ-
specific sympathetic activity but are invasive, expensive and technically challenging (323, 
422). Pharmacological agents (e.g. adrenoreceptor antagonists or sympathomimetics) 
interrogate the ANS system to characterise the precise mechanisms of ANS dysfunction but 
are invasive and carry inherent risk (323).
Cardiovagal BRS assesses cardiovascular control mechanisms that are important for 
beat-to-beat regulation of BP. Baroreflex assessment involves simultaneous measurement of 
HR and BP while subjects are resting quietly (e.g. spontaneous methods), and during 
perturbations of BP either by non-invasive procedures (e.g. Valsalva’s manoeuvre, lower 
body negative pressure or neck suction pressure) or pharmacological agents (e.g. 
phenylephrine infusion) (323, 414). The relative strengths and weakness of spontaneous 
versus dynamic methods used for assessing baroreflex function have been debated (410, 430-
432) (Table 2.5). Dynamic assessments have the advantage of assessing baroreflex function
across a wide BP range, and allow a baroreflex function curve to be determined. The MOT 
(sequential infusion of SNP and PE one minute apart) is thought to be a “gold standard” 
assessment of baroreflex function (433). The technique was first developed by Smyth et al.
(1969)(434) and later improved by Ebert et al. (1992)(435) and Rudas et al. (1999)(433). The 
main limitations are the invasive nature, risk of complications during the infusions and a 
concern that the vasoactive drugs may exert unwanted effects on baroreflex structures that 
may influence results. Spontaneous baroreflex assessments provide measures of baroreflex 
function at rest. They have the advantage of being non-invasive and there is no risk of 
unwanted side effects of BP perturbation. In addition they allow baroreflex assessment over a 
24-hour period with the use of ambulatory ECG monitors to provide a “real world” measure 
of BRS (426). The Sequence method uses an automated computer model to identify 
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spontaneous fluctuations in BP and HR (426, 427) while the transfer function gain is 
calculated using cross-spectral analysis (436). The main limitations are that the Sequence 
method relies on the presence of sequences of 3 or more consecutive cardiac cycles with 
changes in BP (of at least 1 mmHg), which may vary from patient to patient, and that these 
indices do not always correlate with each other or with barororeflex determined using 
pharmacological measures (410, 430-432, 437).
The microneurography technique uses tungsten microelectrodes to make intra-neural 
recordings (typically from the peroneal nerve) of sympathetic outflow to the muscle (blood 
vessel vasoconstrictor impulses) or skin (323, 422). MSNA correlates well with cardiac 
sympathetic activity; is reproducible and well-tolerated in numerous disease populations; and 
allows quantification of resting activity and response to various stimuli. Its technically 
challenging nature is the main limitation of this procedure (422).
Cardiac sympathetic imaging is a minimally invasive research technique that allows 
for visualisation of various imaging agents (e.g. radio-labelled sympathomimetic amines) 
using single photon emission computed tomography (323, 422). This technique has been used 
in cardiovascular disease and demonstrated prognostic significance; however its use is limited 
due to expense and lack of availability (323). 
Other assessments such as pupillary light reflex responses (420) or sympathetic skin 
responses (418, 421) can provide an estimation of autonomic dysfunction; however their 
significance in cardiac autonomic function is not clear .
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Table 2.6 ANS assessments
Parameter Definition Abnormalities
PARASYMPATHETIC FUNCTION
Clinical Cardiovascular Tests
HR response to orthostasis (415) HR response to standing up unaided following a period of lying quietly 
on a couch. Normal response is an immediate increase in HR (around the 
15th beat) after standing followed by a nadir in HR (around the 30th beat). 
The 30:15 ratio (of the longest inter-beat (RR) interval around the 30th
beat to the shortest RR-interval around the 15th beat) forms part of the 
Ewing battery of cardiovascular tests.
30:15 ratio ≤1 indicate 
parasympathetic 
dysfunction
HR response to Valsalva’s 
manoeuvre (415)
HR response to straining against a closed glottis at a pressure of 
40mmHg for 15 seconds. The Valsalva ratio (of the longest RR- interval 
shortly after the manoeuvre followed by a rebound bradycardia after 
release) forms part of the Ewing’s battery of cardiovascular tests.
Valsalva ratio ≤1.1 
indicates parasympathetic 
dysfunction
HR variation to deep breathing HR variation to deep breathing at a rate of 6 breaths per minute. The HR difference ≤10 indicates 
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(415) mean differences between the maximum and minimum heart rates during 
each breathing cycle forms part of the Ewing’s battery of cardiovascular 
tests.
parasympathetic 
dysfunction
Strengths: Simple, bedside tests; non-invasive; inexpensive; normative values available; allows grading of severity when tests used in 
combination (415).
Weaknesses: Indirect measures of parasympathetic activity; some parameters also influenced by sympathetic and baroreflex activity (e.g. 
Valsalva’s manoeuvre)(414); relies on experienced practitioners; multiple factors can affect responses to Valsalva’s maneouvre (volume 
and rate of pre-strain breath, strain pressure, depth and duration, standing v supine) and deep breathing (rate and depth of breathing)(323); 
provides limited information about the mechanism of autonomic dysfunction; single tests are not reliable in detecting autonomic 
dysfunction as there is a poor correlation between the various indices (323).
HRV
rMSSD (196) Square root of the mean of the sum of the squares of difference between 
adjacent inter-beat (NN) intervals. Time domain estimate of short-term 
components of HRV.
Reduced levels indicate low 
HRV and parasympathetic 
dysfunctionNN50 (196) Number of pairs of adjacent NN intervals differing by more than 50 
milliseconds in the entire recording. Time domain measure.
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pNN50% (196) NN50 as a percentage of the total number of all NN intervals. Time 
domain measure.
SDNN (196) Standard deviation of all NN intervals. Estimate of overall HRV. Time 
domain measure.
SDANN (196) Standard deviation of the averages of NN intervals in all 5 minute 
segments of the entire recording. Time domain estimate of long-term 
components of HRV.
SDSD (196) Standard deviation of differences between adjacent NN intervals. Time 
domain measure.
HF power (196) High frequency power of pulse interval in the range 0.15-0.4 Hz. 
Frequency domain measure.
Reduced levels indicate 
reduced parasympathetic
activity
SD1, SD2 (423) Standard deviation of the Poincare plot (non linear technique). Estimate 
of short (SD1) and long-term (SD2) HRV.
Reduced levels indicate 
reduced HRV
Strengths: Non-invasive; inexpensive; reproducible; automated analysis; resting activity and responses to stimuli can be measured; Task 
Force guidelines (196) exist for the optimum utility of this technique; 24-hour ambulatory ECG monitoring provides a measure of 
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autonomic function in “real life” environment therefore a good clinical technique to monitor responses to interventions.
Weaknesses: Indirect measure of autonomic activity; no normative values exist; despite the availability of guidelines the variability in 
methodology makes it difficult to compare values between studies.
Heart rate turbulence (HRT) –
turbulence onset (424)
Early acceleration of the heart rate immediately following a ventricular 
premature beat is a result of parasympathetic withdrawal.
Impaired HRT represent 
reduced parasympathetic 
activity
Strengths: Non-invasive; inexpensive; automated analysis; 24-hour holter monitoring provides a measure of autonomic function in “real 
life” environment therefore a good clinical technique to monitor responses to interventions.
Weaknesses: Indirect measure of autonomic activity; no normative values exist; relies on the presence of premature ventricular beats 
(424).
Respiratory sinus arrhythmia
(89)
Rhythmical fluctuations in heart rate periods during inspiration (rise) and 
expiration (fall) represent parasympathetic activity.
Reduced represents reduced 
parasympathetic activity
Strengths: Non-invasive; inexpensive; selective index of vagal control of the heart (89).
Weaknesses: Results can be affected by rate and depth of breathing; provides a measure of resting autonomic activity only.
Pupillary Light Reflex
Constriction latency (420) Measure of the onset of pupillary constriction in response to light A delay can reflect 
58
stimulus. parasympathetic 
dysfunction
Maximum velocity latency (420) Measure of the maximum constriction velocity in response to light 
stimulus.
A reduced velocity 
indicates parasympathetic 
dysfunction
Strengths: Non-invasive; inexpensive; validated (420); normative values available; allows grading of severity.
Weaknesses: Provides limited information about the mechanism of autonomic dysfunction; can be confounded by impairments in ocular 
muscle function and retinopathy (420).
SYMPATHETIC FUNCTION
Clinical Cardiovascular Tests
Systolic BP response to 
orthostasis (415)
Systolic BP response to standing up unaided following a period of lying 
quietly on a couch. The postural drop in systolic BP forms part of the 
Ewing’s battery of cardiovascular tests.
Decrease in systolic BP≥20 
mmHg indicates 
sympathetic dysfunction
BP response to sustained 
handgrip (415)
BP response to sustained handgrip (30% of the maximum voluntary 
contraction using a handgrip dynamometer for up to 5 minutes). The 
Increase in diastolic BP≤10 
mmHg indicates 
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difference between diastolic BP before starting and just prior to releasing 
handgrip forms part of the Ewing’s battery of cardiovascular tests.
sympathetic dysfunction
BP response to CPT (323) BP response to immersion of hand in a container of ice water for 1-3 
minutes, which results in sympatho-excitation.
Diminished responses 
indicate sympathetic 
dysfunction, increased 
responses indicate 
exaggerated sympatho-
excitation
BP and HR response to mental 
stress (323)
BP and HR response to mental stress tasks (e.g. mental arithmetic or the 
Stroop colour-word naming test) which results in sympatho-excitation.
Strengths: Non-invasive; inexpensive; normative values available for responses to orthostasis and handgrip (415); allows grading of 
severity (415).
Weaknesses: Relies on experienced practitioners; difficult to standardise muscle effort during sustained handgrip; wide variability in inter-
subject responses to CPT and mental stress; provides limited information about the mechanism of autonomic dysfunction; single tests are 
not reliable in detecting autonomic dysfunction(415); CPT, mental stress and handgrip responses have a low sensitivity and specificity for 
detecting sympathetic dysfunction (323).
HRV
LF power (196) Low frequency power of pulse interval in the range 0.04-0.15 Hz. Increased levels indicate 
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Frequency domain measure indicating sympathetic activity (but also has 
a significant parasympathetic component).
heightened sympathetic 
activity
LF/HF ratio (196) Ratio of low frequency / high frequency power of pulse intervals. 
Frequency domain measure of sympatho-parasympathetic balance.
Increased levels indicate 
predominantly heightened 
sympathetic activity
Strengths: Non-invasive; cheap; reproducible; automated analysis; resting activity and responses to stimuli can be measured; Task Force 
guidelines(196) exist for the optimum utility of this technique; 24-hour ECG holter monitoring provides a measure of autonomic function 
in “real life” environment therefore a good clinical technique to monitor responses to interventions.
Weaknesses: Indirect measure of autonomic activity; no normative values exist; despite the availability of guidelines the variability in 
methodology makes it difficult to compare values between studies; LF power has contributions from the parasympathetic nervous system 
and hence not purely a measure of sympathetic activity (430).
Pre-ejection period (PEP) (416, 
419)
The interval from the onset of the Q wave (on an ECG) to the left 
ventricular ejection (detected using impedence cardiography). PEP is 
inversely related to myocardial contractility and can represent 
sympathetic influences on the heart.
Reduced PEP indicates 
increased sympathetic 
activity
Strengths: Non-invasive; provides a reliable measure of systolic time intervals; can provide a measure of resting activity and response to 
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stimuli (419).
Weaknesses: Indirect measure of cardiac autonomic influences; lack of standardised methodology; derived values of stroke volume and 
cardiac output are less reliable (416); PEP may be confounded by changes in preload or afterload (419).
Microneurography
MSNA (323, 422) Intra-neural recordings of MSNA using tungsten microelectrodes 
inserted percutaneous into a peripheral nerve (typically peroneal nerve) 
allow direct measurement of vasoconstrictor sympathetic outflow. 
Increased levels indicate 
sympathetic over-activity
Strengths: Direct and continuous measure of muscle sympathetic outflow; correlates with cardiac sympathetic activity; reproducible; well 
tolerated in healthy disease populations; can record for several hours at a time; allows quantification of resting activity as well as response 
to stimuli (422).
Weaknesses: Invasive; technically challenging procedure.
Catecholamines or Biomarkers of Sympathetic Activity
Catecholamines (323) Catecholamines such as adrenaline, noradrenaline and their metabolites 
detected in the plasma or urine (24-hour collection) may represent 
sympathetic activity. Confounding factors include medications, diurnal 
variations and concomitant diseases.
Increased levels may 
indicate sympathetic over-
activity
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Plasma NPY (425) Peripheral marker peptide released with noradrenaline following 
sympathetic activation.
Serum chromogranin A (417) Acidic, soluble proteins with widespread neuroendocrine distribution in 
secretory vesicles, co-released with catecholamines by exocytosis from 
vesicles in adrenal medulla and sympathetic nerve endings.
Strengths: Minimally invasive; inexpensive; plasma levels allow measurement of resting activity and response to stimuli.
Weaknesses: Difficult to measure; represents global sympathetic activity and cannot delineate regional variances; plasma levels of 
catecholamines reflect uptake, release and clearance whilst urinary levels are dependent on renal function; can be confounded by 
medications, diurnal variations and concomitant diseases (422).
Noradrenaline spillover (323, 
422)
Regional or organ-specific noradrenaline spillover measurements can 
characterise regional sympathetic activity. 
Increased spillover rates 
indicate regional 
sympathetic over-activity
Strengths: Allows direct measurement of organ specific sympathetic activity.
Weaknesses: Invasive; considerable costs; technically challenging (422).
Cardiac sympathetic imaging
(323, 422)
Imaging agents (e.g. radio-labelled sympathomimetic amines) can be 
detected using single photon emission computed tomography, providing 
Provides images showing 
areas of  sympathetic over-
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visual representation of sympathetic activity. Has been used to 
demonstrate cardiac sympathetic denervation in cardiovascular disease 
and has prognostic significance.
or under-activity
Strengths: Allows direct measurement of organ specific sympathetic activity; provides structural and functional assessment of the 
sympathetic nervous system; can provide quantification of organ specific noradrenergic uptake (422).
Weaknesses: Minimally invasive; considerable costs; limited availability; assessing sympathetic activity in the heart can be technically 
difficult (422).
Other Assessments
Pupillary light reflex maximal 
pupillary area in darkness (420)
Measure of maximal pupillary area in response to darkness. A reduced area indicates 
sympathetic dysfunction
Strengths: Non-invasive; inexpensive; validated; normative values available; allows grading of severity (420).
Weaknesses: Provides limited information about the mechanism of autonomic dysfunction; can be confounded by impairments in ocular 
muscle function and retinopathy (420).
Sympathetic skin responses (418, 
421)
Changes in skin electrical conductance in response to various stimuli 
(such as electrical, acoustic) represent sympathetic cholinergic function.
Absent responses indicates 
sympathetic dysfunction
Strengths: Non-invasive; simple; fast; inexpensive. 
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Weaknesses: Wide intra- and inter-subject variability in sympathetic skin responses due to confounding factors (e.g. ambient temperature, 
skin temperature, mental or emotional state, habituation with repeated stimuli); low sensitivity and specificity; poor correlation with other 
autonomic assessments (e.g. sudomotor dysfunction).(421)
BAROREFLEX SENSITIVITY
cBRS
Sequence technique (426, 427) Spontaneous assessment involving simultaneous recording of BP and 
RR-interval whilst the patient rests quietly. A computer is used to 
identify sequences of three or more consecutive beats characterised by a 
progressive increase or decrease in BP which results in lengthening or 
shortening of the RR interval (consecutively). Regression slope of 
Systolic BP and RR interval provides a measure of BRS
Reduced slope indicates 
impaired cBRS
Strengths: Non-invasive; simple; inexpensive; automated analysis; reliable; provides distinct measurements for rising and falling BPs
(206, 427).
Weaknesses: No normative values exist; relies on the presence of sequences; marked within subject variation in BRS (possibly due to 
haemodynamic, temporal and behavioural factors) (427).
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Pharmacological agents (323, 
414)
Phenylephrine (vasoconstrictor) causes increase in BP, which results in 
baroreflex-mediated slowing of the HR. Regression slope of SBP and RR 
interval or HR provides a measure of cBRS.
Strengths: Inexpensive; usually produces a high correlation between BP and RR interval suggesting it is a good indicator of arterial 
baroreflex gain (323).
Weaknesses: Invasive; no normative values exist; only assesses the response to rises in BP which may be reduced in subjects with low 
resting sympathetic outflow (typically young healthy individuals) (323).
Heart rate turbulence -  
turbulence slope (424, 438)
Rate of late deceleration (after early acceleration) of the HR immediately 
following a ventricular premature beat represents cBRS
Reduced turbulence slope 
indicates impaired cBRS
Strengths: Non-invasive; inexpensive; automated analysis; 24-hour ECG holter monitoring provides a measure of autonomic function in 
“real life” environment therefore a good clinical technique to monitor responses to interventions.
Weaknesses: Indirect measure of autonomic activity; no normative values exist; relies on the presence of premature ventricular beats
(424).
BP = blood pressure, BRS = baroreflex sensitivity, cBRS = cardiac baroreflex sensitivity, ECG = electrocardiogram, HR = heart rate, HRV = heart rate variability, 
MSNA = muscle sympathetic nerve activity, NN = inter-beat, NPY = neuropeptide-Y, PEP = pre-ejection period, RR interval = inter-beat interval, SBP = systolic 
blood pressure.
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CHAPTER 3 Systematic literature review
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3.1 Abstract
Objectives RA is a chronic inflammatory condition with increased all-cause and 
cardiovascular mortality. Accumulating evidence indicates that the immune and ANS are 
major contributors to the pathogenesis of cardiovascular disease. The first systematic 
literature review was performed to determine the prevalence and nature of ANS dysfunction
in RA and whether there a causal relationship between inflammation and ANS function exists. 
Methods Electronic databases (Medline, PubMed Central and Cochrane Library) were 
searched for studies of RA patients where autonomic function was assessed. 
Results Forty studies in total were included. ANS function was assessed by CCTs (n=18), 
HRV (n=15), catecholamines (n=5), biomarkers of sympathetic activity (n=5), sympathetic 
skin responses (n=5), cBRS (n=2) and pupillary light reflexes (n=2). 9 small studies reported 
a ~60% (median, range 20-86%) prevalence of ANS dysfunction (defined by abnormal CCTs)
in RA. 73% of studies (n=27/37) reported at least one abnormality in ANS function: 
parasympathetic dysfunction (n=20/26, 77%), sympathetic dysfunction (n=16/30, 53%) or 
reduced cBRS (n=1/2, 50%). An association between increased inflammation and ANS 
dysfunction was found (n=7/19, 37%) although causal relationships could not be elucidated 
from the studies available to date.  
Conclusions ANS dysfunction is prevalent in ~60% of RA patients. The main pattern of 
dysfunction is impairment of cardiovascular reflexes and altered HRV indicative of reduced 
cardiac parasympathetic (strong evidence) and elevated cardiac sympathetic activity (limited 
evidence). The literature to date is underpowered to determine causal relationships between 
inflammation and ANS dysfunction in RA.
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3.2 Introduction
RA is a chronic inflammatory condition predominantly affecting the synovial joints 
but leading to extra-articular manifestations. The increased cardiovascular mortality in RA 
patients (by up to 50%) (20-23) is not fully explained by the presence of traditional risk 
factors and remains an important research focus (21, 24-29, 31, 33, 41).
The ANS plays a critical role in the normal regulation of cardiovascular disease 
through its effects on the heart, peripheral vasculature and kidneys (Figure 3.1) (385). The 
ANS is broadly comprised of the sympathetic and parasympathetic branches, which work 
independently, or in counter-balance to ensure homeostasis is maintained. Accumulating 
evidence indicates that altered ANS function contributes to the pathogenesis of cardiovascular 
disease (51, 439) and is an important predictor of cardiovascular mortality (113, 206, 384, 
385). Indeed, recent animal studies have demonstrated mechanistic and reciprocating links 
between inflammation and ANS dysfunction (52, 153, 273, 314, 440-442). Elevations in 
circulating pro-inflammatory cytokines increase sympathetic activity (52, 153), reduce cBRS
(314) and reduce HRV derived indices of cardiac parasympathetic activity (Figure 3.1) (273); 
these are all features of ANS dysfunction associated with cardiovascular disease and 
increased mortality in humans (113, 206, 384, 385). Therefore, determining ANS function in 
RA may provide prognostic benefit as well as improve understanding of underlying 
pathological mechanisms, and hence new improved therapeutic strategies.
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Figure 3.1 Simplified schematic showing ANS regulation and the effects of inflammatory cytokines on the ANS.
A. Nerve signals from the brain stem are relayed to various organs in the ANS. Parasympathetic activation results in slowing of the HR, whereas sympathetic 
activation causes increased ventricular contraction, peripheral and renal vasoconstriction, activation of the renin-angiotensin-aldosterone system, increased sodium 
retention (kidneys), adrenaline and noradrenaline release (adrenal glands) and increased inflammation (leukocyte activation and increased cytokine production in the 
spleen). Central and peripheral feedback mechanisms are in place (e.g. arterial and cardiopulmonary baroreceptors, chemoreceptors) to ensure homeostasis is 
maintained. B. Experimental studies have shown that pro-inflammatory cytokines (e.g. IL1-β, IL-6 and TNF-α) attenuate (-) cardiovagal baroreflex sensitivity and 
heart rate variability, as well as heighten (+) sympathetic activity. ANS = autonomic nervous system, HR = heart rate, IL = interleukin, TNF = tumour necrosis factor.
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3.3 Aims and hypothesis
Central hypothesis: In patients with RA, elevated concentrations of circulating inflammatory 
cytokines are associated with autonomic dysregulation (heightened sympathetic activity, 
reduced parasympathetic activity, reduced BRS and impaired cardiovascular responses to 
stressors).
Aim: To begin to test this, the first systematic literature review on ANS function in RA was 
performed to: 
i) investigate whether there is sufficient evidence to determine if patients with 
RA have altered ANS function; 
ii) determine the prevalence and nature of any autonomic dysregulation in 
patients with RA; 
iii) elucidate whether there is a causal relationship between systemic 
inflammation (e.g. clinical markers of disease activity, elevated 
concentrations of specific circulating pro-inflammatory molecules) and ANS 
dysfunction in RA.
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3.4 Methods
3.4.1 Search criteria
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (443), electronic databases (Medline, PubMed Central and Cochrane 
Library) were searched to identify articles between January 1974 and June 2013, in English. 
The search term “rheumatoid arthritis” was used in combination with each of the following 
terms (incorporating common assessments of ANS function, Table 2.4): “autonomic”, 
“sympathetic”, “parasympathetic”, “vagal”, “heart rate variability”, “baroreflex”, 
“catecholamine”, “epinephrine”, “norepinephrine”, “adrenaline”, “acetylcholine”, 
“noradrenaline”, “cardiovascular battery”, “Ewing”, “Valsalva”, “hand grip”,  “cold pressor”, 
“orthostasis” and “tilt”.
6350 citations were identified and the summaries and/or abstracts were screened for 
relevance; clinical studies of adults with RA where at least one aspect of ANS function was 
assessed were deemed relevant. Following removal of duplicate and irrelevant articles 44 full 
articles were accessed. Irrelevant articles included those that were non-original research (e.g. 
review articles, editorials, letters etc.), non-RA and animal studies. The following eligibility 
criteria were applied: articles written in the English language; involving adults with RA; at 
least one known parameter of ANS function assessed and reported; and an attempt to assess 
the association between inflammation and ANS function either by inclusion of a non-RA 
control group, by statistical analysis within a cohort of RA patients, or by intervention with 
anti-inflammatory therapy. Four articles were excluded as they failed to meet the eligibility 
criteria (association between inflammation and ANS function not assessed and did not include 
a non-RA control group). In total 40 articles were included in the review (Figure 3.2).
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3.4.2 Quality assessment
Data extraction was performed and a quality assessment was made for each study by 
adapting a known quality assessment tool (Appendix 1) (444). The following indices were 
assessed: study design, inclusion/exclusion criteria, disease characteristics, standardised 
testing conditions (e.g. time of test, subject position), standardised methodology for 
autonomic assessment (e.g. adhering to published guidelines), quality of autonomic 
assessment tool (e.g. more than one technique used), appropriate sample size (e.g. use of 
power calculations to determine sample size), appropriate statistical tests (e.g. adjustment 
made for group differences), and associations between ANS function and inflammation tested. 
Each index was graded between 0-2, and the total points added to give a final score between 
0-18. A percentage was calculated to give a Quality Index Score (QIS). The quality 
assessments were performed by two investigators (Ahmed Adlan and James Fisher) and 
disagreements were discussed until a consensus was reached. Each study was placed into one 
(or more) category representing parasympathetic function, sympathetic function and cBRS 
and scored as either normal or abnormal. At least one abnormal parameter of autonomic 
function was required to qualify as an abnormal study (i.e. no studies could be classified as 
both normal and abnormal in a single domain). Furthermore each study was classified 
according to the type of autonomic function test performed and placed into one category if 
comparisons were made between RA patients and controls: RA worse than control, no 
difference or RA better than control. Due to the large heterogeneity in the patient 
characteristics, tools of ANS assessment employed and parameters reported, no meta-analysis 
was performed.
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Figure 3.2 Flow diagram showing literature search
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3.5 Results
Forty articles were included in the review (445-484). Thirty-six studies were case-
control, cross-sectional, observational (Appendix 2), of which 3 had an interventional arm
(Appendix 3); 3 were cohort studies, of which 1 was cross-sectional; and 1 study utilized a 
randomized, placebo-controlled, single-blind, cross-over design (Appendix 3).
In all but six studies the diagnosis of RA was based on the 1987 revised criteria of the 
American Rheumatism Association (8). Approximately 80 % of patients studied were female 
with a mean age of ~50 years (estimated calculation from reported values). Mean reported 
disease duration (from 26 studies) was ~9 years; 4 studies included RA patients diagnosed <2 
years. Twenty three (of forty) studies reported RA medications which included disease 
modified anti-rheumatic drugs of which methotrexate was the most common. Other 
medications and co-morbidities were only reported in a few studies; but most studies (30 of 
40) excluded patients with conditions or medications affecting the ANS (e.g. diabetes 
mellitus, neurological disease, hypertension, heart failure, vaso-active drugs).
3.5.1 Assessment of ANS Function
Eighteen studies utilized CCTs of ANS function (447, 449, 450, 454, 456, 458, 465, 
470-479, 481); 15 studies assessed HRV (445-447, 451, 453, 455, 457, 461, 464, 467, 469, 
473, 482-484) of which 5 assessed HRV in combination with clinical cardiovascular 
reactivity (447, 464, 473, 482, 483); and 16 studies used other methods of assessing ANS 
function including catecholamines (n=5) (462, 463, 480, 482, 483), biomarkers (n=5) (452, 
459, 460, 482, 483), sympathetic skin responses (SSR)(n=5) (456, 458, 465, 466, 478), cBRS
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(n=2)(446, 447) and pupillary light reflexes (PLR)(n=2) (448, 476). Studies assessed one 
(n=30), two (n=8) or three (n=2) parameters of ANS function.
Assessments of ANS function undertaken in RA patients can be broadly categorised 
into parasympathetic activity (414), sympathetic activity (422) and cBRS (323). Resting 
activity was assessed in addition to the response to stimuli. For the purposes of this review 
ANS dysfunction is defined as either: abnormality in CCTs; impaired HRV and/or disrupted 
sympatho-vagal balance; reduced cBRS; altered concentrations of catecholamines or 
biomarkers of sympathetic activity; impairment in SSR; impairment in PLR; abnormalities in 
the above parameters occurring either at rest or following various stimuli.
3.5.2 Prevalence of ANS dysfunction
Seventy three percent of studies (n=27/37) reported at least one abnormality in ANS 
function in RA patients. Nine studies reported the prevalence of ANS dysfunction, determined 
from abnormal CCTs, in RA patients with varying results (median prevalence 60 %, range 33-
86 %) (Appendix 4) (447, 450, 454, 456, 458, 473, 476, 477, 479). The wide range in 
prevalence is reflective of variations in criteria for ANS dysfunction, numbers of patients 
included in studies (n=10-50), and assessments of ANS function performed. CCTs, unlike 
many others assessments of ANS function have validated reference values and established 
criteria for detection of abnormalities and classification of the severity of dysfunction (mild, 
moderate or severe) (415).
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3.5.3 Parasympathetic dysfunction
Parasympathetic activity in RA patients was assessed by 25 case-control, cross-
sectional observational studies and 1 cohort study using: CCTs (n=14) with HR responses to 
deep breathing (447, 449, 454, 458, 470-479) and/or orthostasis (447, 449, 454, 470-477, 479)
and/or Valsalva’s manoeuvre) (447, 449, 454, 472, 474-477, 479); HRV (n=13) with time 
domain (445, 455, 457, 464, 467, 473, 484) and/or frequency domain parameters (447, 451, 
455, 457, 464, 482-484), RSA (453) or heart rate turbulence (HRT) (446); and the PLR (n=2)
(448, 476) with constriction and/or maximum velocity latency (Appendix 2, 3).
Of the 26 cross-sectional studies assessing parasympathetic activity, approximately 77 
% reported parasympathetic dysfunction (Table 3.1). The main pattern of parasympathetic 
dysfunction included impaired clinical cardiovascular reflexes (85 %) and abnormal HRV 
indices (62 %) (Table 3.2). When studies of low quality were excluded (QIS less than 50 %) 
most studies using CCTs found parasympathetic dysfunction (7 of 8), which was supported by 
abnormal HRV in most studies (7 of 12). Most of the studies that failed to demonstrate an 
abnormality in parasympathetic function assessed females only (n=5/7) who were relatively 
young (mean age range 31-56 years); a demographic known to have elevated HRV indices of 
parasympathetic activity possibly reflecting the effects of oestrogen (485-488).
For example, Piha et al. (474) found a higher resting HR in 43 female RA patients 
(mean age 49 years) compared to 69 female controls (mean age 43 years) which may suggest 
reduced resting parasympathetic activity in the RA group. They reported impaired HR 
(parasympathetic) responses to orthostasis and Valsalva’s manoeuvre in RA patients, which 
was statistically non-significant when age and resting HR were used as covariates. Although 
elevations in resting HR may be a result of autonomic dysfunction other factors are known to 
contribute (e.g. anaemia, infection, anxiety, medications).
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Table 3.1 Number of studies with abnormal ANS function in RA patients from cross-
sectional studies
Abnormal studies Quality Index Score %; range
Number/Total % Normal Abnormal Total
Parasympathetic 20/26 77 65%; 44-78 65%; 33-89 65%; 33-89
Sympathetic 16/30 53 59%; 28-89 66%; 44-89 63%; 28-89
Cardiac BRS 1/2 50 56% 89% 73%; 56-89
Avsar et al. (446) reported no difference in HRT in 26 RA patients (18 females, mean 
age 56 years) compared to 26 age- and gender-matched healthy controls. HRT assesses the 
autonomic response to ventricular premature complexes (VPC) and hence there is a selection 
bias inherent to this technique; the ANS function of subjects without VPCs cannot be 
assessed. Secondly, no power calculation was reported and larger studies (>100 patients) were 
required to predict cardiovascular risk using HRT (424).
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Table 3.2 Abnormal ANS tests in RA patients from observational studies
PARASYMPATHETIC RA worse than 
control
No difference RA better than 
control
Clinical Cardiovascular Tests, N (refs)
HR responses to deep 
breathing
8 5 0
(447, 458, 470, 471, 
473, 475, 477, 478)
(449, 454, 472, 474, 
479)
HR responses to 
orthostasis
7 4 0
(447, 454, 470, 473-
475, 477)
(449, 471, 472, 479)
HR responses to 
Valsalva’s Manoeuvre
5 4 0
(447, 474, 475, 477, 
479)
(449, 454, 471, 473)
Total N (QIS %; range) 11 (63; 39-89) 2 (61; 44-78) 0 (NA)
Pupillary light reflex, N (refs)
Maximum constriction 
velocity
1 0 0
(448)
Total N (QIS %; range) 1 (61) 0 (NA) 0 (NA)
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PARASYMPATHETIC RA worse than 
control
No difference RA better than 
control
HRV, N (refs)
Frequency domain 5 4 * 0
(451, 455, 457, 464, 
473)
(447, 482-484)
Time domain 7 0 0
(445, 455, 457, 464, 
467, 473, 484)
Heart rate turbulence 0 1 0
(446)
Respiratory sinus 
arrhythmia
0 1 0
(453)
Total N (QIS %; range) 8 (70; 33-89) 5 (71; 56-89) 0 (NA)
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SYMPATHETIC RA worse than 
control
No difference RA better than 
control
Clinical Cardiovascular Tests N (refs)
BP responses to 
orthostasis
5 4 0
(447, 450, 470, 473, 
477)
(449, 471, 472, 475)
BP responses to hand 
grip
4 0 0
(447, 450, 475, 477)
BP responses to cold 
pressor test
1 0 0
(450)
BP responses to mental 
stress
2 1 0
(456, 465) (481)
Total N (QIS %; range) 8 (67; 44-89) 4 (61; 44-78) 0 (NA)
Catecholamines
Plasma 2 1 1
(463, 482) (483) (463) †
Urinary 0 1 0
(462)
Total N (QIS %; range) 2 (64; 61-67) 2 (61; 44-78) 1 † (63)
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SYMPATHETIC RA worse than 
control
No difference RA better than 
control
Biomarkers
NPY 2 2 0
(460, 468) (459, 482)
Chromogranin 1 0 0
(452)
Total N (QIS %; range) 3 (61; 50-67) 2 (44; 28-61) 0 (NA)
HRV
Frequency domain 2 7 0
(447, 464) (451, 455, 457, 473, 
482-484)
Pre-ejection period 1 0 0
(453)
Total N (QIS %; range) 3 (80;72-89) 7 (71; 61-89) 0 (NA)
Skin sympathetic responses
2
(456, 465)
3
(458, 466, 478)
Total N (QIS %; range) 2 (58; 50-67) 3 (46; 39-56) 0
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BRS RA worse than 
control
No difference RA better than 
control
N (refs) N (refs) N (refs)
Cardiac BRS
Spontaneous 1 0 0
(447)
Heart rate turbulence 0 1 0
(446)
Total N (QIS %; range) 1 (89) 1 (56) 0 (NA)
* This study (484) is included in two categories as the authors reported abnormal time domain HRV parameters 
(worse than control) but normal frequency domain (no difference).
** This study (463) is included in two categories as the authors reported lower resting sympathetic activity 
(better than control) but with an impaired response (worse than control).
BP = blood pressure, BRS = baroreflex sensitivity, HR = heart rate, HRV = heart rate variability, NPY = 
neuropeptide-Y, QIS = quality index score, RA = rheumatoid arthritis.
3.5.4 Sympathetic dysfunction
Sympathetic activity in RA patients was assessed by 29 case-control, cross-sectional 
observational studies and 1 cohort study using CCTs (n=13) with BP responses to orthostasis 
(447, 449, 450, 470-473, 475-477) and/or handgrip (447, 450, 475, 477) and/or CPT (450)
and/or mental stress (456, 465, 481); HRV (n=10) with frequency domain parameters (447, 
451, 455, 457, 464, 473, 482-484), pre-ejection period (PEP) (453); biomarkers of 
sympathetic activity (n=5) with plasma NPY (459, 460, 468, 482), serum chromogranin
(452); SSR (n=5) (456, 458, 465, 466, 478); catecholamines (n=4) with plasma (463, 482, 
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483) or urinary (462) adrenaline, noradrenaline; PLR (n=1) with maximal area in darkness
(476).
Of the 30 studies assessing sympathetic activity over half reported sympathetic 
dysfunction (Table 3.3). The main pattern of sympathetic dysfunction included impaired 
clinical cardiovascular reflexes (67 %), whilst HRV parameters of sympathetic activity were 
normal in the majority of studies (70 %) (Table 3.2). When studies of low quality were 
excluded (QIS less than 50%) most studies using CCTs found sympathetic dysfunction (6 of 
9) however this was not supported by abnormal HRV in the majority of studies (2 of 10).
The majority of studies that failed to demonstrate sympathetic dysfunction in RA 
patients were of predominantly pre-menopausal women, which as discussed previously may 
cause confounding results. Other possible explanations for negative findings include: failure 
to control for medications that are known to have an effect on the ANS (481); underpowered 
studies (459, 471); selection bias when matching controls to RA patients (471); and 
limitations inherent to ANS assessments for example lack of standardised testing conditions. 
3.5.5 BRS
Of the two cross-sectional, case-control, observational studies (446, 447) assessing 
cBRS one reported abnormality in RA compared to controls (447) (Tables 3.1, 3.2). Aydemir 
et al. (447) reported a lower resting cBRS (sequence technique) in 36 RA patients (30 
females, mean age 49 years) compared to 40 age and gender matched controls (447). In the 
other study (previously discussed in section 4.5.3) Avsar et al. found no difference in HRT 
(446).
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3.5.6 Time course of ANS dysfunction
Three studies assessed patients with early RA (duration<2years) (453, 456, 459); and 
in 2 studies sympathetic dysfunction was reported (increased resting sympathetic activity and 
impaired sympathetic responses to mental stress) (453, 456). Dekkers et al. (453) found no 
difference in parasympathetic activity (respiratory sinus arrhythmia) but increased 
sympathetic activity (PEP) in 25 RA patients (19 females, mean age 55 years) compared to 
well matched healthy controls. RA patients included in this study had a low ESR (mean 15 
mm/1st hour) and disease duration <2 years. These few studies suggest that ANS dysfunction 
in RA may not necessarily be a consequence of long-term disease and inflammatory burden, 
and that heightened sympathetic activity may be an early phenomenon that precedes 
parasympathetic dysfunction.
3.5.7 Inflammation and ANS dysfunction
Observational studies
Twenty four studies reported at least one marker of disease severity including ESR 
(n=19; range 14-61 mm/1st hour) (445, 447, 449, 453, 455, 456, 459, 462, 463, 467, 469, 471, 
473, 474, 476-478, 480, 481), CRP (n=12; 5-380 mg/L) (447, 449, 455, 457, 463, 464, 467, 
469, 476, 478, 481, 483) and DAS/DAS28 (n=8; 6 moderate and 2 severe) (445, 447, 451, 
457, 461, 464, 481, 483). ANS dysfunction was reported more frequently in those studies 
with higher CRP values (5 v 2; CRP≥14.5 v <14.5 mg/L) and mainly comprised of 
parasympathetic dysfunction: reduced HRV indices of cardiac parasympathetic control (n=3) 
(455, 457, 467); and impaired HR responses to deep breathing, orthostasis and Valsalva’s 
manoeuvre (n=1) (476). Approximately one third of studies (n=7/19) reported an association 
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between ANS function and inflammation: CCTs (n=2/9); HRV (n=3/5); biomarkers of 
sympathetic activity (n=1/2); and PLR (n=1/1) (Table 3.3). When low quality studies were 
excluded (QIS less than 50 %) only 5 of 14 studies found an association. In 7 more recent 
studies (≥1993) using CCTs (447, 456, 471, 474, 475, 477, 479), no significant correlation 
was found in RA patients between ANS function and any of the following: ESR, CRP, the 
Ritchie articular index (assessment of joint tenderness and swelling), the presence of an 
inflammatory syndrome (not defined), DAS28 (an updated version of DAS with clinical 
assessment of 28 joints), disease duration, presence of rheumatoid factor or articular damage 
on radiograph.
Studies demonstrating associations between inflammation and parasympathetic 
function are conflicting. Yadav et al. (484) studied 45 RA patients (41 females, mean age 41 
years) and found a significant positive correlation between DAS28 and a parasympathetic 
index of HRV. Anichkov et al. (445) in contrast found an inverse correlation between 24-hour 
HRV parameters of parasympathetic function and markers of disease severity and 
inflammation (number of swollen joints, Ritchie articular index, DAS). Barendregt et al. (448)
found that ESR levels were higher in the group with parasympathetic dysfunction (abnormal 
PLR in the RA group with ocular dryness) compared to those without (although significance 
values were not reported). Two studies found no significant correlation between 
catecholamines and inflammatory indices. Vlcek et al. (483) found no significant correlation 
between plasma catecholamines and inflammation (CRP, DAS28-CRP). Van Middendorp et 
al. (480) found no correlation between 24-hour urinary noradrenaline excretion and markers 
of inflammation (ESR or IL-6) in a cohort of 60 RA patients (38 females, mean age 59 years).
In contrast, Dekkers et al. (453) (described earlier) reported that higher sympathetic activity 
(PEP) was associated with higher disease activity (ESR and Thompson joint score). In another
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Table 3.3 Associations between autonomic function and inflammation in RA
Outcome
Association found No association
Clinical cardiovascular tests (n=9) 2 (42; 39-44) 7 (73; 56-89)
Heart rate variability (n=5) 3 (77; 72-88) 2 (72; 56-89)
Catecholamines (n=2) 2 (67; 56-78)
Biomarkers (n=2) 1 (67) 1 (67)
Pupillary light reflex (n=1) 1 (61)
TOTAL 7 (64; 39-88) 12 (71 56-89)
Values are number of studies (% quality index score; range).
study, Igari et al. (462) found that 24-hour urinary adrenaline and noradrenaline significantly 
decreased 2 weeks following synovectomy in 6 RA patients. Although the investigators did 
not assess inflammatory markers following synovectomy, it may be postulated that local joint 
inflammation could have been reduced following synovectomy and hence possibly removing 
the stimulus for sympathetic activation.
Interventional studies
Two studies investigated HRV in RA patients receiving TNF-α inhibitor therapy (461, 
469). Holman et al. (461) studied 33 patients (25 with RA, 8 with psoriatic arthritis) before 
treatment with TNF-α inhibitor therapy and assessed clinical response to treatment (using 
ACR criteria ACR20/50/70 and DAS28) at various time points up to one year. They found 
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that low HRV indices, reduced parasympathetic and increased sympathetic activity were 
predictors of poor response to TNF-α inhibitor therapy. However the study may have been 
underpowered as they found no direct correlation between baseline autonomic function and 
change in DAS28 score following TNF-α inhibitor therapy. Despite limitations of the study 
(one third of patients discontinued therapy by one year; use and dosage of other medications 
were not controlled; small numbers of RA patients) these results suggest that HRV and 
sympatho-parasympathetic balance may play an important role in disease activity. In another 
study Lazzerini et al. tested the acute effects of infliximab (TNF-α inhibitor) on HRV and 
arrhythmia risk in RA patients (461, 469). They found that TNF-α inhibition acutely reduced 
HRV, and that patients who developed new-onset arrhythmia (infliximab-induced) tended to 
have lower HRV and a higher CRP. While the acute effects reported may relate to a direct 
drug effect as opposed to cytokine inhibition, this study suggests an increased arrhythmia risk 
in RA patients with lower resting parasympathetic activity and increased inflammation.
Two studies assessed plasma NPY levels before and after TNF-α inhibitor therapy. In 
a study of 16 female RA patients Kopec-Medrek et al. (468) found that infliximab 
significantly reduced inflammation (CRP, ESR) but did not reduce sympathetic activity 
(plasma NPY). In fact, plasma NPY concentrations rose to a peak after 6 infusions of 
infliximab and fell to baseline levels 8 weeks after the ninth (final) infusion. The authors did 
however report a positive correlation between plasma NPY concentrations and CRP (Kendall 
tau coefficient=0.506, P<0.006) and DAS28 (Kendall tau coefficient=0.393, P<0.033) at 
baseline, indicating that plasma NPY may reflect inflammatory status. Harle et al. (460) found 
that in a cohort of RA patients, adalimumab (TNF-α inhibitor) had no effect on serum NPY 
levels despite good clinical response. They reported higher plasma NPY concentrations in RA 
patients with previous prednisolone use only, indicating a possible HPA axis interaction.
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3.6 Discussion
3.6.1 Epidemiology of ANS dysfunction in RA
The results of this systematic literature review indicate that ANS dysfunction is 
prevalent in ~60 % (33-86 %) of RA patients as determined from observational studies of 
small sample size (10-50 patients). Stronger evidence (from large prospective cohort studies) 
is required to confidently determine the true prevalence of autonomic dysfunction in RA. 
HRV is probably the most feasible ANS assessment in such a large population. Few studies 
have assessed patients with early RA (duration<2years) but have shown that ANS dysfunction 
occurs early in RA and is not necessarily an effect of long-term disease and inflammatory 
burden. More studies of RA patients with early disease are clearly needed and if possible 
ANS assessment preceding the onset of RA, to determine whether altered ANS function 
predisposes to developing RA.
3.6.2 Pattern of ANS dysfunction in RA
Studies using CCTs in RA have shown reduced resting parasympathetic activity and 
impairment in both sympathetic and parasympathetic reflex responses. Strong evidence from 
good quality HRV data supports these findings with the majority demonstrating low HRV 
reflecting reduced resting parasympathetic activity. In addition there is limited evidence for 
elevated resting sympathetic activity with the majority of good quality HRV data failing to 
detect abnormal sympathetic function in RA. Studies employing other methods of ANS 
assessment have shown conflicting results, which may reflect their inherent limitations. There 
is a lack of evidence from the literature to date to determine causal relationships between 
systemic inflammation and autonomic dysfunction. The available literature is too small to be 
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clear whether the lack of evidence represents a lack of relationship or simply inadequate 
power. Only two studies assessed the effects of anti-inflammatory therapy on ANS function 
and failed to demonstrate an effect. However, their results suggest that plasma NPY may not 
be a reliable method of assessing sympathetic activity particularly as the effects of steroids on 
NPY are not known. Further interventional studies are needed to elucidate causation. The 
most feasible and ethical study design would be to assess ANS function in RA patients prior 
to and after anti-inflammatory therapy. This could be achieved for example with HRV 
assessments using a 24-hour ECG holter. Although HRV is not routinely used in clinical 
practice one study suggested a possible clinical role. Holman et al. (461) found that low HRV 
in RA patients predicted a poor response to TNF-α inhibitor therapy indicating a possible 
benefit in determining ANS status prior to initiation of biologic agents. What remains 
unknown however is whether therapy to improve HRV in these patients would improve their 
response to anti-inflammatory agents.
3.6.3 Associations between ANS and inflammation
Less than half the studies demonstrated an association between increased 
inflammation and ANS dysfunction (mainly CCTs and HRV), consistent with the results of 
recent animal studies (52, 153, 314). The lack of associations in the remaining studies may be 
simply due to a lack of statistical power; the majority of studies in our review did not report a 
power calculation. Another possible explanation may be the relatively low inflammatory 
status of patients tested. CRP, ESR and DAS (reported in less than two thirds of studies) were 
only modestly elevated although it is unclear whether cumulative inflammatory burden can be 
determined from assessment at a single time point. Another explanation for a lack of 
association between inflammation and ANS function in the studies included in our review 
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may be the subtle nature of autonomic dysfunction present in RA or simply the inappropriate 
choice of immune markers assessed.
3.6.4 Limitations
The main limitations of this review are the types and number of ANS tests employed 
in RA patients, with the majority of studies making only one assessment of ANS function. 
ANS function is complex and multi-faceted and hence a comprehensive assessment is 
required in order to fully categorise the presence of dysfunction. Future studies should include 
a greater variety of tests including arterial baroreflex assessment, with attempts to measure 
resting ANS function and response to stimuli. Larger sample sizes are required to confirm the 
prevalence of ANS in RA, and in order to ensure that statistical power is achieved. 
3.6.5 Future directions
Future studies in RA should aim to characterise the inflammatory profile of patients 
studied so that causal links between inflammation and ANS dysfunction can be determined. 
The effects of RA medications on ANS function is not fully known and is a difficult 
confounding factor to control for, especially as RA patients often require medications to 
induce and maintain remission of disease. One study showed that infliximab infusion (TNF-α
inhibitor therapy) caused an acute reduction in HRV and sympathetic activity compared to a 
placebo. The effects of other RA medications on the ANS tests employed to date are unknown 
although studies of healthy subjects may be the most ethically acceptable way to investigate 
this.
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Another difficulty is discerning between the effects of RA and concomitant co-
morbidities or medications on ANS function. Although many studies excluded RA patients 
with conditions or medications affecting the ANS system, cardiovascular disease remains 
under-diagnosed in this population (25, 27, 29). Cardiac imaging (e.g. echocardiography or 
magnetic resonance imaging) to identify such patients and the possible inclusion of a 
cardiovascular disease control group may help tackle this problem.
3.7 Conclusion
In conclusion, the evidence to date supports that ANS dysfunction is a feature of RA,
although not universally found in all patients. The profile of ANS dysfunction found in RA 
patients (low HRV, reduced parasympathetic activity and elevated sympathetic activity) is 
associated with increased cardiovascular and mortality risk and may help to explain the 
increased risk in RA patients. Furthermore, this pattern of ANS dysfunction supports the 
findings from animal studies and may be a consequence of high inflammatory burden.
Although associations between inflammation and ANS dysfunction are present in RA 
patients, the available literature is too small and underpowered to be clear about causality. 
Further studies are required to: determine the true prevalence of ANS dysfunction in RA, 
characterise RA patients who have altered ANS function; determine the prognostic role of 
ANS assessments in predicting cardiovascular and mortality risk; assess the effects of 
biologic agents on ANS function; consider the role of therapeutic strategies targeting the ANS 
in RA patients to help control disease activity or improve response to biologic agents.
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CHAPTER 4 Methodology
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4.1 Subjects
Patients with a diagnosis of RA based on the 1987 ACR criteria (8) were recruited
from the rheumatology clinics at Russells Hall Hospital, Dudley, UK and Sandwell General 
Hospital, West Bromwich, UK. Exclusion criteria included: age <18 or >75 years; atrial 
fibrillation or other heart rhythm disorder, significant valvular disease, coronary artery 
disease, diabetes, ischemic stroke, chronic renal failure, liver impairment, hormone 
replacement therapy and those who are pregnant or who might be pregnant. Age-, sex- and 
BMI-matched control participants were recruited from the hospitals and surrounding areas. 
Normotensive control (NC) participants were free from major illnesses, whilst hypertensive 
controls (HTN) either had a prior diagnosis of hypertension or BP≥140/90 mmHg. In addition 
10 healthy young male controls (HC) free from major illnesses or medications were recruited 
from the University of Birmingham, UK and surrounding areas. Figure 4.1 shows a flow-chart 
of recruitment and group allocation for the experiments. Ethical approval was obtained by the 
local Research Ethics Committee (National Research and Ethics Service Committee West 
Midlands - Edgbaston, 11/WM/0298). Written informed consent was received from 
participants prior to inclusion in the study, in accordance with the Declaration of Helsinki
2013.
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Figure 4.1. Flow chart summary showing subject recruitment and group allocation.
CPT = cold pressor test, HTN = hypertension, MOT = modified Oxford technique, MSNA = muscle sympathetic nerve acticity, NC = normotensive control, PASAT = 
paced auditory serial arithmetic task, RA = rheumatoid arthritis, TNF = tumor necrosis factor
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4.2 Experimental protocol
Experiments 1, 2 and 3
Participants attended the research laboratory at 09:00 h following an overnight fast 
(from food, caffeine and alcohol). Additionally all medications were withheld on the morning 
of testing. A detailed clinical history was obtained and physical examination performed in RA 
patients to count the number of swollen and tender joints in order to determine the DAS28-
CRP (489). Pain VAS was used as a measure of pain (490). Participants were instructed to 
“mark the point on the line that best describes your overall pain at the moment” ranging from 
a score of 0 indicating “no possible pain” to 100 indicating “worst possible pain”. Height and 
weight was measured, and BMI index was determined (weight/height2). All subsequent 
measurements were performed under uniform conditions in a temperature-controlled room 
whilst resting quietly in the supine position. Measurement equipment (HR, BP, leg blood 
flow, MSNA) was attached to the participant and an intravenous catheter was inserted into a 
superficial vein in the antecubital fossa for blood sampling and injections (Figure 4.1). Data 
was recorded during the protocol, which involved a resting 10-minute baseline period 
followed by the MOT, CPT and PASAT mental stress test, consecutively.
Experiment 5
Each participant was investigated on two occasions separated by one week, according 
to a placebo-controlled, single-blinded, cross-over design. Participants were randomised to 
receive either placebo or HCN on the morning of the first visit using a randomisation method 
in two groups of five (491). The choice was blinded to the participant throughout the duration 
of the study but not the investigator. Computer generated random sequences were used to 
96
determine the order of drug administration. None of the subjects reported any side effects and 
were unable to distinguish between HCN and placebo administration.
Participants attended the research laboratory at 09:00 h. An intravenous catheter was 
inserted into a superficial vein at the antecubital fossa for blood sampling and injections. 
Baseline blood samples were taken for biochemistry including renal function (serum 
creatinine), electrolytes (sodium, potassium), plasma osmolality, baseline cortisol and ACTH. 
All participants were then administered either 200 mg hydrocortisone (Solu-Cortef ®) or 
placebo (9 % saline solution) intravenously. Following this, subjects were given a 
standardised light breakfast (a single sachet of Quaker Oats So Simple ® porridge Apple & 
Blueberry, Golden Syrup or Original with 200 ml of semi-skimmed milk, one banana and 200 
ml carton of Vitafit © Apple or Orange juice) and observed in a quiet, temperature-controlled 
room. At 12:00 h height and weight were measured and BMI was determined 
(weight/height2). The participants assumed a comfortable supine position and were 
instrumented with the measurement equipment (HR, BP, leg blood flow). Further blood 
samples were taken (cortisol, ACTH, catecholamines, serum electrolytes, serum osmolality 
and haematocrit) following which participants rested quietly for a further 30 min. During the 
final 10 min of this period data were recorded. The protocol involved a resting 10-minute 
baseline period followed by the MOT, CPT and PASAT mental stress test, consecutively.
4.3 Variables
Data was acquired using the Powerlab 16/35 data acquisition system and a personal 
computer equipped with Labchart Pro software (ADInstruments, Bella Vista, Australia). All 
analyses were performed offline. Cardiovascular variables were sampled at 1 kHz, and beat-
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to-beat values of HR, systolic BP, diastolic BP and mean BP calculated. MSNA signals were 
sampled at 10 kHz. Using a macro (Microsoft Office Excel 2007, Microsoft Corporation, 
Washington, USA) beat-to-beat values were averaged over 1 minute intervals.
4.3.1 Haemodynamic
HR was continuously recorded using a lead II ECG (BioAmp, ADInstruments, Bella 
Vista, Australia). Beat-to-beat BP was recorded using finger photoplethysmography 
(Portapres, Finapres Medical Systems, Amsterdam, The Netherlands) and was calibrated with 
brachial BP recordings using an automated sphygmomanometer (Omron 705IT, Omron 
Corporation, Hoopddorp, The Netherlands). 
4.3.2 MSNA
Multi-unit recordings of MSNA were obtained (FE185 NeuroAmp EX, 
ADInstruments, Bella Vista, Australia) from the peroneal nerve using tungsten 
microelectrodes (200 μm, 1-3 μm uninsulated tip; UNA32F2S, FHC, Bowdoin, USA) via the 
microneurography technique (sampling frequency 10 kHz). Electrical stimulation on the skin 
surface was used for nerve mapping, and a reference electrode was inserted subcutaneously 2 
to 3 cm away from the recording electrode which was inserted into the nerve fascicle (Figure 
4.1). The neural signals were amplified, filtered (2000 Hz high pass, 100 Hz low pass, 60 Hz 
notch), rectified and integrated (absolute value, time constant decay 0.1 s) to obtain a mean 
voltage of sympathetic nerve activity. MSNA was confirmed by: listening to the amplified 
signal on speakers; observing the characteristic bursting pattern on a computer screen; 
palpating the skin and muscle fibres; and performing a breath hold (422, 492). Sympathetic 
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bursts were identified and scored by a trained observer (Ahmed Adlan – author) using a semi-
automated macro created using Spike2 (Cambridge Electronic Design, Cambridge, UK). 
Identifiable features of sympathetic bursts include: a characteristic spike (rapid rise and fall in 
signal) which can be seen on the screen and heard from the speaker; cardiac cycle linked; 
larger amplitude compared to background noise; increase in activity following breath hold. 
MSNA burst frequency (bursts/minute) and incidence (bursts/100 heart beats) was determined
(Figure 4.2). 
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Figure 4.2 Experimental setup.
(A) Participants lay in the supine position with the measurement equipment as shown. MSNA was recorded 
using the microneurography technique whereby a tungsten microelectrode (200 µm length, 1-3 µm tip) was 
placed subcutaneously approximately 2 to 3 cm away from the recording electrode that was inserted into the 
peroneal nerve (magnified in B). BP = blood pressure, ECG = electrocardiogram, MSNA = muscle sympathetic 
nerve activity
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Figure 4.3 Original record showing MSNA burst identification.
Original record of an RA patient showing raw MSNA, integrated MSNA, ECG and arterial BP during a breath hold with expanded section below (dashed line). MSNA 
bursts (*) can be identified by the following features: characteristic spikes (rapid rise and fall in signal); cardiac cycle linked (see arrow); activity greater than the 
background noise; and increased burst frequency following breath hold. Muscle sympathetic nerve activity can be quantified by dividing the number of MSNA bursts 
by time to give MSNA burst frequency (MSNA bursts/min), and by dividing the number of MSNA bursts by (number of heart beats x 100) to give MSNA burst 
incidence (MSNA bursts/100 heartbeats).
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4.3.3 Cardiovagal BRS (cBRS)
The MOT involves sequential intravenous bolus infusions of sodium nitroprusside 
(100 micrograms) and phenylephrine (150 micrograms) one minute apart, during which 
arterial BP and RR-interval are simultaneously recorded (433). Infusion of these agents results 
in a fall and subsequent rise in arterial BP that activates and deactivates the arterial 
baroreceptors (Figure 4.3). The relationship between the arterial BP and RR-interval was 
analysed during the phenylephrine-induced rise in systolic BP. Analysis began at the first 
concordant change in systolic BP and RR-interval after phenylephrine infusion until the 
systolic BP and RR-interval changes were discordant (433). Baroreflex delays were accounted 
for by associating systolic BP with concurrent (resting RRI greater than 800 ms) and 
subsequent RR-intervals (resting RRI between 500 and 800 ms) (493, 494). RR-interval 
values were averaged over 3 mmHg pressure bins to account for respiratory-related variations 
(495). Saturation and threshold regions of the baroreflex curve were excluded and the linear 
relationship between systolic BP and RR-interval was determined using piecewise regression 
(GMOT) (Figure 4.5) (496). A minimum of 10 points was required and only values with r
2≥0.6 
were accepted.  
The ‘sequence technique’ was used to provide a spontaneous measure of cBRS (427).
Commercially available computer programs (CardioSeries v2.4, CardioSeries, Sao Paulo, 
Brazil) were used to identify sequences of three or more consecutive cardiac cycles where 
increases/decreases in systolic BP (of at least 1 mmHg) were related to 
lengthening/shortening in RR-interval of the following cardiac cycle (i.e. lag +1). The slope 
of the regression line (RRI v systolic BP) was calculated individually and all slopes were 
averaged to provide an overall sensitivity gain (GSEQ) (497). A minimum threshold of 1 
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mmHg for systolic BP and 1 ms for RRI was applied, and only sequences with an R2>0.8 
were accepted. 
Low frequency transfer function gain (GLFTF) was determined using cross-spectral 
analysis of systolic BP (input) and subsequent RR-interval (output) in the low frequency 
range (0.047-0.156 Hz) (436). Only values with a coherence ≥ 0.5 were included. The low 
frequency range has the advantage of representing spontaneous oscillations in BP and RR-
interval without the effects of breathing (206).
Figure 4.4 Original record showing the modified Oxford technique.
Original record of an RA patient showing HR, BP (systolic and diastolic) and MSNA responses during the 
modified Oxford technique. Following a period of rest sequential infusions of sodium nitroprusside (100 µg) and 
phenylephrine (150 µg) one minute apart induce a fall then rise in BP, a rise then fall in HR and MSNA.
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Figure 4.5 Original record showing baroreflex function curves derived from the modified 
Oxford technique.
Original record of a healthy control showing (A) sympathetic and (B) cardiovagal baroreflex function curves 
derived from the modified Oxford technique.
4.3.4 Sympathetic BRS
Assessment of baroreflex control of MSNA was determined using linear regression 
(diastolic BP v MSNA burst activity) during the phenylephrine-induced rise in BP (498). 
Briefly, each cardiac cycle was scored according to the presence or absence of a sympathetic 
burst. Data was binned according to the diastolic BP of the previous cardiac cycle (DBP-1, 3 
mmHg bins). Linear regression analysis was then performed on the relationship between the 
mean of each diastolic BP bin and MSNA activity (% MSNA bursts/beat). All data was 
weighted for the number of cardiac cycles in each diastolic BP bin (498). The slope of the 
linear regression (DBP-1 mmHg v % [MSNA bursts/beat]/mmHg) was used as an index of 
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sympathetic BRS (Figure 4.5). Sympathetic BRS was also determined from 10-minute resting 
period (spontaneous).
4.3.5 Blood flow and vascular conductance
Leg and forearm blood flow was measured using venous occlusion strain gauge 
plethysmography (Hokanson EC-6 plethysmograph, D E Hokanson, Bellevue, United States 
of America, USA) (499). A lightweight indium-in-silastic strain gauge was positioned around 
the right calf and the right forearm at the point of greatest circumference. The length of the 
strain gauge was 2 cm less than the widest girth of the calf or forearm. Calibration was 
performed by measuring the change in voltage produced by a 1 % change in length of strain 
gauge. Cuffs were placed around the ankle and wrist and inflated to a pressure of 200 mmHg 
and maintained for 1 minute to achieve arterial occlusion. Sixty seconds later cuffs placed 
around the thigh and forearm were rapidly inflated to 50 mmHg (Hokanson E20 rapid cuff 
inflator and AG101 air source, Hokanson, Bellevue, USA) to evoke venous occlusions. 
Venous occlusion was repeated three times during 1 min, with the thigh and forearm cuffs 
inflated for 5 s and then deflated for 10 s each time. LabChart software (ADInstruments, Bella 
Vista, Australia) was used to measure the slope during venous occlusion. The following 
formulae were then used to calculate leg and forearm blood flow and vascular conductance 
using a Microsoft Office Excel 2007 (Microsoft Corporation, Washington, USA):
Leg/forearm blood flow (ml/100ml/min) = ([slope (V/s) / 1 % calibration (ml/100 ml)] x 60)
Leg/forearm vascular conductance (LVC/FVC, arbitrary units, AU) = ([Blood flow (ml/100 
ml/min) / Mean BP (mmHg)] x 1000))
106
Blood flow measurements were obtained three times during the 10 minute resting 
baseline period, five times during the CPT and seven times during the PASAT (Table 4.1).
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Table 4.1 Blood flow measurements obtained during resting baseline, CPT and PASAT
Phase Duration (mins) Limb blood flow 
recorded (min)
Baseline Rest 10 2, 5 and 8
CPT Rest 4 1, 3
Test 2 2
Recovery 4 1, 3
PASAT Rest 4 1, 3
Test 6 1, 3 and 5
Recovery 4 1, 3
CPT = cold pressor test, PASAT = paced auditory serial mental arithmetic task
4.3.6 HRV
Time domain, frequency domain and non-linear indices of short-term HRV were 
determined from a 10 min resting period (Kubios HRV, Kuipio, Finland) in accordance with 
guidelines from the Task Force of the European Society of Cardiology and the North 
American Society of Pacing Electrophysiology (196). Data was pre-screened for ectopics and 
these were corrected using the Kubios software (accounted for <1 % of all recordings) (196).
Time domain indices included square root of the mean sum of the squares of difference 
between adjacent inter-beat intervals (rMSSD), number of pairs of adjacent inter-beat 
intervals differing by more than 50 ms in the entire recording expressed as an absolute value 
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(NN50) and a percentage of all inter-beat intervals (pNN50 %). Frequency domain indices 
(using fast Fourier transform) of R-R intervals included total power (TP), very low frequency 
power (VLF, range 0-0.04 Hz), low frequency power (LF, range 0.04-0.15 Hz) and high 
frequency (HF, range 0.15-0.4 Hz). Absolute values for TP, VLF, LF and HF were 
determined in addition to normalised units for LF, HF and ratio of LF/HF power. In addition 
non-linear indices of HRV were determined; standard deviation of the Poincare plot SD1, 
SD2 and the SD1/SD2 ratio. rMSSD, NN50, pNN50 % and HR fluctuations in the HF power 
range are suggested to be principally indicative of cardiac parasympathetic activity (196). The 
physiological correlates to LF power fluctuations and the LF/HF ratio remain uncertain (429). 
The Poincare plot is a scatter diagram where each RR-interval is plotted against the previous 
RR-interval (500). SD1 provides an estimate for short term HRV whilst SD2 is representative 
of long term HRV (501) and is influenced by both parasympathetic and sympathetic activity 
(502). The SD1/SD2 ratio provides a measure of the relationship between SD1 and SD2.
4.3.7 Cardiovascular reactivity 
For the CPT participants lay still in a supine position whilst baseline measurements for 
4 minutes were obtained. The right hand was then immersed completely in a container of cold 
water at 4 oC for 2 minutes (324). Following this recovery measurements were obtained for 4 
minutes. Brachial BP and leg flow measurements were obtained during minutes 1 and 3 
(baseline and recovery) and in the second minute of cold-water immersion. During the 
PASAT test a series of single digit numbers were presented to the participants for 6 min using 
a pre-recorded audio file on a computer. Participants were instructed to add each number they 
heard to the previous number presented to them, and retain the last number to add to the next 
number they heard (481, 503). In order to make the task progressively more challenging the 
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numbers were presented every 3.5 s, 3.0 s and 2.5 s respectively, in three consecutive blocks 
each lasting two minutes. An experimenter checked their responses against the correct 
answers and alerted the participant with a loud buzzer noise with each incorrect answer, 
hesitation or once during every 10 additions if no mistakes were made. Finally, in order to 
increase social evaluation participants were instructed to view themselves in a mirror for the 
duration of the mental stress test. A 10-point scale was used to obtain perceived pain and 
stress ratings from the subjects following the CPT and the PASAT mental stress test, 
respectively. Cardiovascular variables were averaged during rest, test and recovery phases to 
provide absolute values. Differences between baseline, test and recovery phases of CPT and 
PASAT were reported as absolute or percentage change.
4.3.8 BP variability
Time and frequency domain parameters of systolic and diastolic BP variability were 
determined from a 10 min resting period (CardioSeries v2.4, CardioSeries, Sao Paulo, Brazil). 
Time domain indices included standard deviation (SD) and variation of coefficient (VC = 
SD/BP x 100). Frequency domain indices (using fast Fourier transform) included LF power 
(range 0-0.04 Hz) and HF power (range 0.15-0.4 Hz). BP oscillations in the LF range are 
believed to principally represent vasomotor activity whilst HF oscillations represent 
respiratory influences (497).
4.3.9 QT interval
QT interval (time between beginning of a Q wave and then end of a T wave) was 
manually measured by two experts and corrected for HR using Bazett’s formula (QTBAZ); 
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methods described in detail elsewhere (35). QT interval, HR and QTBAZ data was obtained 
from a previous study (35). Additionally QT was corrected using the Framingham Heart 
Study formula (QTFHS = QT + 0.154x [1-RR]) (504). The Minnesota Code Classification 
System was used to code for the presence of ST abnormality on the ECG (505).
4.3.10 Blood sampling
Blood samples for inflammatory markers were centrifuged immediately and the 
plasma stored at -80 oC. Commercially available enzyme-linked immunosorbent assay 
(ELISA) kits were used to determine hs-CRP (MP Biomedicals, California, USA) and 
cytokines (IL-6, TNF-α, IL-10; BioSupply UK, Bradford, UK). The intra- and inter-assay 
coefficients of variations were 7.5 % and 4.1 % respectively for hs-CRP, 4.9 % and 6.0 % for 
IL-6, 8.5 % and 9.8 % for TNF-α and 6.8 % and 7.5 % for IL-10. Local routine clinical 
laboratories were used to analyse full blood count, renal function, fasting lipid profile and 
fasting glucose.
4.3.11 Statistical analyses
Statistical analyses were performed using Statistical Package for the Social Sciences
(SPSS) software, version 19 (SPSS Inc, Chicago, USA). Continuous variables were assessed 
for normality using the Kolmogorov-Smirnov test. Unless otherwise specified data are
expressed as mean± SD, geometric mean (95% confidence interval, CI) or frequency (%).
Significance levels were set at P≤0.05. Further details are found within the specific 
experimental chapters.
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CHAPTER 5 Experiment One. Heightened sympathetic nerve activity and reduced BRS in 
RA: a case control study
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5.1 Abstract
Objectives To test the hypothesis that MSNA was increased and BRS was decreased in RA, a 
chronic inflammatory condition associated with increased cardiovascular mortality and poorly 
understood pathophysiology.
Methods MSNA (microneurography), beat-to-beat BP (Portapres), and HR (lead II ECG) 
were recorded in age- and sex-matched RA normotensive (n=13), RA hypertensive patients 
(RA-HTN; n=17), normotensive (NC; n=17) and hypertensive controls (HTN; n=16). BRS 
was determined with sequential bolus infusions of SNP and PE (MOT). Inflammation and 
pain were determined using serum hs-CRP and a pain VAS, respectively. 
Results MSNA was elevated similarly in RA, RA-HTN and HTN patients (32±9, 35±14, 
37±8 bursts/min) compared to NC (22±9 bursts/min; p=0.004). Sympathetic BRS was not 
different between groups (p=0.927), while cBRS was reduced in RA, RA-HTN and HTN 
patients (geometric mean 5, 95 % CI [3-8], 4[2-7], 6[4-9] ms/mmHg) compared to NC (11[8-
15] ms/mmHg; p=0.002). hs-CRP was independently associated with HR (positive), but 
associations with MSNA (positive) and cBRS (inverse) were confounded in this study. Pain 
VAS was independently associated with MSNA burst frequency, cBRS and HR. 
Conclusions This study provides the first direct evidence for heightened central sympathetic 
outflow and reduced cBRS in RA that can be independent of hypertension. ANS 
dysregulation in RA is strongly associated with pain and to a lesser extent with inflammation. 
Further studies are required to determine whether anti-inflammatory therapy can restore ANS 
function.
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5.2 Introduction
A heightened central sympathetic outflow to the heart and/or vasculature has been 
identified in numerous cardiovascular diseases (439), and is associated with the pathogenesis 
of hypertension (439), cardiac arrhythmias (506) and increased mortality (113, 384). 
Reciprocal links between inflammation and the sympathetic nervous system have been 
identified (52, 61, 153). Central sympatholytic agents have anti-inflammatory actions in 
human hypertension (183), whereas infusion of inflammatory cytokines elevated in RA 
patients, such as IL-6 (52), TNF-α (61) and IL-1β (153), increase sympathetic nerve activity 
in rats. Thus, the chronic activation of inflammatory cytokines in RA may elicit deleterious 
increases in sympathetic neural outflow that further promote activation of pro-inflammatory 
cytokines. In addition, microinjection of IL-6 into the NTS is reported to reduce BRS (314). 
Depressed BRS in RA could precipitate further increases in central sympathetic outflow, 
reduce cardiac electrical stability and contribute to the recognised increase in cardiovascular 
risk (21, 507).  
Whether sympathetic activity is increased and BRS is reduced in RA is presently 
equivocal, partly owing to the indirect methods of assessment used to examine this (508). 
Elevations in plasma noradrenaline have been reported in RA patients (482), but it is not clear 
if this is a consequence of increased central sympathetic outflow, an enhanced release from 
peripheral adrenergic stores, or from an altered local reuptake mechanisms (509). Such 
limitations are overcome by the microneurography technique, which provides a direct 
assessment of sympathetic nerve activity to the skeletal muscle vasculature (MSNA), 
although such measures have not been undertaken previously in RA. It is also unknown 
whether baroreflex regulation of MSNA is altered in RA. Although a reduction in cBRS has 
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been suggested in RA patients (447, 510), baroreflex control of the heart and vasculature do 
not always function in a parallel fashion (433).
5.3 Aims and hypothesis
Central hypothesis: In patients with RA, elevated concentrations of circulating inflammatory 
cytokines are associated with increased MSNA and reduced BRS.
Aim: To test this, an observational, case-control study in RA patients (with and without 
hypertension) and controls (with and without hypertension) was undertaken to measure 
baseline serum inflammatory cytokine concentrations, MSNA and BRS. 
Hypothesis:
i) central sympathetic outflow (MSNA) is elevated in RA compared to 
normotensive controls;
ii) sensitivity of the baroreflex control of the heart and MSNA is reduced in RA
compared to normotensive controls;
iii) elevated circulating concentrations of inflammatory cytokines are associated 
with increased MSNA and reduced BRS. 
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5.4 Methods
5.4.1 Subjects
Thirty patients with a diagnosis of RA based on the 1987 ACR criteria (8) were 
recruited from the rheumatology clinics at Russells Hall Hospital, Dudley, UK and Sandwell 
General Hospital, West Bromwich, UK. Thirty three age-, sex- and BMI-matched control 
participants were recruited from the hospitals and surrounding areas.
5.4.2 Experimental protocol
Participants were studied according to an observational, case-control study that 
included four groups: 13 RA patients, 17 RA-HTN patients, 16 HTN and 17 NC. Participants 
attended the research laboratory at 09:00 h following an overnight fast (from food, caffeine 
and alcohol). Data was recorded during the protocol which involved a resting 10 minute 
baseline period followed by the MOT: sequential infusion of SNP (100 μg) and PE (150 μg) 
one minute later (433).
5.4.3 Measurements
HR (lead II ECG), beat-to-beat BP (finger photoplethysmography) and MSNA
(microneurography) were continuously recorded during baseline and the MOT. Brachial BP 
recordings (automated sphygmomanometer) were obtained for calibration. Leg blood flow 
(venous occlusion strain gauge plethysmography) was measured during the resting baseline.
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5.4.4 Data analysis
Data analysis was performed offline. MSNA burst frequency (bursts/minute) and 
incidence (bursts/100 heart beats) was determined. cBRS was determined during the 
phenylephrine induced rise in BP (GMOT) (433, 496) and during the 10 minute rest period 
using the Sequence Technique (GSEQ). The slope of the linear regression (DBP-1 mmHg v % 
[MSNA bursts/beat]/mmHg) was used as an index of sympathetic BRS during the MOT and 
at rest (spontaneous). Some patients were unsuitable for microneurography (e.g. discomfort 
laying still for an extended period, or declined microneurography) and it was not possible to 
obtain sufficiently high quality MSNA recordings in all patients, thus these were omitted from 
the MSNA analyses. Participant numbers are stated in the legend of each Table and Figure.
5.4.5 Blood sampling
Commercially available ELISA kits were used to determine hs-CRP and cytokines 
(IL-6, TNF-α, IL-10). Local routine clinical laboratories were used to analyse full blood 
count, renal function, fasting lipid profile and fasting glucose.
5.4.6 Statistics
Statistical analysis was performed using SPSS software, version 19 (SPSS Inc, 
Chicago, Ilinois). Continuous variables were tested for normality using the Kolmogorov-
Smirnov test. Non-parametric data was (naturally) logarithmically transformed. Group 
differences were assessed using a one way analysis of variance (ANOVA) with least 
significant difference (LSD) post-hoc for continuous variables, and Pearson Chi-square test 
for categorical data. Differences between RA normotensive and RA-HTN group were 
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assessed using an independent t-test. Associations between autonomic parameters and 
inflammation were assessed before (Pearson product/Spearman’s rank correlation coefficient) 
and after adjustment for potential confounders. Data expressed as mean±SD for parametric 
data; geometric mean (95 % CI) for non-parametric data; and frequency (%) for categorical 
variables. A P value of less than 0.05 was considered statistically significant.
5.5 Results
5.5.1 Subject characteristics
Baseline subject characteristics are represented in Table 5.1. Aside from hypertension 
there were no significant differences in other cardiovascular risk factors between the groups. 
Compared to RA normotensive patients and age-matched NC, RA RA-HTN and HTN 
patients had a higher prevalence of osteoarthritis (RA 15 %; RA-HTN 53 %; NC 0 %; HTN 
25 %; p=0.003) and statin therapy (p=0.032). RA and RA-HTN patients had a higher 
prevalence of proton pump inhibitor (p=0.016) and folic acid (p<0.001) therapy, whilst 
calcium/ vitamin D supplementation tended to be highest in the RA-HTN group (p=0.06). 
Similar anti-hypertensive agent use was noted in RA-HTN and HTN patients (Table 5.1). 
RA disease-related characteristics are represented in Table 5.2. RA normotensive and 
RA-HTN patients had similar disease duration, sero-positivity and RA drug therapy. RA-
HTN patients had a greater number of swollen joints (p=0.045) and a trend for higher disease 
activity (DAS28-CRP, p=0.063) compared to RA patients. 
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Table 5.1 Subject characteristics
RA RA-HTN NC HTN P value
N 13 17 17 16
Age, years 55.9±11.7 60.5±9.6 53.6±13.0 59.6±10.1 0.257
Female, n (%) 8 (62) 12 (71) 10 (59) 11 (69) 0.876
BMI, kg/m2 27.8 
(25.4-30.4)
29.6 
(26.4-33.3)
26.4 
(23.8-29.2)
25.8 
(24.5-27.2)
0.130
Total cholesterol, 
mmol/L
4.8±1.1 5.1±1.0 5.1±0.9 5.1±1.0 0.804
Triglycerides, mmol/L 1.1 (0.9-
1.5)
1.0 (0.8-
1.4)
1.1 (0.8-
1.3)
1.1 (0.9-
1.3)
0.968
HDL, mmol/L 1.3 (1.1-
1.5)
1.5 (1.3-
1.8)
1.4 (1.2-
1.6)
1.4 (1.2-
1.7)
0.498
LDL, mmol/L a 2.9±0.9 2.9±0.9 3.1±0.8 3.0±0.9 0.866
eGFR, ml/min/1.73 m2 100.4±20.3 89.9±14.6 88.0±19.6 83.5±17.9 0.099
Haemoglobin, g/L 126±12 *† 133±14 138±10 138±12 0.019
Smoking, n (%) 4 (31) 1 (6) 3 (18) 0 0.064
Osteoarthritis, n (%) 2 (15) 9 (53) 0 4 (25) 0.003
Antihypertensive - 7 (41) - 11 (69) 0.112
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agent, n (%)
ACEi or ARB, n (%) - 5 (29) - 5 (31) 0.909
Calcium channel 
blocker, n (%)
- 4 (24) - 7 (44) 0.218
Thiazide, n (%) - 2 (12) - 5 (31) 0.171
β-blocker, n (%) - 2 (12) - 1 (6) 0.582
α-blocker, n (%) - 0 - 2 (13) 0.133
Aspirin, n (%) 1 (8) 1 (6) 0 1 (6) 0.748
Statin, n (%) 1 (8) 6 (35) 0 4 (25) 0.032
Proton pump inhibitor, 
n (%)
4 (31) 6 (35) 0 1 (6) 0.016
Folic acid, n (%) 8 (62) 12 (71) 0 0 <0.001
Adcal D3, n (%) 2 (15) 5 (29) 1 (6) 0 0.060
Values expressed as mean±SD (parametric) for continuous variables and frequency (%) for discrete variables. 
Non parametric data was (natural) log transformed and displayed as geometric mean (95% CI). One way 
ANOVA with post-hoc LSD. Pearson Chi-Square for categorical data. Significance P≤0.05. Post hoc P≤0.05 * v 
HC, † v RA-HTN. a calculated using the Friedewald formula.
ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin-renin blocker, BMI = body mass index, 
CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, HDL = high-density lipoprotein, 
HTN = hypertensive, LDL = low-density lipoprotein, NC = normotensive control, RA = rheumatoid arthritis.
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Table 5.2 RA-related characteristics
RA RA-HTN P value
N 13 17
RA duration, years 7.6 (4.6-12.4) 5.5 (2.9-10.5) 0.443
RF positive, n (%) 9 (69) 10 (59) 0.768
Swollen joints, n (%) 5.2 (2.9-9.0) 2.6 (1.6-4.0) 0.045
Tender joints, n (%) 6.7 (2.8-14.7) 3.5 (1.7-6.7) 0.194
DAS28-CRP 4.8±1.9 3.7±1.2 0.063
Disease activity, n (%)
     Remission 4 (31) 5 (31) 0.088
     Low 3 (23) 9 (56)
     High 6 (46) 2 (13)
Pain VAS, % 36.8 (21.7-62.0) 12.9 (5.3-30.1) 0.047
DMARD, n (%) 11 (85) 15 (88) 0.773
No of DMARDs 1.8 (1.2-2.4) 1.8 (1.3-2.2) 0.850
Methotrexate, n (%) 8 (62) 12 (71) 0.602
Hydroxychloroquine, n (%) 5 (38) 10 (59) 0.269
Sulfasalazine, n (%) 4 (31) 3 (18) 0.400
Leflunomide, n (%) 2 (15) 1 (6) 0.390
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Glucocorticoid, n (%) 1 (8) 6 (35) 0.077
     Prednisolone, n (%) 1 (8) 4 (24) 0.249
     Prednisolone dose, mg 3 5±3 0.534
     Intra-muscular, n (%) 0 1 (6) 0.374
     Intra-articular, n (%) 0 1 (6) 0.374
NSAID, n (%) 5 (38) 6 (35) 0.858
Opioid, n (%) 6 (46) 7  (41) 0.785
     Weak, n (%) 5 (38) 7 (41) 0.880
     Strong, n (%) 1 (8) 0 0.245
Biologic agent, n (%) 4 (31) 3 (18) 0.400
TNF-α inhibitor, n (%) 4 (31) 1 (6) 0.070
     Certolizumab, n (%) 2 (15) 0 0.094
     Etanercept, n (%) 2 (15) 0 0.094
     Golilumab, n (%) 0 1 (6) 0.374
Rituximab, n (%) 0 2 (12) 0.201
Values expressed as mean±SD for continuous variables (parametric) frequency (%) for discrete variables. Non 
parametric data was (natural) log transformed and displayed as geometric mean (95% CI). Statistical differences 
were tested using an independent t-test for continuous variables and Pearson Chi-Square for categorical data. 
Significance P≤0.05.
CRP = C-reactive protein, DAS = disease activity score, DMARD = disease modifying anti-rheumatic drug, 
HTN = hypertensive, NSAID = non-steroidal anti-inflammatory drug, RA = rheumatoid arthritis, RF = 
rheumatoid factor, TNF = tumour necrosis factor, VAS = visual analogue scale.
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5.5.2 Haemodynamic parameters
MSNA (burst frequency) was higher in RA, RA-HTN and HTN groups compared to 
NC (p=0.004; Figure 5.1). When adjusted for HR, there was a significant difference in MSNA 
(burst incidence) between the groups (p=0.029). Post-hoc analysis showed higher MSNA 
burst incidence in HTN (p<0.05) and RA-HTN (trend, p=0.111) compared to NC, and higher 
burst incidence in HTN compared to RA normotensives (trend, p=0.056). Mean BP was 
higher in HTN and RA-HTN compared to RA patients and NC (p<0.001), with no significant 
difference between RA-HTN and HTN, or between RA and NC (Figure 5.2). Resting HR was 
higher in RA and RA-HTN patients compared to NC and HTN groups (p=0.008). Leg blood 
flow was significantly higher in the RA and RA-HTN groups compared to NC and tended to 
be higher than in the HTN group (RA geometric mean 2.0, 95 % CI 1.5-2.6; RA-HTN 2.0, 
1.4-2.8; NC 1.2, 0.9-1.7; HTN 1.4, 1.0-1.8 ml/100ml/min; p=0.047; post-hoc analysis RA v 
HTN p=0.101, RA-HTN v HTN; p=0.086). LVC was similar between all groups (RA 21, 15-
27; RA-HTN 18, 12-26; NC 14, 10-19; HTN 13, 10-17 arbitrary units; p=0.148). 
5.5.3 BRS
cBRS (GMOT) was lower in RA, RA-HTN and HTN groups compared to NC 
(p=0.002). Spontaneous arterial baroreflex control of MSNA was slightly lower in RA and 
RA-HTN groups (although not significant p=0.315) however during MOT there were no 
differences between all groups (p=0.927; Figure 5.3). GSEQ was higher in NC compared to 
RA, RA-HTN and HTN groups although post-hoc analysis showed only significant 
differences between RA-HTN and NC (RA 9.2, 7.0-11.9; RA-HTN 6.4, 4.5-9.0; NC 13.0, 
10.9-15.4; HTN 8.1, 5.8-11.4 ms/mmHg; p=0.004). 
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Figure 5.1 Muscle sympathetic nerve activity.
Bar charts showing group mean±SEM data for MSNA burst frequency (A) and MSNA burst incidence (B) and 
sympathetic neurograms showing MSNA (C) in individual subjects from RA, RA-HTN, NC and HTN groups. 
Overall effect P<0.05. Post hoc * P<0.05.
BP = blood pressure, HTN = hypertensive, MSNA = muscle sympathetic nerve activity, NC = normotensive 
control, RA = rheumatoid arthritis. A and B, RA n = 7, RA-HTN n = 7, NC n = 13, HTN n= 11.
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Figure 5.2 Resting BP and HR.
Box and whisker plot showing mean BP (A, geometric mean and 95 % CI) and bar chart showing HR (B, 
mean±SEM) in RA, RA-HTN, NC and HTN groups. Overall effect P<0.05. Post hoc * P<0.05. BP = blood 
pressure, HR = heart rate, HTN = hypertensive, NC = normotensive control, RA = rheumatoid arthritis. A and B, 
RA n = 13, RA-HTN n = 17, NC n = 17, HTN n= 16.
5.5.4 Inflammation and pain
RA and RA-HTN patients had higher hs-CRP compared to NC and HTN (p<0.001; 
Figure 5.4) with no significant difference between RA and RA-HTN. IL-6 was higher in RA 
patients compared to RA-HTN and NC, and higher in RA-HTN patients compared to NC 
(p<0.001). Additionally, RA patients had a higher IL-6 compared to RA-HTN and HTN 
patients (post hoc p<0.05). RA patients had higher TNF-α compared to NC and HTN 
(ANOVA p=0.027; post hoc RA vs. NC and RA vs. HTN p<0.05), and numerically (but not 
statistically significantly) higher TNF-α than RA-HTN patients (post hoc RA v RA-HTN 
p>0.05). IL-10 tended to be higher in RA patients compared to the other groups (p=0.159).
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RA and RA-HTN groups had more pain than NC and HTN groups (as measured by pain 
VAS), and RA patients had more pain than RA-HTN (RA 37, 22-62; RA-HTN 13, 5-30; NC 
1, 0-2; HTN 1, 0-3; p<0.001).
5.5.5 Associations between inflammation and autonomic function
Inflammatory cytokines (IL-6, TNF-α, and IL-10) were positively associated with 
each other, whilst hs-CRP was only associated with IL-6 (Appendix 5). Both hs-CRP and IL-
6 were positively associated with HR although TNF-α and IL-10 were not. MSNA burst 
frequency was positively associated with hs-CRP but not with inflammatory cytokines; 
however this association was not evident when MSNA was adjusted for HR (MSNA burst 
incidence). cBRS (GMOT) was inversely associated with inflammation (hs-CRP, IL-6 and 
TNF-α), whilst arterial baroreflex control of MSNA was not. Spontaneous cBRS (GSEQ) was 
also inversely associated with inflammation (hs-CRP)
Table 5.3 shows the association between inflammation markers and autonomic 
function before and after multivariable adjustment. Following multivariable adjustment (i.e. 
age, sex, BMI, haemoglobin, presence of hypertension, RA) hs-CRP remained positively 
associated with HR (adjusted R squared 0.375, p<0.001, Appendix 6) while the associations 
with MSNA burst frequency and cBRS were attenuated. Similarly, the associations between 
inflammatory cytokines and autonomic parameters disappeared following multivariable 
adjustment. In patients with RA, disease activity (DAS28-CRP) was independently associated 
with HR (adjusted R squared 0.204, p=0.034) after multivariable adjustment.
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Figure 5.3 Cardiovagal and arterial sympathetic BRS.
Box and whisker plots showing cardiovagal BRS (A, GMOT; B, GSEQ geometric means and 95 % CI) and bar 
charts showing baroreflex control of MSNA (C, MOT; D, spontaneous means±SEM) in RA, RA-HTN, NC and 
HTN groups. Overall effect P<0.05. Post hoc * P<0.05.
BRS = baroreflex sensitivity, HTN = hypertensive, MOT = modified Oxford technique, MSNA = muscle 
sympathetic nerve activity, NC = normotensive control, RA = rheumatoid arthritis. SEQ = sequence method. 
A, RA n = 13, RA-HTN n = 17, NC n = 17, HTN n= 16. B, RA n = 6, RA-HTN n = 5, NC n = 9, HTN n= 7.
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Figure 5.4 Inflammatory markers
Box and whisker plots showing concentrations (geometric mean and 95 % CI) of hs-CRP (A), IL-6 (B), TNF-α 
(C) and IL-10 (D) in RA, RA-HTN, NC and HTN groups. Overall effect P<0.05. Post hoc * P<0.05.
hs-CRP = high sensitivity C-reactive protein, HTN = hypertensive, IL = interleukin, NC = normotensive control, 
RA = rheumatoid arthritis, TNF = tumour necrosis factor
RA n = 13, RA-HTN n = 17, NC n = 17, HTN n= 16.
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Table 5.3 Associations between inflammation, pain and ANS function 
N Univariable a Multivariable c
Rho P R2 F P
Dependent variable: MSNA burst frequency
hs-CRP 36 0.418 0.011 0.222 1.452 0.238
Pain VAS 38 0.238 0.150 0.345 7.237 0.012
Dependent variable: cBRS (GMOT)
hs-CRP 50 -0.332 0.019 0.364 0.683 0.413
IL-6 55 -0.408 0.002 0.364 0.039 0.845
TNF-α 55 -0.322 0.016 0.364 0.055 0.815
Pain VAS 55 -0.506 <0.001 0.417 4.279 0.044
Dependent variable: cBRS (GSEQ)
hs-CRP 57 -0.338 0.010 0.252 2.591 0.114
Pain VAS 63 -0.318 0.011 0.162 5.113 0.028*
Dependent variable: HR
hs-CRP 62 0.362 0.006 0.366 13.705 0.001
IL-6 62 0.339 0.010 0.208 0.230 0.634
DAS28-CRP d 29 0.499 b 0.006 0.204 5.123 0.034
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Pain VAS 63 0.464 <0.001 0.526 36.661 <0.001
a Spearman’s rank or b Pearson’s correlation. c After adjustment for age, sex, BMI, presence of hypertension, RA 
diagnosis and haemoglobin concentration. d After adjustment for age, sex, BMI, presence of hypertension, 
haemoglobin concentration and RA duration.
cBRS = cardiovagal baroreflex sensitivity, DAS = disease activity score, hs-CRP = high sensitivity C-reactive 
protein, IL = interleukin, MSNA = muscle sympathetic nerve activity, RA = rheumatoid arthritis, TNF = tumour 
necrosis factor, VAS = visual analogue scale.
5.5.6 Associations between pain and autonomic function
Pain VAS was independently associated with HR (positively), MSNA burst frequency 
(positively) and cBRS (inversely) after multivariable adjustment (Table 5.3).
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5.6 Discussion
This study provides the first direct evidence for heightened central sympathetic outflow 
and reduced arterial baroreflex control of the heart in RA, whilst baroreflex control of MSNA 
remains preserved. These autonomic alterations could occur independently of hypertension 
and were associated with increased pain and inflammation. 
5.6.1 Increased MSNA in RA
Heightened sympathetic outflow to the heart and/or vasculature can have a multitude 
of deleterious consequences (439) and is associated with increased mortality risk (113, 384, 
506). Experimental data from animals showing that inflammatory cytokines (IL-6, TNF-α, 
IL-1β) can increase sympathetic nerve activity (52, 61, 153) led to the hypothesis that 
elevated circulating cytokine concentrations are associated with increased MSNA in RA. By 
using microneurography to provide a direct assessment of central sympathetic outflow 
limitations associated with the measurement of plasma catecholamines which reflect tissue 
clearance and uptake as well as production (509), were circumvented. This study
demonstrated that RA is characterised by increased MSNA, which may contribute to the 
increased cardiovascular risk and mortality seen in RA. Further interventional studies that 
inhibit cytokines and reduce inflammation in RA are needed to determine whether the 
relationship between MSNA and inflammation is causal.
5.6.2 Reduced cBRS in RA
Reduced cBRS is present in cardiovascular diseases such as hypertension, chronic 
heart failure and predicts mortality risk following MI (284, 294). Using the MOT, which 
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provides an assessment of BRS control across a wide BP range (433), we observed that cBRS 
was reduced in patients with RA. The underlying mechanisms may relate to altered central 
baroreflex modulation, disruptions in afferent or efferent pathways. Nevertheless, this reduced 
cBRS may contribute to the increased cardiovascular and mortality risk seen in RA (21, 507). 
Interestingly, the baroreflex dysfunction was specific to the cardiovagal limb as the control of 
MSNA was not different between groups. The prognostic significance of alterations in 
sympathetic BRS has not been studied, however baroreflex activation therapy has been shown 
to reduce MSNA, improve symptoms and increase ejection fraction in chronic heart failure 
patients (511). Studies of elderly individuals (512) and patients with HTN (62) have 
previously reported a discrepancy between baroreflex control of the heart and MSNA as 
observed in the present study. Such observations may reflect disparate changes in vagal and 
sympathetic motoneuronal modulation, and/or cholinergic signalling at the sinoatrial node 
(433, 513, 514).
5.6.3 Pain and autonomic interactions
In the present study, pain was independently associated with MSNA burst frequency 
and cBRS. These findings are in agreement with work showing that experimentally evoked 
chronic pain can heighten sympathetic outflow (515-518) and reduce cBRS (519). Although 
the precise mechanisms are not fully understood interactions between pain and cardiovascular 
control may be explained by an overlap in anatomical structures and pathways including 
afferent pathways (e.g. baroreceptor and nociceptor projections), central modulation (e.g. 
nucleus of the solitary tract) and efferent pathways (e.g. descending pain inhibitory, 
sympathetic and parasympathetic projections) (520). In the present study RA patients had 
greater self reported pain than RA-HTN patients despite similar serum concentrations of hs-
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CRP. This may reflect the higher pain threshold observed in hypertensive individuals (i.e., 
hypertensive hypoalgesia) (521) or possibly an effect of the higher concentration of 
inflammatory cytokines in the RA group. Evidence from animal (522, 523) and human 
experiments show that inflammatory cytokines have a direct role in modulation of pain 
perception (524). TNF-α inhibition acutely blocked both central nociceptive activity and 
activation of the limbic system in RA patients (524). While disease control improves survival 
in RA (412, 525, 526), further clarification is needed to distinguish between the effects of 
pain management and disease control on autonomic function. 
5.6.4 Elevated HR in RA
Elevated HR is an independent predictor of mortality in the general population (527)
and in other conditions (e.g., chronic heart failure, coronary artery disease, MI, hypertension 
and diabetes mellitus) (528-532). Patients with RA were observed to have an elevated HR in 
the present study, independent of hypertension. Aside from an increase in cardiac sympathetic 
nerve activity and decrease in parasympathetic activity there are a several potential 
mechanisms: chronic anaemia (533, 534), increased metabolic rate due to chronic 
inflammation (41) or concomitant thyroid dysfunction (535, 536), medication (534, 537); 
anxiety or depressive illness (538) and low physical activity (539). Attempts to lower HR 
with the use of β-blockers following MI or in chronic heart failure has been shown to improve 
survival (540). In an experimental model of arthritis the use of carvedilol (non selective β-
blocker) was associated with reduction in markers of oxidative stress and release of 
inflammatory cytokines (TNF-α, IL-6) (541). Whether such benefits would be manifest in RA 
patients treated with β-blockers requires further study. In this present study, MSNA burst 
frequency (bursts per minute) was higher in RA patients but MSNA burst incidence (bursts 
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per 100 heart beats) was not, likely on account of the elevated HR. Nevertheless, the 
observation that bursts per unit time are elevated in RA and RA-HTN compared to NC may 
be interpreted as being indicative of heightened sympatho-excitation. The relatively small 
sample size is a potential limitation of the present study however this did not prevent a 
significantly elevated MSNA burst frequency being detected in the RA, RA-HTN and HTN 
groups compared to control. 
5.6.5 Strengths and limitations
An important strength of this study design is the inclusion of hypertensive control 
groups allowing to control for the presence of hypertension in RA. Whilst increased MSNA 
and reduced cBRS are known to be present in hypertension (542), this study shows that in RA 
these autonomic alterations can occur independently of hypertension suggesting an alternative 
mechanism. Although the cross-sectional design precludes establishment of causality, it may 
be postulated that heightened sympathetic outflow can occur prior to the development of 
hypertension and may possibly contribute to the development of hypertension in some 
patients with RA. Autonomic dysfunction may be a causal agent in the pathogenesis of RA or 
a consequence of the disease, or both. This study could not discern between the influence of 
pain and inflammation on autonomic dysfunction. 
5.6.6 Future directions
Future randomised controlled interventional studies are needed to clarify whether 
autonomic dysfunction is a cause or consequence of RA and in particular to discern between 
the contributions of inflammation and pain to autonomic dysfunction in RA. In light of the 
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evidence that heightened sympathetic outflow can evoke T cell activation (159) and may 
reduce blood flow (543) causing cytokine release and increased oxidative stress thus 
compounding problems of inflammation and afferent sensitisation, it should be examined 
whether therapeutic lowering of central sympathetic outflow in RA has anti-inflammatory 
actions.
5.7 Conclusion
In conclusion, this study is the first to demonstrate heightened MSNA and reduced 
cBRS using the MOT in RA. Heightened sympathetic outflow and reduced baroreflex control 
of HR in RA may potentially contribute to the recognised increase in cardiovascular risk. 
Further studies in RA are warranted to determine whether anti-inflammatory agents restore 
autonomic balance, whether sympatholytic agents reduce inflammation, and whether this 
translates into improved morbidity and mortality. Such interventional studies may help 
improve understanding of the pathophysiology of RA, and in particular shed light on the 
interplay between inflammation, pain and the ANS.
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CHAPTER 6 Experiment Two. HRV and cardiovascular reactivity in RA: a case control 
study
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6.1 Abstract
Objectives RA is a chronic inflammatory condition characterised by reduced HRV and 
impaired cardiovascular reflexes. It is unknown whether cardiovascular reactivity to stress is 
altered in RA. This study sought to determine HRV and cardiovascular reactivity in RA, and 
to assess for associations with inflammation.
Methods Beat-to-beat BP (Portapres), HR (ECG), LVC and FVC (strain gauge 
plethysmography) were recorded in age- and sex-matched RA-normotensive (n=13), RA-
HTN (n=17), NC (n=17) and HTN (n=16) controls during rest, CPT and PASAT mental 
stress test. Short-term HRV (rMSSD) and inflammation (serum hs-CRP, TNF-α and IL-10) 
were determined. 
Results. HRV was reduced in RA, RA-HTN and HTN groups compared to NC (p=0.001). 
CPT increased HR and BP and reduced LVC while PASAT increased HR, BP and FVC in all 
groups. During CPT: ∆HR was greater in HTN compared to NC and RA-HTN (p=0.05), but 
similar to RA; ∆LVC was greater in RA and RA-HTN compared to controls (p=0.065). 
During PASAT: ∆BP tended to be higher in RA compared to RA-HTN patients (p=0.183); 
∆FVC was greater in RA, RA-HTN and HTN groups compared to NC (p=0.110). 
Multivariable analysis revealed independent positive associations between: IL-10 and ∆HR 
CPT (F=6.192, p=0.016), ∆HR PASAT (F=5.831, p=0.02), ∆FVC PASAT (F=4.555, 
p=0.039); TNF-α and ∆HR CPT (F=4.715, p=0.034); and a trend for inverse association 
between hs-CRP and rMSSD (F=3.036, p=0.088).
Conclusions. Vascular responses to stress are exaggerated in RA although further work is 
required to determine the prognostic significance. Independent relationships are present 
between inflammatory cytokines and cardiovascular reactivity (positive) but not HRV.
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6.2 Introduction
RA is a chronic inflammatory condition associated with increased cardiovascular 
mortality and risk (20-23). Low HRV predicts mortality risk following MI (204-206) and 
hence may contribute to the increased cardiovascular risk seen in RA. Studies to date have 
shown that HRV indices of parasympathetic function are reduced in RA, compared to healthy 
controls (445, 451, 455, 457, 464, 467, 473, 484)(Chapter 4), although the mechanisms are 
not known. One possible mechanism is the effect of circulating inflammatory cytokines. 
Reciprocal relationships have been demonstrated between HRV and inflammatory cytokines 
in animals. Cholinergic stimulation has been shown to inhibit inflammatory cytokines (IL-1, 
IL-6 and TNF) (255-258), whilst TNF-α reduced HRV in animals (273). In one human study 
of inflammatory arthritis, hs-CRP was independently inversely associated with HRV although 
cytokines were not measured (377). To the author’s knowledge no human studies have 
assessed for relationships between cytokine concentrations and HRV.
The ANS is responsible for cardiovascular regulation at rest and in response to stressors 
(72, 81, 82). Exaggerated cardiovascular responses to a CPT (immersion of a limb into cold 
water) or mental stress can predict the development of cardiovascular disease (329-338) (339, 
340). In RA, one prior study demonstrated impaired diastolic BP responses to CPT (450)
while cardiovascular responses to mental stress appear conflicting (456, 465, 481, 544, 545),
although limb blood flow was not measured. Evidence from animal studies suggests that 
inflammatory cytokines released during sepsis (IL-6, IL-1β and TNF-α) may play an 
important role in mediating vasodilatory responses (355-360). It remains unknown whether 
chronic elevations of inflammatory cytokines as occurs in RA would impair cardiovascular 
reactivity to stressors.
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6.3 Aims and hypothesis
Central hypothesis: In patients with RA, elevated concentrations of circulating inflammatory 
cytokines are associated with reduced HRV and impaired cardiovascular reactivity. 
Cardiovascular responses to the CPT and PASAT mental stress would be impaired in RA.
Aim: To test this, an observational, case-control study in patients with RA (with and without 
hypertension) and controls (with and without hypertension) was undertaken to measure 
baseline serum inflammatory cytokine concentrations, HRV and cardiovascular responses to 
CPT and PASAT mental stress. 
Hypothesis:
i) Reduced HRV is associated with increased inflammatory cytokine 
concentrations;
ii) Cardiovascular reactivity to CPT and mental stress are impaired in RA
compared to controls;
iii) Cardiovascular responses to CPT and mental stress are associated with serum 
inflammatory cytokine concentrations.
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6.4 Methods
6.4.1 Subjects and experimental protocol
Participants and study design was the same as in Chapter 5, 6. The protocol involved a 
resting 10-minute baseline period followed by CPT, and PASAT mental stress test.
6.4.2 Measurements
HR (lead II ECG) and beat-to-beat BP (finger photoplethysmography) were
continuously recorded at rest and during the cardiovascular tests. Brachial BP recordings 
(automated sphygmomanometer) were used to calibrate BP. Leg blood flow (venous 
occlusion strain gauge plethysmography) was recorded during rest, test and recovery phases 
of the CPT and PASAT. In addition forearm blood flow was recorded during the PASAT.
Pain and stress ratings (10 point scale) were taken after the CPT and PASAT, respectively. 
6.4.3 Data analysis
Time domain, frequency domain and non-linear indices of HRV were determined 
during the 10-minute resting baseline period (Kubios HRV software). Some participants 
declined or were unable to tolerate the cardiovascular reactivity tests, and blood flow signals 
were not analysable in a number of cases due to movement artefacts, thus these were omitted 
from the analyses. Participant numbers are stated in the legend of each Table and Figure. BP, 
HR, forearm and leg blood flow and FVC, LVC were averaged during rest, test and recovery 
phases, and change from rest calculated.
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6.4.4 Blood sampling
Blood samples for inflammatory markers were centrifuged immediately and the 
plasma stored at -80 oC. Commercially available ELISA kits were used to determine hs-CRP
(MP Biomedicals, California, USA) and cytokines (IL-6, TNF-α, IL-10; BioSupply UK, 
Bradford, UK).
6.4.5 Statistics
Statistical analysis was performed using SPSS software, version 19 (SPSS Inc, 
Chicago, Ilinois). Continuous variables were tested for normality using the Kolmogorov-
Smirnov test. Non-parametric data was logarithmically transformed. Group differences were 
assessed using an ANOVA (LSD post-hoc) for continuous variables. For cardiovascular 
reactivity an ANOVA with repeated measures (Bonferroni adjustments for multiple 
comparisons) was used to test for significant differences between groups and phase (rest, test, 
recovery) during CPT and PASAT. Post-hoc LSD analysis was performed if significant group 
x phase interactions were found. Differences in changes from baseline (∆test, ∆recovery) in 
HR, BP, leg and forearm blood flow, LVC and FVC were tested using a one-way ANOVA.
Associations between autonomic parameters and inflammation were assessed before (Pearson 
product/Spearman’s rank correlation coefficient) and after adjustment for potential 
confounders. Data expressed as mean±SD for parametric data; geometric mean (95 % CI) for 
non-parametric data; and frequency (%) for categorical variables. A P value of ≤0.05 was 
considered statistically significant.
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6.5 Results
6.5.1 HRV
Time domain (rMSSD, pNN50 %), frequency domain (HF, LF absolute powers) and non-
linear parameters (SD1, SD2) of HRV were lower in RA, RA-HTN and HTN groups 
compared to NC (Table 6.1). VLF and TP were also lower in RA and RA-HTN groups 
compared to NC. There was a trend for difference in normalised frequency domain 
parameters of HRV. RA normotensive patients had higher normalised HF power (p=0.053), 
but lower normalised LF power (p=0.053) and LF/HF ratio (0.059) compared to RA-HTN. 
6.5.2 Cold pressor test
As expected, HR and BP rose during the CPT while LVC fell (Figure 6.1). HTN controls 
had a significantly higher rise in HR compared to NC and RA-HTN (RA +6±5, RA-HTN 
+5±4, NC +3±5, HTN +9±8 beats/min, p=0.05). There was no statistically significant 
difference in BP responses between the groups. The fall in LVC tended to be highest in RA 
and RA-HTN groups compared to HTN and NC (p=0.065). Leg blood flow rose in the HTN 
group but was unchanged in the remaining groups, although this difference was not 
statistically significant. RA, RA-HTN and HTN patients tended to have higher pain rating 
(RA geometric mean 8.3, 95 % CI 6.1-9.5; RA-HTN 7.8, 6.1-9.5; NC 5.6, 4.3-7.2; 7.4, HTN 
7.4, 5.4-8.6 max score 10; p=0.10) compared to NC.
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Table 6.1 HRV
RA RA-HTN NC HTN P value
N 13 17 17 16
rMSSD, ms 25 (18-36) * 20 (13-29) * 48 (38-60) 29 (20-40) * 0.001
pNN50, % 5 (2-12) * 3 (1-7) * 18 (11-29) 5 (2-12) * 0.005
SD1 18 (13-26) * 14 (9-21) * 38 (27-43) 20 (14-29) * 0.001
SD2 48 (36-63) * 46 (35-61) * 79 (67-94) 58 (45-76) 0.005
HF, ms2 256 
(131-500) *
116 
(52-260) *
759 
(436-1322)
240 
(116-496) *
<0.001
LF, ms2 272 
(153-482) *
245 
(132-456) *
1097
(746-1612)
357 
(186-683) *
<0.001
VLF, ms2 556 
(304-1020) *
567 
(315-1017) *
1431 
(951-2151)
946 
(552-1621)
0.025
TP, ms2 1135 
(631-2042)*
1014 
(569-1807) *
3104 
(2010-4793)
1665 
(943-4793)
0.010
HF, nu 49±15 † 34±14 42±15 41±15 0.053
LF, nu 51±15 † 67±14 58±15 59±15 0.053
LF/HF ratio 1.1 (0.7-1.5) 2.1 (1.5-3.0) 1.5 (1.0-2.1) 1.5 (1.0-2.1) 0.059
Values expressed as mean±SD (parametric). Non-parametric data was (natural) logarithmically
transformed and displayed as geometric mean (95% CI). Statistical differences were tested using a one-
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way ANOVA with post-hoc LSD. Significance P≤0.05. Post hoc P≤0.05 * v healthy control, † v RA 
hypertensive.
BMI = body mass index, BP = blood pressure, HF = high frequency power (0.15-0.4Hz), HR = heart 
rate, LF = low frequency power (0.04-0.15), RA = rheumatoid arthritis, pNN50 = NN50 as a percentage 
of all NN intervals, RMSSD = root mean square of successive differences, TP = total power, VLF = very 
low frequency power (0-0.04 Hz)
6.5.3 PASAT mental stress
As expected HR, BP, leg blood flow, forearm blood flow and FVC rose during the 
PASAT in all groups. There were no significant differences in HR responses between the 
groups (Figure 6.2). There was a trend for higher BP responses in HTN controls compared to 
RA-HTN patients (p=0.183). RA, RA-HTN and HTN groups tended to have higher forearm 
blood flow (p=0.110) and FVC (p=0.107) responses compared to NC. LVC and leg blood 
flow responses were higher in RA, RA-HTN and HTN groups compared to NC although the 
differences were not statistically significant. No difference in self-reported stress was found 
between groups (4.9±3.7, 5.3±3.7, 5.3±3.3, 4.4±2.7 max score 10; p=0.962).
6.5.4 Associations between inflammation and autonomic function
Time domain (rMSSD and pNN50), frequency domain (TP, LF power, HF power) and 
non-linear (SD1, SD2) parameters of HRV were inversely associated with hs-CRP (Appendix 
5). Following adjustments for multiple variables (i.e. age, sex, BMI, presence of hypertension, 
RA diagnosis and serum haemoglobin concentration) associations between rMSSD, pNN50,
SD1 and hsCRP were attenuated (Table 6.2). Inflammatory cytokines were inversely
associated with HRV parameters (IL-6 and rMSSD, LF power, SD1, SD2; IL-10 and LF/HF
ratio; trend for TNF-α and LF power) although these associations disappeared after
multivariable analysis.
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Figure 6.1 Cardiovascular reactivity to the CPT.
HR (Panel A), mean BP (Panel B), LVC (Panel C) and leg blood flow (Panel D) during rest, CPT and recovery. Data represented as group means±SEM. Times series 
is shown on the left. Significance for phase (rest, CPT and recovery), group (RA, RA-HTN, NC and HTN) and interaction were assessed using ANOVA with repeated 
measures. Bar charts on the right represent changes from baseline. Significant group differences were assessed using a one-way ANOVA. * P≤0.05. BP =blood 
pressure, CPT = cold pressor test, HR = heart rate, HTN = hypertensive, LVC = leg vascular conductance, NC = normotensive control, RA = rheumatoid arthritis.
RA n = 12, RA-HTN n = 16, NC n = 16, HTN n = 16
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∆HR CPT was positively and independently associated with the inflammatory cytokines 
TNF-α and IL-10 (Appendix 5 and 6). There were trends for positive association between 
∆mean BP CPT and TNF-α, and ∆HR CPT and DAS28-CRP although these disappeared after 
multivariable adjustment. There was a trend (p=0.057) for an inverse association between IL-
10 and ∆mean BP CPT following multivariable analysis (Table 6.2). There were no 
associations seen between leg vascular responses to CPT and inflammation.
∆Systolic BP PASAT was inversely associated with IL-6 (Appendix 5), while there were 
trends for positive association between leg vascular responses to PASAT and inflammation
(hs-CRP, IL-6). Following multivariable analysis IL-10 was independently positively 
associated with ∆HR PASAT (p=0.020) (Appendix 6), while ∆mean BP PASAT was 
independently associated with the number of tender joints (p=0.029, Table 6.2). IL-10 was 
independently positively associated with ∆FVC PASAT (p=0.039), and ∆forearm blood flow 
PASAT (p=0.025) (Appendix 6). Trends for association between leg vascular responses to 
mental stress and inflammation (hs-CRP and IL-6) disappeared after multivariable 
adjustment.
6.5.5 Associations between pain and autonomic function
Pain was independently and inversely associated with time domain (rMSSD, pNN50) and 
non-linear (SD1, SD2) parameters of HRV (Table 6.2). There was a trend for an inverse 
association between pain and HR responses to mental stress however this disappeared after 
adjustment for multiple variables (Table 6.5). No other relationships were found between pain 
and cardiovascular responses to CPT or mental stress (Appendix 5).
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Figure 6.2 Cardiovascular reactivity to the PASAT mental stress test.
HR (Panel A), mean BP (Panel B), LVC (Panel C), leg blood flow (Panel D), FVC (Panel C), forearm blood flow (Panel D) during rest, PASAT mental stress test and 
recovery. Data represented as group means±SEM. Times series is shown on the left. Significance for phase (rest, PASAT and recovery), group (RA, RA-HTN, NC and 
HTN) and interaction were assessed using ANOVA with repeated measures. Bar charts on the right represent changes from baseline. Significant group differences 
were assessed using a one-way ANOVA. * P≤0.05. BP =blood pressure, CPT = cold pressor test, FVC = forearm vascular conductance, HR = heart rate, HTN = 
hypertensive, LVC = leg vascular conductance, NC = normotensive control, PASAT = paced auditory serial arithmetic task, RA = rheumatoid arthritis.
RA n = 10, RA-HTN n = 10, NC n = 16, HTN n = 14
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Table 6.2 Association between inflammation, pain and ANS function
N Univariable a Multivariable c
Rho P R2 F P
HEART RATE VARIABILITY
Dependent variable: rMSSD
hs-CRP 57 -0.420 0.001 0.334 3.036 0.088
IL-6 62 -0.258 0.043 0.216 0.230 0.633
Pain VAS 63 -0.437 <0.001 0.303 7.015 0.011*
Dependent variable: pNN50
hs-CRP 57 -0.430 0.001 0.388 3.270 0.077
Pain VAS 63 -0.419 0.001 0.356 7.179 0.010*
Dependent variable: SD1
hs-CRP 57 -0.420 0.001 0.334 3.038 0.088
Pain VAS 63 -0.437 <0.001 0.303 7.017 0.011*
Dependent variable: SD2
Pain VAS 63 -0.390 0.002 0.227 4.531 0.038*
Dependent variable: LF/HF ratio
IL-10 62 -0.262 0.040 -0.01 2.639 0.110
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N Univariable a Multivariable c
Rho P R2 F P
COLD PRESSOR TEST RESPONSES
Dependent variable: ∆HR CPT
TNF-α 60 0.254 0.050 0.175 4.715 0.034 *
IL-10 60 0.299 0.020 0.196 6.192 0.016 *
DAS28-CRP d 28 -0.308 0.111 0.399 0.901 0.354
Dependent variable: ∆Mean BP CPT
TNF-α 60 0.232 0.074 0.094 0.724 0.399
IL-10 60 -0.179 0.171 0.143 3.783 0.057
Dependent variable: ∆Systolic BP CPT
IL-10 60 0.112 0.395 0.133 3.396 0.071
Dependent variable: ∆Diastolic BP CPT
TNF-α 60 0.245 0.059 0.077 1.664 0.203
IL-10 60 0.212 0.103 0.109 3.536 0.066
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N Univariable a Multivariable c
Rho P R2 F P
MENTAL STRESS TEST RESPONSES
Dependent variable: ∆HR PASAT
IL-10 50 0.187 0.194 0.203 5.831 0.020 *
Pain VAS 50 -0.244 0.088 0.119 1.257 0.269
Dependent variable: ∆Mean BP PASAT
Number of tender joints 20 -0.376 0.102 0.610 5.996 0.029 *
Dependent variable: ∆Systolic BP PASAT
Number of tender joints 20 -0.403 0.078 0.529 4.455 0.055
Dependent variable: ∆leg blood flow PASAT
hsCRP 45 0.287 0.056 0.133 0.451 0.506
Dependent variable: ∆LVC PASAT
hsCRP 45 0.246 0.103 0.083 0.337 0.565
IL-6 49 0.237 0.101 0.085 0.473 0.495
Dependent variable: ∆forearm blood flow PASAT
IL-10 50 0.198 0.168 0.220 5.435 0.025
DAS28-CRP d 20 -0.394 0.086 0.434 2.008 0.182
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Tender 20 -0.394 0.110 0.407 3.253 0.095
Dependent variable: ∆FVC PASAT
IL-10 50 0.250 0.080 0.197 4.555 0.039
DAS28-CRP d 20 -0.402 0.079 0.115 0.219 0. 642
a Spearman’s rank or b Pearson’s correlation. c After adjustment for age, sex, BMI, presence of 
hypertension, RA diagnosis and haemoglobin concentration. d After adjustment for age, sex, BMI, 
presence of hypertension, haemoglobin concentration and RA duration.
BP = blood pressure, CPT = cold pressor test, DAS = disease activity score, FVC = forearm vascular 
conductance, HF = high frequency, HR = heart rat, hs-CRP = high sensitivity C-reactive protein, IL = 
interleukin, LF = low frequency, LVC = leg vascular conductance, NN50 = number of pairs of adjacent 
NN intervals differing by more than 50 ms, pNN50 = NN50 as a percentage of all NN intervals, 
PASAT = paced auditory serial arithmetic test, RA = rheumatoid arthritis, rMSSD = root mean square 
of successive differences, SD = standard deviation of the Poincare plot, TNF = tumour necrosis factor, 
VAS = visual analogue scale.
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6.6 Discussion
The main findings in this study were that RA patients had reduced resting HRV, 
increased leg vasoconstrictor responses to CPT and increased vasodilatory responses to 
mental stress compared to normotensive controls. Inverse associations were found between 
HRV and inflammation (hs-CRP, IL-6) although confounded, while independent associations 
were found between cardiovascular reactivity and inflammation (IL-10, TNF-α). Additionally
independent inverse associations were found between pain and HRV, while differences in 
cardiovascular reactivity between RA and non-RA patients with hypertension were observed.
6.6.1 Reduced HRV in RA
This study demonstrated reduced HRV in RA, consistent with prior studies, and weak 
inverse associations between HRV indices and inflammation (hs-CRP, IL-6, TNF-α) although 
confounded. In one prior animal study, TNF-α reduced HRV in a pattern similar to LPS-
induced sepsis although the mechanism is not clear (273). One potential mechanism for the 
reduced HRV is via altered baroreflex modulation of HR, which is impaired in RA (Chapter 
6). Administration of the inflammatory cytokine IL-6 directly into the NTS (a key ANS 
cardiovascular regulatory site) reduced BRS in rats (314) suggesting a direct effect of 
inflammatory cytokines. The strong independent inverse relationship found between pain and 
HRV in this study suggests that pain may have a significant contribution to the reduced HRV 
seen in RA and other chronic pain conditions (546). Another possible explanation for reduced 
HRV in RA is due to the effects of respiration, which has an important contribution to short-
term HR fluctuations (88, 89). Unfortunately one limitation of this study is that respiration
was not measured.  Further interventional studies with agents that inhibit cytokines are needed 
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to establish the mechanisms for reduced HRV in RA, and to distinguish between the influence 
of inflammation and pain.
6.6.2 Altered cardiovascular reactivity in RA
The present study demonstrated altered cardiovascular reactivity to CPT and mental 
stress in RA patients, which include increased HR (although not statistically significant) and 
leg vasoconstrictor responses to CPT and increased vasodilatory responses to mental stress in 
RA. BP responses to CPT and HR and BP responses to mental stress in RA were not 
significantly different compared to controls. The exaggerated leg vasoconstrictor responses 
observed in RA patients suggest a heightened MSNA response or increased sensitivity to 
MSNA within the peripheral vasculature. Resting MSNA was reported to be elevated in RA 
(Chapter 6) however no studies have assessed MSNA responses to CPT or indeed adrenergic 
sensitivity in the peripheral vasculature in RA. Another explanation is increased sensitivity to 
cold stimuli (547) due to chronic pain sensitisation. In this present study self reported pain 
ratings were higher in RA, RA-HTN and HTN patients compared to normotensive controls 
however no associations between pain and cardiovascular responses to the CPT were found, 
suggesting alternative mechanisms. This study is the first to demonstrate exaggerated forearm 
vasodilatory responses to mental stress in RA. The mechanisms underlying mental stress-
induced vasodilation are not fully understood and include: regional sympathetic withdrawal 
(548), β-adrenergic mediated vasodilation(548), flow (shear stress) and nitrate mediated 
vasodilation (549), acetycholine-mediated (550) and circulating factors (e.g. including 
adrenaline (551). One potential factor is the influence of inflammatory cytokines.
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6.6.3 Inflammation and vascular reactivity
In this study, serum concentrations of IL-10 were positively and independently 
associated with forearm vasodilatory responses to mental stress whilst no relationship was 
found with other inflammatory cytokines. The release of inflammatory cytokines during acute 
sepsis is thought to contribute to hypotension via vascular hyporeactivity though a number of 
suggested mechanisms (355-360). However, while prior studies have shown that TNF-α and 
IL-1β reduce vascular reactivity in animals (357, 358), no studies have assessed the effects of 
IL-10 on the vasculature. During acute inflammation the release of serum pro-inflammatory 
cytokines stimulates the production and release of IL-10 (45). Although IL-10 inhibits the 
synthesis and actions of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) elevated
circulating IL-10 is likely to represent inflammation. This is likely given the strong positive 
association between IL-10 and other cytokines (TNF-α, IL-6) found in this study. The results 
of the present study implicate a role for IL-10 in exaggerated vasodilation although further 
studies are required to determine the precise mechanisms.
6.6.4 Strengths and limitations
The inclusion of a hypertensive control group was a major strength in this study and 
provided insights into the mechanisms of cardiovascular disease in RA. The differences in 
cardiovascular profiles between RA and non-RA hypertensive individuals, namely that RA-
HTN patients had reduced HR and leg vasoconstrictor responses to CPT, and reduced BP 
responses to mental stress (trend) compared to non-RA HTN, suggest alternative 
pathophysiological mechanisms for hypertension in RA. Another major strength is the 
inclusion of limb blood flow measurements, which were absent in prior studies. The major 
limitations of this study include the cross-sectional design, which prevents establishment of 
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causality and the relatively small numbers, which increases the risk of a type II error. 
Nevertheless despite this strong links between inflammation and cardiovascular responses 
were demonstrated suggesting a true relationship. The lack of strong associations between 
HRV and inflammation probably relate to insufficient sample size. Another important 
limitation is that respiration and the HPA system (co-activated along with the sympathetic 
nervous system during stress) were not assessed and therefore may have been a potential 
confounder.
6.6.5 Future directions
Further interventional studies are required in RA using biological agents to target and 
inhibit cytokines to confirm whether elevated concentrations of inflammatory cytokines 
contribute to the altered cardiovascular reactivity seen in RA. In addition further larger studies 
are required to confirm the presence of altered cardiovascular reactivity in RA, explore the 
underlying mechanisms and to establish the prognostic implications. Further studies are also 
needed to determine the interactions between autonomic and HPA systems during stress and 
their influence on cardiovascular responses.
6.7 Conclusion
In conclusion, this study is the first to demonstrate increased forearm vasodilatory 
responses to mental stress and increased leg vasoconstrictor responses to CPT in RA
compared to controls. Independent associations were found between inflammation and 
cardiovascular reactivity however further studies are needed to determine causal relationships, 
and to determine their prognostic significance. 
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CHAPTER 7 Experiment Three. Effects of TNF-α inhibitor on autonomic function in RA: a 
longitudinal case-study
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7.1 Abstract
Objectives RA is a chronic inflammatory condition associated with increased cardiovascular 
mortality. In animal studies, inflammatory cytokines increase sympathetic activity and reduce
cBRS. This study sought to determine the effects of TNF-α inhibition on autonomic function
in an RA patient.
Methods Whilst resting supine, beat-to-beat BP (Portapres), HR (lead II ECG) and MSNA
(microneurography) were continuously recorded at rest (10 mins) and following sequential 
bolus infusions of SNP and PE (MOT) in a chronic RA male patient (age 60 years). MSNA 
burst incidence (burst/100 heartbeats) and short-term HRV (rMSSD) were determined at rest. 
Sympathetic and cBRS were determined during the MOT. Inflammation (serum hs-CRP) and 
pain (Pain VAS) were assessed. Experiments were undertaken before and after (2 weeks and 3 
months) initiation of TNF-α inhibitor therapy.
Results Inflammation (∆hs-CRP -18.8 mg/L) and pain (∆pain VAS -30 mm) fell within 2 
weeks. MSNA (+6.8 bursts/100 heart beats) increased after 3 months, whilst sBRS remained 
unchanged (+0.5 %[bursts/beat]/mmHg). At 2 weeks cBRS (+3.2 ms/mmHg) and rMSSD 
(+4.4 ms) rose, while mean BP (-18 mmHg) and HR (-5 beats/min) fell although these 
changes were not sustained at 3 months.
Conclusion These results suggest that TNF-α inhibition in RA elicits acute improvements in 
autonomic function in parallel with reductions in inflammation and pain, although not 
sustained. Further studies are warranted to confirm these findings.
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7.2 Introduction
RA is a chronic inflammatory condition associated with synovial joint destruction, 
systemic inflammation and elevated cytokine concentrations (6). Traditionally disease-
modifying drugs were the mainstay agents in controlling disease activity during acute flares
(11, 13). In recent years biologic agents have been developed to target and counteract specific 
immune cells and cytokines (411). TNF-α is one such example; a pro-inflammatory cytokine 
that plays a key role in regulating inflammatory responses in RA (6). TNF-α has multiple 
actions including activation of leucocytes, endothelial cells and synovial fibroblasts leading to 
production of further cytokines, adhesion and inflammatory molecules (552). TNF-α also has 
a role in promoting atherosclerosis (553), angiogenesis, endothelial dysfunction (554, 555)
and induction of pain (524). Recent evidence suggests that TNF-α has deleterious effects on 
the ANS. In animal studies peripheral (58, 61) and central (57, 59) administration of TNF-α 
increased sympathetic activity whilst central administration of IL-6 (an inflammatory 
cytokine elevated in RA patients and stimulated by TNF-α (556) reduced BRS (314).  
Heightened sympathetic activity and reduced BRS are pathogenic features of hypertension
(62, 279, 280), ischemic heart disease (64, 284), chronic heart failure (63, 281-283) and RA 
(Chapter 6), and are associated with increased mortality risk (113, 206, 284, 290-294, 384). 
While studies have demonstrated that TNF-α inhibition effectively reduces disease activity 
(411) and improves cardiovascular (557) and mortality risk (412, 558) in RA patients, the 
mechanisms are unknown. Prior studies assessing the effects of TNF-α inhibition on 
autonomic function showed conflicting results. In one study, TNF-α inhibition reduced BP
and serum noradrenaline concentrations after 2 weeks (559) whilst in two other studies no 
effect on serum NPY (biomarker of sympathetic activity) concentrations were seen (468). 
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Previous studies have suggested that increased inflammation is associated with 
increased MSNA (Chapter 6), reduced BRS (Chapter 6), reduced HRV (Chapter 7) and 
exaggerated vascular responses to mental stress (Chapter 7). This is the first study to report 
the acute and medium-term effects of TNF-α inhibitor therapy on MSNA as measured using
the microneurography technique, a direct measure of sympathetic outflow, in a patient with 
RA. In addition BRS, resting HRV and cardiovascular reactivity to mental stress before and 
after TNF-α inhibition was assessed.
7.3 Aims and hypothesis
Central hypothesis: In patients with RA, elevated concentrations of circulating inflammatory 
cytokines are associated with increased MSNA, reduced BRS, reduced HRV and impaired
cardiovascular reactivity to stressors.
Aim: To test this, a longitudinal, case study in RA patients was undertaken to measure 
baseline serum inflammatory cytokine concentrations, MSNA, BRS, HRV and cardiovascular 
responses to mental stress before and after TNF-α inhibitor therapy.
Hypothesis: In RA, TNF-α inhibition
i) reduces sympathetic outflow (MSNA);
ii) increases sensitivity of the baroreflex control of the heart;
iii) increases HRV;
iv) normalises cardiovascular responses to mental stress. 
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7.4 Methods
7.4.1 Subjects
Patients fulfilling the ACR 1987 diagnostic criteria for RA were recruited from the 
Rheumatology clinic at Russells Hall Hospital, Dudley Group of Hospitals, Dudley, UK to 
take part in an observational longitudinal study. Patients were assessed by a qualified 
Rheumatologist and deemed eligible to receive TNF-α inhibitor therapy for control of an 
acute RA flare as part of routine clinical care. Ethical approval was obtained from the local 
research ethics committee and informed written consent was obtained in accordance with the 
Declaration of Helsinki 2013. Patients were invited to the research laboratory for assessments 
prior to initiation of TNF-α inhibition and again at 2 weeks and 3 months after starting 
treatment. Patients were contacted by telephone to check they remained on the treatment, and 
those who discontinued treatment were excluded from the study. Clinical history and 
examination was performed at each visit to record changes in medications, the number of 
swollen and tender joints and to record pain (pain VAS). 
7.4.2 Measured variables
HR, beat-to-beat BP and MSNA were recorded continuously during a 10 minute resting 
baseline and during the MOT as described in Chapters 3, 5 and 6. MSNA activity was 
reported as burst frequency and incidence. Cardiac baroreflex gain was determined using the 
MOT (GMOT) and rest using the “sequence method” (GSEQ) and low frequency transfer 
function (GLFTF). Sympathetic BRS was also determined using the MOT and during rest 
(spontaneous). HRV was assessed using time domain, frequency domain and non-linear 
indices. In addition SDNN was also used as a time domain index of HRV. HR, BP, leg blood 
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flow, LVC, forearm blood flow and FVC responses to the PASAT mental stress test were also 
recorded. 
7.4.3 Blood sampling
Commercially available ELISA kits were used to determine hs-CRP and cytokines (IL-
6, TNF-α, IL-10). ESR (Starrsed compact Mechatronics BV, The Netherlands) was also 
analysed.
7.5 Results
Of 4 patients recruited into the study, 2 dropped out due to discontinuation of TNF-α
inhibitor therapy, 1 was excluded due to frequent ectopics on their ECG and 1 completed the 
study (60 year old Caucasian male, RA disease duration 4.0 years, RF antibody negative, anti-
CCP antibody positive, DAS28-CRP 6.6) receiving TNF-α inhibitor therapy (Adalimumab 40 
mg subcutaneous every 2 weeks) for at least 3 months without interruption. There were no 
changes in concomitant medications, which included hydroxychloroquine, leflunomide, an 
NSAID, weak opioid and a proton pump inhibitor. BMI fell at 2 weeks but returned to pre-
treatment level at 3 months (Pre v 2 weeks v 3 months 27.2 v 26.5 v 27.8 Kg/m2).
7.5.1 Inflammation and pain
Inflammation and pain were reduced after 2 weeks of TNF-α inhibitor therapy and 
remained low at 3 months (Table 7.1). Of the cytokines tested serum concentrations of TNF-α
rose at 2 weeks and returned to pre-treatment levels at 3 months.
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7.5.2 MSNA and haemodynamic parameters
Following 3 months of treatment MSNA increased (burst frequency pre v 3 months 
23.0 v 27.4 bursts/min; burst incidence 36.0 v 42.8 bursts/100 heart beats). HR and BP fell at 
2 weeks but returned to pre-treatment levels at 3 months (Table 7.2). LVC increased at 2 
weeks and fell to below pre-treatment level at 3 months, while leg blood flow did not change 
at 2 weeks and fell at 3 months.
7.5.3 BRS
Spontaneous and pharmacological measures of BRS demonstrated different responses. 
At 3 months sympathetic BRS during the MOT increased whilst spontaneous sympathetic 
BRS fell (Figure 7.1). GMOT and GLFTF increased at 2 weeks but returned to pre-treatment 
levels at 3 months (Figure 7.2) while GSEQ fell at 2 weeks and remained lower at 3 months. 
7.5.4 HRV
Time domain and non-linear indices of HRV increased at 2 weeks and fell to pre-
treatment levels at 3 months (Table 7.3). Absolute VLF and LF powers increased at 2 weeks 
and fell to pre-treatment levels at 3 months. Absolute HF power fell at 2 weeks and increased 
to higher than pre-treatment levels at 3 months. 
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Table 7.1 Effects of TNF-α inhibition on pain and inflammation
Pre 2 weeks 3 months
Pain VAS, mm 64 34 24
DAS28-CRP 6.6 5.1 4.9
Swollen joints, n 8 5 4
Tender joints, n 24 17 1
hs-CRP, mg/L 26.0 7.2 2.1
ESR, mm 1st hour 37 8 8
TNF-α, pg/ml 63 71 63
IL-6, pg/ml 92 73 72
IL-10, pg/ml 135 125 108
DAS = disease activity score, ESR = erythrocyte sedimentation rate, hs-CRP = high sensitivity C-reactive 
protein, IL = interleukin, TNF = tumour necrosis factor, VAS = visual analogue scale
7.5.5 PASAT mental stress test
As expected HR increased during the PASAT (Figure 7.3). Pre-stress resting HR was 
lower at 2 weeks, as were HR responses. Prior to treatment BP responses to the PASAT were 
blunted, however these increased at 2 weeks and again at 3 months following TNF-α inhibitor 
therapy. Leg vasodilatory responses were blunted prior to treatment and although improved at 
2 weeks this was not sustained at 3 months. Prior to treatment forearm vasodilation was seen 
in response to mental stress. Forearm vasodilatory responses were increased at 2 weeks but 
were blunted at 3 months (Figure 7.3).
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Table 7.2 Effects of TNF-α inhibition on haemodynamic parameters
Pre 2 weeks 3 months
MSNA burst frequency 
(bursts/min)
23.0 - 27.4
MSNA burst incidence (bursts/100 
heart beats)
36.0 - 42.8
Systolic BP, mmHg 136 108 128
Diastolic BP, mmHg 87 73 83
Mean BP, mmHg 103 85 98
HR, beats/min 64 59 64
Leg blood flow, ml/100ml/min 3.0 3.0 2.4
LVC, arbitrary units 29 35 24
BP = blood pressure, HR = heart rate, LVC = leg vascular conductance, MSNA = muscle sympathetic nerve 
activity
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Figure 7.1 Effects of TNF-α inhibition on BRS.
Plot displaying cardiac and sympathetic BRS prior to (pre, black) and 2 weeks (white) and 3 months (grey) after 
TNF-α inhibitor therapy. Cardiac baroreflex gain determined using the MOT (GMOT, Panel A), the sequence 
technique (GSEQ, Panel B) and low frequency transfer function gain (GLFTF, Panel C). Sympathetic baroreflex 
gain determined using MOT (Panel D) and spontaneous measures (Panel E). 
BRS = baroreflex sensitivity, LFTF = low frequency transfer function, MOT = modified Oxford technique, TNF 
= tumour necrosis factor.
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Figure 7.2 Effects of TNF-α inhibitor therapy on cBRS (original record).
Original record showing baroreflex function curves during the MOT prior to (pre, +), 2 weeks (X) and 3 months (O) after TNF-α inhibitor therapy. At 2 weeks, the 
slope of the baroreflex slope increased and shifted upwards and to the left but this was not sustained at 3 months. BRS = baroreflex sensitivy, TNF = tumor necrosis 
factor
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Table 7.3 Effects of TNF-α inhibition on HRV
Pre 2 weeks 3 months
     SDNN, ms 23.6 49.1 33.2
     rMSSD, ms 16.1 20.5 16.7
     NN50, count 0 21 0
     pNN50, % 0 3.7 0
     VLF abs, ms2 262 875 288
     LF, ms2 114 344 83
     HF, ms2 150 83 175
     TP, ms2 264 427 258
     LF, nu 43.3 80.6 32.2
     HF, nu 56.7 19.4 67.8
     LF/HF ratio 0.8 4.1 0.5
     SD1 11.4 14.5 11.8
     SD2 31.4 67.9 45.4
HF = high frequency (0.15-0.4 Hz), LF = low frequency (0.04-0.15 Hz), NN50 = number of pairs of adjacent 
NN intervals differing by more than 50 ms, pNN50 = NN50 as a percentage of all NN intervals, nu = normalised 
units, rMSSD = root mean square of successive differences, SD = standard deviation of the Poincare plot,
SDNN = standard deviation of all NN intervals, TP = total power, VLF = very low frequency (0-0.04 Hz).
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Figure 7.3 Effects of TNF-α inhibition on PASAT mental stress responses
HR (Panel A), mean BP (Panel B), LVC (Panel C), leg blood flow (Panel D), FVC (Panel E) and forearm blood flow (Panel F) during rest, PASAT mental stress test
and recovery prior to (pre, black), and after 2 weeks (white) and 3 months (grey) of TNF-α inhibitor therapy. Times series is shown on the left. Bar charts on the right 
represent changes from baseline.
BP = blood pressure, FVC = forearm vascular conductance, HR = heart rate, LVC = leg vascular conductance, PASAT = paced auditory serial arithmetic task
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7.6 Discussion
This study, to the author’s knowledge is the first to describe the effects of TNF-α
inhibition on MSNA and BRS in RA. A modest increase in MSNA was seen following 3 
months of treatment with TNF-α inhibitor that was accompanied by a small reduction in 
resting BP, increased resting leg vasoconstriction and reduced forearm vasodilatory responses 
to mental stress. In addition BP responses to mental stress were increased. With the exception 
of serum TNF-α concentrations all other markers of inflammation and pain improved after 3 
months of treatment; TNF-α concentrations however remained unchanged. 
Animal studies showing that peripheral and central administration of inflammatory 
cytokines (TNF-α, IL-6) increase sympathetic nerve activity (52, 57-59, 61) led to the 
hypothesis that anti-inflammatory agents would reduce MSNA. However in this study 
cytokine inhibition increased MSNA. One simple explanation for the apparent rise in resting 
MSNA is a shift in the operational point of the baroreflex function curve as a result of a lower 
resting BP (Figure 7.4), an effect seen with chronic anti-hypertensive medication use (560). 
This is possible given that sympathetic BRS was relatively unchanged. In prior studies plasma 
concentrations of NPY were unchanged in RA patients after 2 months of infliximab (468) and 
3 months of Adalimumab (460). NPY, a co-transmitter released with noradrenaline, may be 
used as a plasma biomarker of sympathetic activation (425). Plasma biomarkers of 
sympathetic activation however may be confounded by numerous factors (including 
medications and diurnal variation) and are affected by metabolism and clearance, which can 
make interpretation difficult (323, 422). In contrast, MSNA using the microneurography 
technique provides a direct measure of sympathetic outflow that appears to be relatively stable 
(422) and correlates with cardiac sympathetic activity (422). Prior studies have also shown 
that plasma biomarkers of sympathetic activity do not always correlate with MSNA (122, 
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561, 562). Unfortunately MSNA was not measured at 2 weeks therefore it is not possible to 
comment on the effects of TNF-α on sympathetic activity in this study.
Figure 7.4 Baroreflex function curve.
A change in the operational point (open circle) can occur when resting BP falls causing a rise in resting MSNA, 
whilst the slope of the baroreflex function curve (BRS) remains unchanged.
BP = blood pressure, BRS = baroreflex sensitivity, MSNA = muscle sympathetic nerve activity
In this study Adalimumab effectively reduced pain and inflammation within 2 weeks 
of treatment. This was accompanied by reductions in resting BP and HR, and improvements 
in parasympathetic activity and cBRS. These results build upon the results of prior work, 
which demonstrated associations between inflammatory cytokines and HR, cBRS (Chapter 6) 
and HRV (Chapter 7). The present study suggests that inflammation and pain are two 
important mechanisms involved in autonomic dysregulation in RA, although it was not 
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possible to discern between them. This is consistent with a prior study showing that TNF-α 
inhibition acutely reduces pain in RA patients by blocking central nociceptive activity and 
limbic system activation (524). To the author’s knowledge this is the first study to assess the 
effects of TNF-α inhibition on cBRS. TNF-α inhibition acutely altered the baroreflex curve in 
two ways. Firstly there was a shift in the position of the curve and secondly the slope of the 
linear portion of the curve was changed (Figure 7.2). This supports the hypothesis that 
inflammatory cytokines have a role in the central modulation of baroreflex function. The 
mechanisms by which inflammatory cytokines exert their effects are not fully known, as they 
are too large to pass the blood brain barrier. Wei and colleagues have performed a series of 
animal experiments suggesting that cytokines can exert central effects via the 
circumventricular organs and in particular the SFO (48, 49). Intra-carotid artery injection of 
TNF-α and IL-1β dramatically increased BP, HR and sympathetic activity in rats with an 
intact SFO however these responses were significantly reduced in rats with SFO lesions (49). 
Additionally using immunofluorescent techniques they were able to demonstrate a dense 
distribution of TNF-α receptor within the SFO. In a subsequent experiment they directly 
injected the SFO with TNF-α, which increased BP, HR and sympathetic responses. Pre-
treatment of the SFO with angiotensin II type-1 receptor blocker, ACE inhibitor and COX-2 
inhibitor attenuated the TNF-α responses. Furthermore they demonstrated that 4 hours 
following direct injection of TNF-α into the SFO, mRNA expression of angiotensin II type-1 
receptor blocker, ACE inhibitor and COX-2 inhibitor were increased within the SFO and 
downstream within the hypothalamic PVN (a key autonomic regulatory site). While these 
experiments suggest that inflammatory cytokines can modulate autonomic control further 
studies are required to demonstrate whether these mechanisms occur in RA. In this study 
acute improvements in autonomic function were not sustained following 3 months of TNF-α 
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inhibitor therapy despite adequate control of inflammation and pain. This finding is surprising 
and may reflect the development of resistance to therapy (e.g. via upregulation of TNF-α 
receptors) or the effects of other pro-inflammatory cytokines not measured (e.g. IL-1β).
This study found that TNF-α inhibition evoked transient vascular changes. At rest, 
compared to pre-treatment leg vasodilation occurred at 2 weeks, but at 3 months there was 
vasoconstriction. Forearm and leg vasodilatory responses to mental stress were increased at 2 
weeks but blunted at 3 months. These findings suggest an acute increase in vasodilatory 
capacity, which may be related to a fall in sympathetic vasoconstriction or alterations in 
endothelial function. In one study of RA patients TNF-α inhibition resulted in a significant 
improvement in microvascular endothelial-dependent function after 2 weeks however this was 
not sustained at 3 months (563). One possible explanation is an improvement in 
bioavailability of NO. TNF-α has deleterious consequences on the endothelium (555)
resulting in reduced NO availability via down-regulation of endothelial NOS expression 
(554). In healthy humans, TNF-α acutely inhibited acetylcholine-mediated vasodilation with 
no further effect seen with NOS inhibition. In another study of metabolic syndrome patients, 
TNF-α inhibition acutely improved acetylcholine-mediated vasodilation. These studies 
suggest that TNF-α has an important role in mediating vascular reactivity likely via increasing 
NO bioavailability. Increased NO availability may also contribute to the reduction in BP seen 
at 2 weeks; although does not account wholly as HR would have expected to rise (via 
baroreflex activation). Further work is required to explain why the increased vascular 
responses were not sustained 3 months following TNF-α treatment.
The main limitation of this study is that it is a case study of one individual. Whilst 
interesting insights may be gleaned from this study further studies with larger sample size are 
needed to confirm these findings before firmer conclusions may be drawn. Another limitation 
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is that MSNA was not recorded 2 weeks post-treatment, due to the nature of the 
microneurography technique. 
7.7 Conclusions
In conclusion this case study demonstrates that TNF-α inhibition induces transient 
improvements in autonomic function that parallels a reduction in inflammation and pain. 
Adalimumab acutely reduces BP and HR likely via central modulation of baroreflex function 
resulting in increased BRS and parasympathetic activity. Despite adequate control of 
inflammation and pain these changes were not sustained in the long term and sympathetic 
activity increased. Further larger studies are required to confirm these findings.
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CHAPTER 8 Experiment Four. Associations between cytokines and QTc interval in RA: a 
cohort study
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8.1 Abstract
Objectives QTc interval predicts all-cause and cardiovascular mortality and may contribute to 
the increased mortality risk in RA. Animal experiments have shown that pro-inflammatory 
cytokines (TNF-α and IL-1) can prolong cardiomyocyte action potential. This study sought to 
determine whether elevations in circulating inflammatory cytokines were independently 
associated with QTc prolongation in RA patients.
Methods One hundred and twelve patients (median age 62 [inter-quartile range 17] years; 80 
[71%] women) from a well-characterised RA cohort underwent baseline 12-lead 
electrocardiograms for QT interval measurement and contemporary blood sampling to assess 
concentrations of inflammatory markers including CRP, TNF-α, IL-1α, IL-1β, IL-6 and IL-
10. QTc was calculated using Bazett’s (QTBAZ=QT/√RR) and Framingham Heart Study 
(QTFHS=QT+0.154[1-RR]) HR correction formulae.
Results Inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10) were positively correlated with 
QTBAZ (spearman’s rank correlation coefficient rho=0.199, 0.210, 0.222, 0.333; all p<0.05).  
In multivariable regression analysis these associations were all confounded by age except IL-
10, where higher tertile groups were independently and positively associated with QTBAZ
(β=0.202, p=0.023) and QTFHS (β=-0.223, p=0.009) when compared to the lower tertile. CRP
(per unit increase) was independently associated with QTBAZ (β=0.278, p=0.001) but not 
QTFHS.
Conclusions This is the first study demonstrating a contemporary link between inflammatory 
cytokines and QT interval in humans. These results suggest that a lower inflammatory burden 
may protect against QTc prolongation in RA patients, however further studies are required to 
confirm the effects of pro- and anti-inflammatory cytokines on QTc interval.
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8.2 Introduction
The QT interval represents the time from onset of ventricular depolarization 
(beginning of the Q wave) to completion of repolarization (end of the T wave). QTc
prolongation is a weak independent predictor of all-cause and cardiovascular mortality in the 
general population (564) but a more significant one in patients with RA (35). Risk of sudden 
cardiac death is almost doubled in RA compared to the general population (21), which may in 
part be explained by prolonged QTc interval, a likely surrogate of sudden arrhythmic death 
(35, 565).
Given the variability of the QT interval in relation to HR, several formulae are used to 
yield a corrected measure (QTc). Bazett’s formula (QTBAZ = QT/√RR), one of the earliest and 
most commonly used HR correction formulae, has been criticised due to an over- and under-
correction of QT interval at high and low heart rates respectively (364). To overcome this 
problem, a linear regression model using data from the Framingham Heart Study (QTFHS = QT 
+ 0.154 x [1-RR]) was recently developed (504). 
Prior studies (including one in RA patients) have suggested that QTc prolongation 
(QTBAZ) may be driven by increased inflammatory burden (35, 377, 386, 388-390), however 
few studies have assessed the direct effects of inflammatory cytokines on QT interval. In one 
animal experiment TNF-α prolonged the cardiomyocyte action potential by inhibiting the 
hERG (the human Ether-à-go-go-Related Gene) gene (KCNH2) that codes for a protein 
known as Kv11.1, the alpha subunit of a potassium ion channel (390). In another animal study 
IL-1 was found to prolong cardiomyocyte action potential via its effects on calcium channels
(566). QTc prolongation may occur as a consequence of structural heart disease (i.e. ischemic 
heart disease, heart failure), which is more prevalent in RA patients (567) and the 
development of which may be accelerated by systemic inflammation (565). Alterations in 
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ANS function may also result in QTc prolongation (377, 565). Reduced cardiac 
parasympathetic activity (568) and increased sympathetic activity (569), a pattern of ANS 
dysfunction prevalent in RA patients (445, 464, 468, 484, 570), have been shown to 
contribute to QTc prolongation. The relationship between inflammation and ANS remains to 
be fully elucidated and is a focus of current research (51, 242, 571, 572). Evidence from 
animal experiments demonstrates that IL-1β (153), IL-6 (52) and TNF-α (573) cause 
sympatho-excitation, which potentially may prolong QT interval. Collectively, these studies 
in animal models suggest several potential mechanisms by which pro-inflammatory cytokines 
may lead to prolongation of the QT interval but it remains unclear whether such pathways are 
involved in humans. 
8.3 Aims and hypotheses
Central hypothesis: In patients with RA, elevated concentrations of circulating inflammatory 
cytokines are associated with increased QTc interval. 
Aim: To test this, an observational cohort study was undertaken to measure baseline serum 
inflammatory cytokine concentrations, QT interval and relevant clinical parameters.
Hypothesis:
i) Serum inflammatory cytokine concentrations are correlated with QTc interval 
ii) Associations between cytokines and QTc interval are affected by the QT 
correction method used (QTBAZ vs. QTFHS).
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8.4 Methods
8.4.1 Subjects
One hundred and forty six subjects from a well-characterised RA patient cohort (29, 
30) were assessed with 12 lead ECG for QTc interval and contemporary blood samples, which 
were analysed for biochemical markers of inflammation. Patients with an RA diagnosis, based 
on the revised 1987 ACR classification criteria (8), were recruited from routine outpatient 
clinics at the Department of Rheumatology of the Dudley Group of Hospitals, Dudley, UK.
The study was approved by the local ethics committee and all subjects gave written informed 
consent. Clinical information was obtained from history, medical records and clinical 
examination (joint swelling and tenderness) performed to determine co-morbidities, 
medications, disease duration and DAS (16). Weight and height were measured to determine 
BMI. 
8.4.2 QT measurements
QT interval (time between beginning of a Q wave and then end of a T wave) was 
manually measured by two experts and corrected for HR using Bazett’s formula (QTBAZ = 
QT/√RR)(574) and the Framingham Heart Study formula (QTFHS = QT + 0.154x [1-RR])
(504). 
8.4.3 Blood sampling
Serum was collected following an overnight fast and frozen immediately at -70oC until 
analysed. Concentrations of IL-6, TNF-α, IL-1β and IL-10 were analysed by flow cytometry 
using FlowCytomix kits (Bender MedSystems GmbH, Vienna, Austria). CRP (Vitros®5.1-
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FS, USA) and ESR (Starrsed compact Mechatronics BV, The Netherlands) were also 
analysed.
8.4.4 Statistics
Statistical analysis was performed using SPSS software, version 19 (SPSS Inc, 
Chicago, Illinois). Continuous variables were tested for normality using the Kolmogorov-
Smirnov test. Correlations between QTc (QTBAZ, QTFHS) interval and continuous variables 
was assessed using Pearson’s correlation for parametric and Spearman’s correlation 
coefficient (rho) for non-parametric data. Associations between QTc (QTBAZ, QTFHS) interval 
and dichotomous categorical variables were assessed using a two-tailed, independent t-test. In 
addition cytokines and CRP were divided into tertiles. Differences in QTc interval between 
tertiles were assessed using an ANOVA with Tukey’s post-hoc test. Step-wise multi-variable 
linear regression analysis was performed to determine independent associations between QTc 
(QTBAZ and QTFHS separately) interval and other pertinent measured variables (variables 
considered clinically significant or those with a univariate association with QTc 
demonstrating a p-value<0.1 were included in the model). Cytokine tertile groups were 
entered into the regression models as continuous variables (calculating a beta per tertile 
increase). In order to minimise the risk of collinearity, variables that are known to interact 
were entered into separate models (e.g. β-blocker, ischemic heart disease, cytokines). Values 
expressed as mean±SD for parametric data; median (inter-quartile range) for non-parametric 
data; and frequency (%) for categorical variables. A P value of less than 0.05 was considered 
statistically significant throughout.
181
8.5 Results
8.5.1 Subject characteristics
Of the 146 patients studied 34 (23%) were excluded due to the presence of bundle 
branch block precluding QT interval assessment. Analysis was performed on the remaining 
112 patients. Baseline patient characteristics are summarised in Table 8.1. Median age (inter-
quartile range) was 62.4 (17.2) years with 80 (71%) females. 
8.5.2 HR correction
Mean QTc interval was 423.2±22.5 ms (QTBAZ) and 412.5±18.0 ms (QTFHS). QTBAZ
was positively correlated with HR whilst QTFHS was not (Appendix 7).
8.5.3 Associations between QTc and demographic variables
QTc interval (QTBAZ and QTFHS) was weakly positively correlated with age and was 
higher in women compared to men (QTBAZ = 12.5ms and QTFHS = 7.8ms higher) (Table 8.2). 
Patients with history of ischemic heart disease had a higher QTc interval (QTBAZ = 16.8ms 
and QTFHS = 20.4ms higher). Hydroxychloroquine use was associated with a higher QTc 
interval (QTBAZ = 12.9ms, QTFHS = 9.8ms higher). There was a trend for β-blockade to lower 
QTBAZ but not QTFHS. Aside from hydroxychloroquine, no other medications, including those 
with a known association with risk of Torsades de Pointes (thiazide diuretics, amitriptyline 
and other anti-depressants, http://www.crediblemeds.org/), were associated with QTc interval. 
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Table 8.1 Baseline characteristics for RA patients
Characteristic (n=112)
Demographic
   Age, years 62.4 (51.5-68.6)
   Female, n (%) 80 (71%)
   BMI*, kg/m2 27.9±5.2
Co-morbidities and medications
   Osteoarthritis, n (%) 44 (39%)
   Hypertension†, n (%) 88 (79.5%)
   Ischemic heart disease, n (%) 12 (10.7%)
   Hypercholesterolaemia, n (%) 16 (42%)
   Antihypertensive agent, n (%) 47 (42%)
   ACE inhibitor, n (%) 29 (25.9%)
   β -blocker, n (%) 22 (19.6%)
   Diuretic, n (%) 18 (16.1%)
RA-related
   Disease duration, years 9 (3-15)
   RF positive, n (%) 87 (78%)
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   Anti-CCP positive‡, n (%) 77 (69%)
   Disease Activity Score § 4.2±1.3
   Methotrexate, n (%) 98 (88%)
   Sulphasalazine, n (%) 80 (71%)
   Hydroxychloroquine, n (%) 22 (20%)
   Gold, n (%) 20 (18%)
   NSAID, n (%) 26 (23%)
   Biological agent, n (%) 10 (9%)
ECG features
   QT interval, ms 393.6±31.0
   Corrected QTc interval, ms
        Bazett’s correction (QTBAZ) 423.2±22.5
        Framingham Heart Study correction 
(QTFHS)
412.5±18.0
   HR, beats/min 71.0±13.1
   Left ventricular hypertrophy (Sokolow-
Lyon)
7 (6%)
   Q wave abnormality 6 (5%)
   ST abnormality ¶ 6 (5%)
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Inflammatory markers
   CRP, mg/L 9 (5-19.8)
   ESR, mm/hr 21.5 (10-38.8)
   IL-6, pg/ml 16.8 (4-52.7)
   TNF-α, pg/ml 8.3 (5-35.8)
   IL-1α, pg/ml 2.7 (0-24.1)
   IL-1β, pg/ml 1.1 (0-7.4)
   IL-10, pg/ml 1.0 (0-5.9)
Data expressed as mean ± standard deviation for parametric data, median (inter-quartile range) for non-
parametric data or frequency (%) for categorical data. * n=109, † blood pressure ≥ 140/90 or on anti-
hypertensives, ‡ n=105, § n=111, ¶ coded using the Minnesota Code Classification System.
ACE = angiotensin converting enzyme, anti-CCP = anti-cyclic citrullinated peptide. CABG = coronary artery 
bypass graft, CRP = C-reactive protein, CVD = cardiovascular disease, ESR = erythrocyte sedimentation rate, 
IL = interleukin, NSAID = non-steroidal anti-inflammatory drug, RF = rheumatoid factor, TNF = tumour 
necrosis factor.
Patients with hypercholesterolaemia had a higher QTFHS, whilst there were trends for 
higher QTFHS in patients with co-existent osteoarthritis, those receiving proton pump 
inhibition and in (anti-CCP, RF) sero-positive patients. There were no significant associations 
between QTc interval and ECG abnormalities, other co-morbidities, medications and RA-
related characteristics (Table 8.2). 
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Table 8.2 Significant associations between QTc and selected variables
Variable N QTc interval, ms t P-value
QTBAZ
Sex
     Woman 80 426.7±21.0 2.733 0.007**
     Man 32 414.2±23.9
Ischemic heart disease
     Yes 12 438.2±22.3 2.503 0.014*
     No 100 421.4±22.0
β-blocker
     Yes 22 415.6±19.5 -1.775 0.079
     No 90 425.0±22.9
Hydroxychloroquine
     Yes 22 433.5±22.1 2.448 0.016*
     No 90 420.6±21.8
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Variable N QTc interval, ms t P-value
QTFHS
Sex
     Woman 80 414.8±17.3 2.103 0.038
     Man 32 407.0±18.8
Ischemic heart disease
     Yes 12 430.8±17.3 3.948 <0.001
     No 100 410.4±16.9
Hypercholesterolaemia
     Yes 16 424.0±23.9 2.840 0.005
     No 96 410.6±16.2
Osteoarthritis
     Yes 44 416.1±18.0 1.719 0.088
     No 68 410.2±17.7
Proton pump inhibitor
     Yes 22 418.8±18.9 1.847 0.067
     No 90 411.0±17.5
Hydroxychloroquine
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     Yes 22 420.4±16.6 2.336 0.021
     No 90 410.6±17.9
RF positive
     Yes 87 414.1±18.7 1.749 0.083
     No 25 407.0±14.2
Anti-CCP positive
     Yes 77 413.7±18.5 2.016 0.053
     No 28 406.1±18.5
Data expressed as mean±standard deviation. Associations between QTc interval and dichotomous categorical 
variables were tested using two-tailed, unpaired t test. Significance = P<0.05.
Anti-CCP = anti-cyclic citrullinated peptide, df = degrees of freedom, QTBAZ = QT corrected using Bazett’s 
formula, QTFHS = QT corrected using Framingham Heart Study formula, RF = rheumatoid factor.
8.5.4 Associations between QTc and inflammation
Correlation analysis showed that CRP, TNF-α, IL-6, IL-1β and IL-10 were all 
significantly associated with QTBAZ (weakly positive) whilst IL-1α showed only a trend 
(Appendix 7). However, when QTFHS was used, only IL-1β and IL-10 were significantly 
associated (weakly positive) while there was a trend with TNF-α and IL-1α. There was no 
significant association between QTFHS and CRP or IL-6.
QTBAZ and QTFHS were significantly lower in the first tertile for IL-10 compared to the 
second and third; this was attenuated after multivariable adjustment for age, sex, presence of 
ischemic heart disease or hypercholesterolaemia, hydroxychloroquine and β-blocker use 
(Table 8.3). QTFHS was significantly lower in the first tertile for TNF-α compared to the third 
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tertile however this was insignificant after adjustment for age and other variables (Table 8.3). 
QTBAZ tended to be lower in the first tertile for CRP compared to the third tertile. There was 
no significant association between IL-6, IL-1α, IL-1β tertile group and QTc interval.
8.5.5 Multivariable linear regression
Step-wise linear regression analysis showed that age, sex and CRP were independently 
associated with QTBAZ interval, accounting for 22% of the variation (Table 8.4). The 
associations (and trends) found between the cytokines and QTBAZ/QTFHS in univariate 
analysis were all confounded by age with the exception of IL-10 (Table 8.4). IL-10 tertile 
group (when entered into the model as a continuous variable) was independently associated 
with QTBAZ and QTFHS interval independent of other factors (including age, sex, β-blocker or 
hydroxychloroquine use and presence of ischemic heart disease) (Figure 8.1).
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Table 8.3 Associations between QTc and inflammatory markers according to tertiles before and after mulitivariable adjustments
Tertile Univariate Mulitivariable
1 2 3 Age A B or C3
CRP, mg/ml ≤7.0 8-13 >14 F P F P F P F P
N 44 31 37
QTBAZ, ms 417.4±22.9 425.5±18.4 428.0±24.2 2.552 0.083 2.675 0.073 4.078 0.020*† 2.497 0.087
QTFHS, ms 410.9±19.2 414.5±17.0 412.8±17.6 0.362 0.697 0.375 0.688 1.760 1.155 0.177 0.319
IL-6, pg/ml ≤6.3 6.31-37.23 >37.24
N 38 37 37
QTBAZ, ms 417.0±20.7 426.3±21.4 426.3±24.6 2.214 0.114 0.954 0.388 0.972 0.382 0.615 0.543
QTFHS, ms 409.5±16.0 415.1±17.5 413.1±20.2 0.942 0.393 0.892 0.413 0.505 0.605 0.245 0.783
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Tertile Univariate Mulitivariable
1 2 3 Age A B or C3
TNF-α, 
pg/ml
≤6.14 6.15-23.99 >24.0
N 38 37 37
QTBAZ, ms 419.1±23.5 421.4±20.8 429.2±22.5 2.109 0.126 1.174 0.313 0.883 0.417 1.320 0.271
QTFHS, ms 408.6±15.7 410.8±17.3 418.4±19.7 3.153 0.047† 1.823 0.167 1.381 0.256 1.570 0.213
IL-1α, pg/ml 0.0 0.01-9.45 >9.46
N 41 34 37
QTBAZ, ms 422.9±27.4 419.1±18.1 427.1±19.9 1.123 0.329 1.036 0.358 1.214 0.301 0.860 0.426
QTFHS, ms 410.8±17.9 410.1±16.7 416.8±18.9 1.549 0.217 0.248 0.781 1.141 0.323 0.907 0.407
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Tertile Univariate Mulitivariable
1 2 3 Age A B or C3
IL-1β, pg/ml ≤0.45 0.46-3.51 >3.52
N 38 37 37
QTBAZ, ms 418.4±26.2 423.9±21.2 427.2±19.2 1.460 0.237 0.860 0.426 0.507 0.604 0.838 0.435
QTFHS, ms 408.2±17.1 411.7±18.0 412.5±18.0 2.806 0.065 2.004 0.140 1.584 0.210 1.800 0.170
IL-10, pg/ml 0.0 0.01-2.0 >2.01
N 40 35 37
QTBAZ, ms 413.4±20.8 429.8±23.7 427.4±19.9 6.506 0.002*† 5.555 0.005*† 3.255 0.042*† 4.212 0.017*†
QTFHS, ms 405.6±14.9 415.6±18.2 417.1±19.0 4.989 0.008*† 3.976 0.022*† 2.498 0.087 3.344 0.039†
Univariate analysis performed using one way analysis of variance (ANOVA) with Tukey’s post-hoc test. Multivariable analysis performed with adjustments for age 
alone; model A = age, sex, presence of ischemic heart disease and hydroxychloroquine use; and 3either model B = age sex, β-blocker use and hydroxychloroquine use 
(for QTBAZ) or model C = age, sex, presence of hypercholesterolaemia and hydroxychloroquine use (for QTFHS), with LSD post-hoc test. Post-hoc Significance P<0.05 
*Tertile 1 v 2, †Tertile 1 v 3, ‡Tertile 2 vs. 3
CRP = C-reactive protein, IL = interleukin, QTBAZ = QT corrected using Bazett’s formula, QTFHS = QT corrected using Framingham Heart Study formula, TNF = 
tumour necrosis factor.
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Table 8.4 Step-wise multivariable linear regression with QTc interval as dependent variable
QTBAZ as dependent variable
Step-wise linear regression
Variable beta B 95% CI P
Model 1 R2 = 0.220
Age 0.263 0.487 0.175 0.800 0.003
Sex (woman) 0.236 11.719 3.354 20.083 0.006
CRP 0.278 0.300 0.118 0.483 0.001
Model 2 R2 = 0.211
Age 0.264 0.489 0.169 0.808 0.003
Sex (woman) 0.210 10.441 1.894 18.987 0.017
β-blocker -0.177 -9.973 -19.647 -0.298 0.043
IL-10 
(Tertiles, per 
unit increase)
0.202 5.457 0.754 10.160 0.023
QTFHS as dependent variable
Step-wise linear regression
Variable beta B 95% CI P
Model 3 R2 = 0.238
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Heart disease 0.351 20.321 10.562 30.080 <0.001
HCQ 0.248 11.197 3.650 18.744 0.004
IL-10 
(Tertiles, per
unit increase)
0.223 4.830 1.205 8.455 0.009
The following variables were entered into the step-wise multivariable regression analysis: Model 1, 2: Age, sex 
(woman), CRP, IL-6, TNF-α, IL-1α, IL-1β, IL-10, heart disease, β-blocker, hydroxychloroquine; Model 3: Age, 
sex (woman), TNF-α (Tertiles), IL-1β (Tertiles), IL-10 (Tertiles), heart disease, hypercholesterolaemia, 
hydroxychloroquine, RF positive, anti-CCP positive. In order to minimise risk of collinearity β-blocker, heart 
disease and hypercholesterolaemia as well as anti-CCP positive and RF positive were entered into separate 
models. Standardised (beta) and unstandardised (B) coefficients, with 95 % CI shown. Significance = P <0.05.
Anti-CCP = anti-cyclic citrullinated peptide, CRP = C-reactive protein, IL = interleukin, QTBAZ = QT corrected 
using Bazett’s formula, QTc = corrected QT interval, QTFHS = QT corrected using Framingham Heart Study 
formula, RF = rheumatoid factor, TNF-α = tumour necrosis factor-α.
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Figure 8.1 Association between QTc and IL-10
Bar chart demonstrating lower QTc interval (QTBAZ = blue, QTFHS = red) in patients in the lowest tertile for 
serum IL-10 following multivariable analysis. * P<0.05 v Tertile 1.
195
8.7 Discussion
This study is the first to report a correlation between QTc interval and contemporary 
serum concentrations of pro- and anti-inflammatory cytokines in humans. CRP and IL-10 
demonstrated a positive correlation with QTc suggesting that a higher inflammatory burden 
associates independently with longer duration of QTc interval. Given that QTc prolongation 
increases risk of potentially life threatening arrhythmias (e.g. Torsades de Pointes) these
results suggests a possible mechanistic link between increased inflammatory burden in RA 
and cardiovascular mortality.
8.7.1 Interleukin-10 and QTc interval
Of the cytokines analysed, IL-10 was independently associated with QTc interval 
prolongation. IL-10, the major anti-inflammatory cytokine is released by monocytes, 
macrophages and B-cells in response to inflammatory stimuli and is known to inhibit the 
production and release of pro-inflammatory cytokines (including TNF-α, IL-1β and IL-6) (45, 
575-577). In addition IL-10 reduces the surface expression of TNF receptors and promotes the 
release of TNF receptors into the circulation (578, 579). There are a number of possible 
explanations for the positive correlation between IL-10 concentration and QTc prolongation 
found in this study. The surge of IL-10 production is known to follow that of pro-
inflammatory cytokines (45) and hence increased levels of IL-10, as seen in RA (580), may 
represent increased inflammation. Conversely, undetectable levels of IL-10 may indicate 
lower circulating concentrations of TNF-α and IL-1 and hence may result in a lower QTc 
interval; given that both TNF-α (390) and IL-1 (566) were shown to prolong cardiomyocyte 
action potential duration in animal studies. This is supported by the finding that IL-10 was 
strongly correlated with other pro-inflammatory cytokines including TNF-α (rho=0.775, 
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p<0.001), IL-1α (rho=0.853, p<0.001) and IL-1β (rho=0.902, p<0.001). Additionally, given 
that the release of IL-10 is stimulated by adrenaline (45) and that sympatho-excitation may be
associated with QTc prolongation (569), lower levels of IL-10 may reflect lower resting 
sympathetic nerve activity. Finally, the direct effects of IL-10 on cardiomyocyte action 
potential are currently unknown and further studies are warranted to explore the mechanisms 
by which IL-10 and other inflammatory cytokines may affect QTc interval.
8.7.2 CRP and QTc interval
In this study a significant and independent association between CRP and QTBAZ was 
found but no association between CRP and QTFHS. This is the first study to report such a 
discrepancy between QTBAZ and QTFHS; to the author’s knowledge prior studies showing 
associations between QTc interval and CRP used the Bazett’s HR correction formula. In one 
study of 101 patients with inflammatory arthritis elevated concentrations of hs-CRP was 
associated with higher QTBAZ but also a higher resting HR (377). One possible explanation is 
that HR may be confounding the relationship between QTc interval and CRP; once HR is 
adequately corrected with the stricter formula (QTFHS) this relationship disappears. This is 
further supported by the finding that CRP was correlated with HR.
8.7.3 Immune and autonomic interactions
Interactions between the immune and ANS could also explain the associations found 
between QTc interval and inflammation in this study. Both the sympathetic and 
parasympathetic nervous systems contribute to QTc interval (568, 569). Left cardiac
sympathetic denervation shortens QTc interval in patients with the congenital long QT 
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syndrome (569), while cholinergic stimulation with pyridostigmine shortens QTc interval in 
patients with coronary artery disease (568). In patients with RA an increased sympathetic and 
reduced parasympathetic activity has been identified (445, 464, 468, 484) and could 
contribute to QTc interval prolongation. Recent evidence suggests a bi-directional relationship 
between the immune system and ANS. For example, IL-6 has been shown to increase 
sympathetic activity in rats (52), while the ANS has been implicated in regulation of the 
immune response through cholinergic nerve fibres, known as the cholinergic inflammatory 
reflex (242). Indeed, the principle vagal neurotransmitter Ach inhibits the release of cytokines 
TNF-α, IL-1β, IL-6 but not IL-10 (241) and direct electrical stimulation of the vagus nerve in 
rats during endotoxaemia inhibited synthesis of TNF-α (241).
8.7.4 Limitations
One of the major limitations of the present study is the cross-sectional nature of the 
associations between inflammatory cytokines and QTc interval. These results cannot prove 
causality and should be viewed as hypothesis generating. Another limitation is the one off 
blood sampling, which does not allow for cytokine fluctuations over time to be accounted for. 
Finally, the variables included in the regression models explained approximately 21-24% of 
the variation in QTc interval suggesting the presence of other confounders not being 
accounted for. These may include autonomic dysfunction, electrolyte abnormalities, structural 
heart disease and the presence of genetic polymorphisms causing congenital long QT 
syndrome. 
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8.7.5 Future directions
Future studies are needed to further explore the relationship between inflammatory 
cytokines and QTc prolongation. It is likely that concurrent assessments of ANS function and 
QTc interval, with multiple methods of HR correction can help provide greater understanding 
of the precise mechanisms by which inflammatory cytokines contribute to QTc prolongation 
in RA.
8.8 Conclusion
In conclusion this study is the first to report a contemporary association between 
higher serum pro- and anti-inflammatory cytokine concentrations and QTc prolongation in 
RA patients. Undetectable concentrations of IL-10 were independently associated with shorter
QTc interval while pro-inflammatory cytokines (TNF-α, IL-1β) were positively associated 
with prolonged QTc interval - although this association was attenuated when adjusted for age. 
Further studies are needed to confirm the effect of circulating inflammatory cytokine levels on 
QTc interval and assess whether this effect is contemporary or cumulative.
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CHAPTER 9 Experiment Five. Effects of hydrocortisone on BRS, HRV and cardiovascular 
reactivity in healthy humans: a randomised placebo-controlled cross-over study
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9.1 Abstract
Objectives Surges in cortisol concentration during acute stress may increase cardiovascular 
risk, however the interaction between cortisol and the ANS remains poorly understood. This 
study sought to determine the acute effects of cortisol, induced by administration of HCN, on 
cBRS, HRV and cardiovascular reactivity. 
Methods In a randomised placebo-controlled single-blinded crossover study ten healthy males 
received either a single intravenous bolus of saline (placebo) or 200 mg of HCN, one week 
apart. HR, BP and limb blood flow were monitored 3 h later, at rest and during the MOT 
(sequential infusion of SNP and PE), a CPT and a PASAT mental stress test. Short-term HRV 
was assessed using rMSSD. 
Results HCN markedly increased serum cortisol 3 h following infusion (1771±598 vs. 94±37 
nmol/L, p<0.001; HCN vs. placebo). Compared to placebo, HCN elevated resting HR (+7±4 
beats/min; p<0.001) and systolic BP (+5±5 mmHg; p=0.008); lowered cBRS (geometric 
mean, 95 % CI 15.6, 11.1-22.1 v 26.2, 17.4-39.5 ms/mmHg, p=0.011) and HRV (rMSSD 
59±29 v 84±38 ms, p=0.004); and increased leg vasoconstrictor responses to CPT (ΔLVC -
45±20 v -23±26 %; p=0.023). 
Conclusions An acute cortisol surge is accompanied by increases in HR and BP, and 
reductions in cBRS and HRV, potentially providing a pro-arrhythmic milieu that may 
precipitate ventricular arrhythmia or MI and increase cardiovascular risk.
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9.2 Introduction 
Cortisol is the principle glucocorticoid in humans and has important metabolic (e.g. 
mobilisation of glucose, fatty acids and amino acids), immune (e.g. anti-inflammatory) and 
cardiovascular (e.g. maintenance of normal BP) functions. The HPA axis is activated during 
periods of stress and stimulates the production and release of cortisol. The surge in cortisol 
during acute stress may precipitate left ventricular dysfunction, ventricular arrhythmia and MI 
(408). Although, the interaction between cortisol and the ANS has been implicated in the 
increased cardiovascular risk of acute stress (408), the modulatory effects of cortisol on 
cardiac autonomic control remain incompletely understood. 
In healthy humans exogenous administration of cortisol acutely (within 6 hours) 
increases HR (398, 399) via a number of suggested mechanisms including parasympathetic 
withdrawal; reduced cBRS; central baroreflex resetting; increased cardiac sympathetic 
(adrenergic) activity; changes in cardiac ion channel properties; and, alterations in 
hypothalamus-regulated circadian rhythms. Reduced cBRS has been identified in a variety of 
cardiovascular diseases including coronary artery disease, hypertension and heart failure (278)
and has been shown to predict mortality following MI (206) and in patients with chronic heart 
failure (292). BRS has been reported to fall during acute mental stress (403, 404) and may, in 
part, be due to the central effects of cortisol (403). Animal studies support the hypothesis that 
glucocorticoids can elicit centrally mediated alterations in BRS (405-407, 581). In rats, 
administration of glucocorticoids in the RVLM (406) and the NTS (407) rapidly alters 
activity of baroreceptive neurons and depresses baroreflex control of HR. A cortisol-induced 
fall in BRS may be an important mechanism whereby acute stress increases cardiovascular 
risk (408). However, to the authors’ knowledge there have been no prior studies assessing the 
direct acute effects of cortisol on resting cardiovagal BRS in humans. HCN acutely augments 
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the diastolic BP response to a CPT (398). However, whether this is attributable to an 
exaggerated peripheral vasoconstrictor response is unclear.
9.3 Aims and hypothesis
Central hypothesis: During acute stress, surges in serum cortisol elicit deleterious changes in 
ANS function that may predispose an individual to adverse cardiac events. Glucocorticoid-
induced elevations in HR are mediated by changes in autonomic cardiovascular control.
Aim: To test this, a randomized placebo-controlled single-blinded cross over study was 
performed in healthy male volunteers assessing cBRS, HRV, BP variability and 
cardiovascular reactivity to a CPT and PASAT mental stress test 3 hours after bolus infusion 
of HCN or placebo.
Hypothesis: HCN
(i) reduces cBRS;
(ii) reduces HRV;
(iii) increases BP variability; and 
(iv) exaggerates cardiovascular responses to the CPT and PASAT mental stress test.
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9.4 Methods
9.4.1 Subjects
Ten male participants (median age 27.0 interquartile range 23.8-34.5 years, BMI 24±3 
Kg/m2) were recruited from the University of Birmingham, UK and surrounding areas. 
Participants comprised of university students and members of staff. All participants were free 
from cardiovascular, pulmonary, renal, metabolic and neurological conditions, and none were 
taking any prescription or over-the-counter medications. 
9.4.2 Experimental protocol
Detailed methods are described in Chapter 3.2. Using a placebo-controlled, single-
blinded, cross-over design participants were randomised to receive either placebo or HCN on 
the morning of the first visit. Blood tests were taken prior to infusion and three hours later. 
The protocol began 3 hours after infusion and involved rest (10 min), MOT, CPT and PASAT 
mental stress test.
9.4.3 Measurements
HR (lead II ECG), beat-to-beat BP (finger photoplethysmography) were recorded 
continuously. Brachial BP (automated sphygmomanometer) was measured for calibration.
Limb blood flow (venous occlusion strain gauge plethysmography) was measured during CPT 
(leg blood flow) and PASAT (leg and forearm blood flow). LVC and FVC were calculated
(described in Chapter 5). 
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9.4.4 Data analysis
Beat-to-beat values of HR and BP were calculated offline, and 1 min averages were 
used to calculate HR and BP responses during CPT and PASAT. Percentage changes in limb 
blood flow and vascular conductance (LVC, FVC) were used to determine vascular responses 
to CPT and PASAT. BRS was assessed using three methods: GMOT, GSEQ and GLFTF. Short 
term HRV were determined from a 10 min resting period (Kubios HRV, Kuipio, Finland) 
using time domain (rMSSD, NN50 and pNN50 %), frequency domain (TP, VLF, LF, and HF 
absolute powers, LF, HF normalised power, LF/HF ratio) and non-linear indices (SD1, SD2, 
SD1/SD2 ratio) as described in the methods section. Systolic and diastolic BP variability
(CardioSeries v2.4, CardioSeries, Sao Paulo Brazil) were determined from a 10-min resting 
period using time (SD, VC) and frequency domain parameters (LF, HF power). 
9.4.5 Blood sampling
Blood samples for analysis of hormones (ACTH, cortisol) were centrifuged 
immediately and the plasma was stored at -80 oC. Plasma ACTH levels were determined 
using an ELISA (Abnova, Taiwan). The sensitivity was <1 pg/ml and the intra-assay and 
inter-assay coefficients of variation were ≤4.2 and ≤6.2 % respectively. Serum cortisol levels 
were determined using ELISA (Abcam, Cambridge, UK). The sensitivity was 2.44 ng/ml and 
the intra-assay and inter-assay coefficients of variation were ≤9.0 and ≤9.8 % respectively. 
Serum electrolyte concentrations, glucose, serum osmolality and haematocrit were determined 
according to standard laboratory methods.
205
9.4.6 Statistics
Statistical analyses were performed using SPSS software, version 19 (SPSS Inc, 
Chicago, USA). Continuous variables were assessed for normality using the Kolmogorov-
Smirnov test. Baseline differences in parameters were tested using a two-tailed paired 
Student’s t-test. Non-parametric data was log-transformed (natural). The effect of treatment 
(with HCN or placebo) during each of the tasks was tested using repeated measures ANOVA
with Bonferroni adjustments for multiple comparisons. Differences between the percentage 
changes (%Δ) in parameters from baseline during each CPT and PASAT mental stress test 
were assessed using a two-tailed paired Student’s t-test. Based on a previous study (398), a 
sample size calculation indicated that 7 patients were required in order to show a mean 
difference in HR of 7±5 beats per minute before and after HCN. Data are expressed as mean±
SD or geometric mean (95% CI). Significance levels were set at P≤0.05.
9.5 Results
9.5.1 Biochemical and haemodynamic parameters
There was no significant difference in baseline concentrations of serum cortisol, 
ACTH, glucose, electrolytes (sodium, potassium), creatinine and plasma osmolality in the 
placebo and HCN trials (Table 9.1). HCN elevated serum cortisol concentrations 3 h after 
infusion and suppressed ACTH compared to placebo. HCN did not influence serum glucose, 
electrolytes, creatinine, plasma osmolality (Table 9.1) or haematocrit (HCN 42±2 v placebo 
41±2 %; p=0.215). 
Resting HR was elevated following HCN administration compared to placebo (+7±4 
beats/min; p<0.001) (Table 9.2). HCN also elevated resting systolic BP (+5±5 mmHg; 
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p=0.008) but did not alter resting diastolic or mean BP, leg blood flow and LVC. Compared 
to placebo there was a trend for increased forearm blood flow (p=0.095) and FVC (p=0.065) 
following HCN. 
9.5.2 cBRS
cBRS was reduced with HCN administration (GMOT geometric mean HCN 15.6, 95% 
CI 11.1-22.1 v placebo 26.2, 17.4-39.5 ms/mmHg; t=-3.165, p=0.011; GSEQ 17.1±5.9 v 
23.2±12.6 ms/mmHg; t=-2.290, p=0.048; GLFTF 12.6±7.6 v 17.2±9.0 ms/mmHg; p=0.05) 
(Figure 9.1). SNP and PE infusion induced a similar fall and rise in systolic BP in the HCN 
and placebo conditions (fall in systolic BP after SNP geometric mean 26, 95% CI 21-34 v 26, 
19-36 mmHg; t=0.107, p=0.917; rise in systolic BP after PE 26±8 v 24±11 mmHg; t=0.628, 
p=0.546).
9.5.3 HRV
Time domain parameters of HRV (rMSSD, NN50, pNN50 %) were reduced following 
HCN compared to placebo (Table 9.3). Absolute HF power was reduced following HCN 
while there was a tendency for LF power to decrease (p=0.057). There was no significant 
difference in normalised values of HF power, LF power and LF/HF ratio between trials. SD1 
was reduced with HCN whilst the numerical fall in SD2 was not statistically significant 
(p=0.215). The ratio of SD1/SD2 fell following HCN administration (p=0.042).
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Table 9.1 Effect of hydrocortisone on biochemical parameters
Placebo HCN ANOVA
Time Drug Interaction
Cortisol, nmol/L
9am 133 (97-181) 155 (108-222) <0.001 <0.001 <0.001
12pm 94±37 * 1771±598 *† 
ACTH, mmol/L
9am 3.0±0.7 3.6±1.5 0.004 0.035 <0.001
12pm 3.4±1.6 0.7±0.4 *†
Glucose, mmol/L
9am 4.5 (4.3-4.8) 4.3 (3.9-4.7) 0.325 0.772 0.158
12pm 4.3±1.1 4.9±1.1
Na+, mmol/L
9am 141±2 142±2 0.623 0.799 0.079
12pm 142±3 141±1
K+, mmol/L
9am 4.4 (4.1-4.6) 4.3 (4.2-4.5) 0.360 0.348 0.087
12pm 4.2±0.2 4.4±0.4
Creatinine, μmol/L
9am 83 (75-92) 82 (74-91) 0.062 0.003 0.207
12pm 79 (70-90) 76 (68-84)
Plasma osmolality, mmol/Kg
9am 291±4 292±3 0.589 0.833 0.564
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12pm 292±6 290±7
Values represent mean±SD or geometric mean (95% CI). Comparisons were made using a repeated measures 
one way analysis of variance (ANOVA) with Bonferroni correction.
Post hoc significance P<0.05 * compared with 9am, † compared with placebo.
ACTH = adrenocorticotrophin hormone.
9.5.4 BP variability
Time domain parameters of systolic BP variability tended to increase with HCN whilst 
frequency domain parameters remained unaffected (Table 9.4). HCN had no effect on 
diastolic BP variability.
9.5.5 Cardiovascular reactivity
CPT
As expected, HR and BP rose during the CPT while leg blood flow and LVC fell 
(Figure 9.2). HCN administration resulted in greater reduction in leg blood flow (-33±24 v -
7±28 Δ %; t=2.713; p=0.027) and LVC (-45±20 v -23±26 Δ %; t=2.798; p=0.023) during the 
CPT. Although there was a trend for increased systolic BP responses with HCN compared to 
placebo (+21±10 v +14±15 Δ mmHg; t=1.640; p=0.135), there were no differences in 
diastolic BP (+11±4 v 10±5 Δ mmHg; t=1.562; p=0.153) or HR (+3±4 v 4±4 Δ beats/min; t=-
0.657; p=0.528) responses. There was no difference in the perceived pain rating during the 
CPT between HCN and placebo (6.6±2.2 v 7.1±2.0; t=-0.785, p=0.453).
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Table 9.2 Effect of hydrocortisone on resting haemodynamic parameters
Placebo HCN t df P Value
HR, beats/min 51±10 58±9 * 6.117 9 <0.001
Systolic BP, mmHg 114±8 118±7 * 3.395 9 0.008
Diastolic BP, mmHg 65 (61-69) 64 (62-67) -0.270 9 0.793
Mean BP, mmHg 81±6 83±4 0.971 9 0.357
Leg blood flow, 
ml/100 ml/min
1.9±0.8 1.9±0.7 -0.492 9 0.635
LVC, AU 25±12 23±8 -0.023 9 0.982
Forearm blood flow, 
ml/100 ml/min
2.4±1.1 3.3±1.2 1.866 9 0.095
FVC, AU 29±14 40±13 2.099 9 0.065
Values represent mean± standard deviation or geometric mean (95% CI).  Non-parametric data was 
transformed and comparisons made using paired t-test. * Significance P≤0.05 compared with placebo.
AU = arbitrary units, BP = blood pressure, FVC = forearm vascular conductance, HR = heart rate, LVC = leg 
vascular conductance
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Figure 9.1 Effect of hydrocortisone on cBRS
Plot displaying baroreflex gain determined using the MOT (GMOT) (Panel A), sequence technique (GSEQ) (Panel 
B) and low frequency transfer function (GLFTF) (Panel C). Individual participants data are shown as thin lines. 
Bold lines indicate geometric mean (95% CI) (Panel A) or group arithmetic mean±SEM (Panels B and C). 
Significance * P≤0.05.
cBRS = cardiac baroreflex sensitivity, HCN = hydrocortisone, MOT = modified Oxford technique. 
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Table 9.3 Effect of hydrocortisone on resting HRV parameters
Placebo HCN t df P Value
rMSSD, ms 84±38 59±29 * -3.801 9 0.004
NN50, count 242±81 188±101 * -2.491 9 0.034
pNN50, % 49±17 34±19 * -4.453 9 0.002
TP, ms2 5627 (3358-9429) 4258 (2757-6576) -1.318 9 0.220
VLF power, ms2 2089 (1210-3605) 2176 (1308-3620) 0.143 9 0.890
LF power, ms2 1523 (816-2842) 982 (647-1491) -2.180 9 0.057
HF power, ms2 1587 (900-2800) 887 (502-1566) * -3.192 9 0.011
LF power, nu 49.0±13.8 52±14 0.711 9 0.495
HF power, nu 51.0±13.8 48±14 -0.711 9 0.495
LF/HF ratio 1.12±0.66 1.28±0.71 0.640 9 0.538
SD1 60±27 42±20 * -3.801 9 0.004
SD2 105 (79-139) 90.1 (74-110) -1.333 9 0.215
SD1/SD2 0.55±0.18 0.44±0.13 * -2.368 9 0.042
Values represent means±SD or geometric mean (95% CI).  Non-parametric data was transformed and 
comparisons made using paired t-test. * Significance P≤0.05 compared with placebo.
HF = high frequency (0.15-0.4 Hz), LF = low frequency (0.04-0.15 Hz), NN50 = number of pairs of adjacent 
NN intervals differing by more than 50 ms, pNN50 = NN50 as a percentage of all NN intervals, nu = 
normalised units, rMSSD = root mean square of successive differences, SD = standard deviation of the 
Poincare plot, TP = total power, VLF = very low frequency (0-0.04 Hz).
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Table 9.4 Effect of hydrocortisone on resting BP variability
Placebo HCN t df P Value
Time domain
Systolic BP
     SD, mmHg 6.4±1.4 7.4±1.2 1.997 9 0.077
     VC, % 5.5 (4.8-6.1) 6.3 (5.5-7.2) 1.731 9 0.117
Diastolic BP
     SD, mmHg 3.5±0.8 3.1±0.8 -1.337 9 0.214
     VC, % 5.4±1.4 5.0±1.4 -0.752 9 0.471
Frequency domain
Systolic BP
     LF power, ms2 7.3±4.7 7.4±3.2 0.061 9 0.953
     HF power, ms2 1.5 (0.8-2.7) 1.4 (0.9-2.3) -0.625 9 0.548
     LF power, % 29.9±7.6 27.7±5.9 -0.887 9 0.398
     HF power, % 12.2±7.3 9.0±5.4 -1.163 9 0.275
Diastolic BP
     LF power, ms2 2.9 (1.9-4.4) 2.2 (1.6-3.1) -1.472 9 0.175
     HF power, ms2 0.5±0.2 0.5±0.3 -0.079 9 0.939
     LF power, % 36.4±6.6 36.9±6.5 0.252 9 0.807
     HF power, % 6.7±1.6 9.1±4.1 1.776 9 0.110
Values represent means±SD or geometric mean (95% CI). Non-parametric data was transformed and 
comparisons made using paired t-test. Significance P≤0.05.
BP = blood pressure, HF = high frequency power range 0.15-0.4 Hz, LF = low frequency power range 0.05-
0.15 Hz, SD = standard deviation, VC = variation of coefficient (SD/BP x100).
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Figure 9.2 Effects of hydrocortisone on cardiovascular responses to CPT
HR (Panel A), mean BP (Panel B), LVC (Panel C) and leg blood flow (Panel D) during rest, CPT and recovery following pre-treatment with intravenous placebo 
(black) and hydrocortisone (white). Data represented as group means±SEM. Times series is shown on the left. No significant interactions were found between time 
(rest, CPT and recovery) and drug (placebo or hydrocortisone) conditions when assessed using ANOVA with repeated measures.  Bar charts on the right represent 
changes from baseline. Significance was determined using paired Student’s t-test * P≤0.05 compared to baseline.
BP = blood pressure, CPT = cold pressor test, HR = heart rate, LVC = leg vascular conductance.
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PASAT mental stress test
As expected HR, BP, leg blood flow, forearm blood flow and FVC rose during the 
PASAT, while LVC tended to rise (Figure 9.3). There was no difference in HR (+10±8 v 
+11±7 Δ beats/min; t=-0.296; p=0.774), systolic BP (+10±13 v +11±14 Δ mmHg; t=-0.279; 
p=0.787), diastolic BP (+6±6 v +6±8 Δ mmHg; t=-0.098; p=0.924), leg blood flow (+19±20 v 
+25±27 Δ %; t=-0.935; p=0.185) and LVC (+10±19 v +16±25 Δ %; t=-0.934; p=0.375) 
responses to the PASAT between HCN and placebo trials. However, there was a trend for 
reduced forearm blood flow (geometric mean +32, 95 % CI 14-69 v +56, 29-107 Δ %; t=-
1.685; p=0.126) and FVC (geometric mean +21, 95 % CI 8-59 v +50, 23-108 Δ %; t=-2.103; 
p=0.069) responses following HCN administration. There was a tendency for reduced 
perceived stress (10 point scale) during the PASAT with HCN (4.8±1.9 v 5.7±1.8 points out 
of 10; t=-0.785, p=0.095); however, there was no difference in performance (geometric mean 
74, 95 % CI 53-103 v 82, 74-91 %; t=-0.828, p=0.429).
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Figure 9.3 Effects of hydrocortisone on cardiovascular reactivity to the PASAT
HR (Panel A), mean BP (Panel B), LVC (Panel C), leg blood flow (Panel D), FVC (Panel E) and forearm blood flow (Panel F) during rest, PASAT mental stress test
and recovery following pre-treatment with intravenous placebo (black) and hydrocortisone (white). Data represented as group means±SEM. Times series is shown on 
the left. No significant interactions were found between time (rest, PASAT and recovery) and drug (placebo or hydrocortisone) conditions when assessed using 
ANOVA with repeated measures. Bar charts on the right represent changes from baseline. Significance was determined using paired Student’s t-test P≤0.05 compared 
to baseline.
BP = blood pressure, FVC = forearm vascular conductance, HR = heart rate, LVC = leg vascular conductance, PASAT = paced auditory serial addition task.
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9.6 Discussion
This study is the first to report that acute HCN administration elicits an increase in HR 
that is associated with a reduction in cBRS and HRV derived indices of cardiac 
parasympathetic nerve activity. In addition, it was observed that HCN administration 
significantly increased systolic BP and exaggerated the leg vasoconstrictor responses to CPT, 
whilst vasodilatory forearm responses to mental stress tended to be reduced. Reduced cBRS 
and HRV are known to have deleterious cardiovascular consequences and are both predictive 
of increased mortality (204, 206, 292, 582). Thus these findings may help explain the known 
associations between acute stress-induced increases in cortisol and cardiovascular risk (408).
9.6.1 Central mechanisms for reduced BRS
Animal studies suggest that cortisol may elicit central effects in areas of the central 
nervous system important for modulation of the baroreflex (e.g. RVLM, NTS) (405-407, 581, 
583). However, it is possible that cortisol acts upon other structures within the baroreflex arc 
i.e. afferent structures (e.g. vascular structures, afferent terminals), efferent target-organ 
structures (e.g. sino-atrial node, or smooth muscle) or the efferent nerves (584). The cortisol-
induced increased HR and systolic BP found in this study and others (398-400, 585, 586) may 
suggest a centrally-mediated resetting of the baroreflex. A rise in systolic BP would be 
expected to increase baroreceptor firing resulting in a compensatory fall in HR and inhibition 
of sympathetic outflow to the peripheral vasculature. Thus, it appears that an upwards and 
rightwards resetting of the baroreflex curve accompanies the observed reduction in cBRS with 
acute HCN administration, as occurs in hypertension and heart failure. A reduction in cardiac 
parasympathetic activity may also explain the cortisol-induced increased HR reported in this 
study. HCN acutely reduced HRV in a pattern consistent with reduced cardiac
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parasympathetic activity. Reduced HRV is a pathogenic feature of cardiovascular diseases 
including hypertension and heart failure, and has been shown to be of prognostic significance 
after MI (196, 204, 582). 
9.6.2 Sympathetic activation
BP responses to the CPT and mental stress have previously been used as an index of 
sympathetic reactivity of the vasculature (323), and if exaggerated can predict the 
development of hypertension (336). In this study cortisol acutely increased leg vasoconstrictor 
and systolic BP (trend) responses to cold water and inhibited forearm vasodilatory (trend) 
responses to mental stress. Cortisol-induced increases in pressor responsiveness have been 
demonstrated in prior studies (398, 587) and may reflect potentiation of catecholamines 
(adrenaline/noradrenaline) by cortisol in vascular smooth muscle (588). The altered vascular 
responsiveness following cortisol may also be explained by changes in endothelial function. 
Glucocorticoids may alter endothelial function via stimulation and production of endothelin 
(circulating peptide with vasoconstrictor properties) (589) and inhibition of the NOS isoforms 
inducible NOS (iNOS) and endothelial NOS (eNOS) (590, 591). In one study cortisol 
inhibition blocked mental-stress induced impairments in endothelial function as assessed by 
flow mediated dilatation (403).
During acute stress there is co-activation of the HPA axis and the sympathetic nervous 
system. While the effects of heightened sympathetic activity are well documented the acute 
cardiovascular effects of a cortisol surge is not fully understood. The increased HR and 
systolic BP noted in this study may represent heightened sympathetic activity, although this 
may not be due to increased central sympathetic outflow. Glucocorticoids can up-regulate 
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cardiac β1-adrenergic receptor sensitivity (592) which can potentiate the effects of circulating 
adrenaline and noradrenaline. In prior studies resting MSNA decreased (399) or did not 
change (398, 400) following acute glucocorticoid administration. Peripheral vasoconstriction 
is unlikely to be contributing to the rise in systolic BP as LVC remained unaffected in this
study and diastolic BP did not increase. The short time course of this study did not allow the 
mineralocorticoid actions of cortisol (i.e. increased sodium and water retention) to take effect 
and cannot explain the rise in systolic BP, especially as haematocrit and plasma osmolality 
were unchanged.
9.6.3 Strengths and limitations
The study design (single-blinded, placebo-controlled crossover) is a strength allowing 
a direct assessment of the effects of HCN. Additionally, a comprehensive assessment of cBRS 
was made using a variety of methods that corroborate one another. The main limitation of this 
study is the difficulty in distinguishing between the direct effects of cortisol and subsequent 
compensatory mechanisms (e.g. cortisol suppresses ACTH through negative feedback of the 
HPA axis). It therefore cannot be ruled out that some of the findings may be due to ACTH 
suppression. Secondly, these findings can only be applied to healthy young males. 
Additionally, the autonomic assessments used in this study have inherent limitations due to 
the inaccessibility of the parasympathetic nervous system (e.g. HRV is used as an indirect 
measure of parasympathetic influences on the sinus node) and sympathetic activity was not 
measured. 
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9.6.4 Future directions
The precise mechanisms and time course by which cortisol elicits the alterations in 
ANS observed in this study and others needs further investigation. For example, further 
assessments of BRS (cardiovagal and sympathetic) are warranted in healthy humans to 
determine whether there is a central resetting of the baroreflex as hypothesised. In addition, 
further studies are also required to determine whether the autonomic responses to HCN are 
affected by the dose and type of glucocorticoid, sex, age and presence of pathological diseases 
(such as RA). During acute stress there is concomitant activation of the HPA and sympathetic 
nervous system therefore assessing autonomic function following cortisol administration and
concomitant sympathetic activation (possibly by administration of sympathomimetics) may 
provide additional insight into the pathophysiology underlying stress induced increases in 
cardiovascular risk. 
9.7 Conclusion
Activation of the HPA axis during acute stress results in a surge in serum cortisol. 
While acute stress is associated with increased cardiovascular risk the effects of acute surges 
in cortisol is not known. The findings in the present study might suggest a possible 
mechanism by which acute stress increases cardiovascular risk (408). During acute stress the 
surge in cortisol may result in acute depression in BRS and HRV, along with increased 
peripheral vasoconstrictor responsiveness, increased sympathetically-mediated positive 
cardiac inotropic activity and impairment in vasodilatory mechanisms. Thus could provide a 
pro-arrhythmic milieu that precipitates ventricular arrhythmia, MI, left ventricular dysfunction 
and increased cardiovascular mortality. 
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CHAPTER 10 Synthesis
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10.1 Overall aims of thesis
RA is a chronic autoimmune condition characterised by synovial destruction with 
associated local and systemic inflammatory responses. The pathophysiology of RA is poorly 
understood but has improved with the advent of biological agents that block specific immune 
targets effectively reducing inflammation (5, 6). Drugs that inhibit the inflammatory cytokines 
IL-6 and TNF-α have demonstrated remarkable efficacy in reducing inflammatory burden and 
achieving disease control in RA patients (6, 47, 48). RA is not a benign condition. 
Epidemiological data demonstrates that RA is associated with increased cardiovascular risk
with up to 50 % cardiovascular mortality, including a doubled risk of MI and sudden cardiac 
death (20-23). Moreover RA has recently been included in a cardiovascular risk prediction 
algorithm as per NICE guidelines (593) as an independent cardiovascular risk factor, in 
addition to diabetes mellitus, hypertension, hypercholesterolaaemia, smoking and others
(594). The reason for the increased cardiovascular risk in RA is not known with numerous 
studies consistently showing that traditional risk factors do not wholly account for the 
increased risk seen in RA (37, 38). The observation that cytokine inhibition improves 
mortality in RA (412, 557, 558) coupled with the increasing recognition of chronic 
inflammation in cardiovascular diseases (51) raises the possibility that inflammation may play 
a major role in the increased cardiovascular and mortality risk in RA. The evidence from 
recent animal studies demonstrating that inflammatory cytokines (TNF-α, IL-6, IL-1β) 
directly affect key cardiovascular regulatory centres in the brain resulting in cardiovascular 
dysregulation suggests that ANS dysfunction may be an important mechanism. In animals 
inflammatory cytokines increased sympathetic activity (52) and reduced BRS (314) and HRV 
(273), a pattern of ANS dysfunction that is prevalent in cardiovascular conditions (e.g. 
hypertension, chronic heart failure) (62, 63, 198, 199, 279-283) but also associated with 
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increased mortality risk (113, 204-206, 284). It is in this context that led to the hypothesis that 
inflammation may lead to ANS dysfunction and increased cardiovascular and mortality risk in 
RA. Therefore the aims of the thesis were to firstly determine whether ANS dysfunction is a 
recognised pathogenic feature of RA, and if so to then determine the prevalence and nature of 
ANS dysfunction as well as the presence of known associations between ANS dysfunction 
and inflammation. This was achieved with the systematic literature review (Chapter 4), which 
demonstrated that ANS dysfunction was prevalent in ~60% of RA patients predominantly 
manifesting as impaired cardiovascular reflexes and reduced HRV indices of parasympathetic 
activity. The review showed that there was limited data regarding sympathetic activity or 
baroreflex function in RA and insufficient data to determine causal relationships between 
inflammation and ANS dysfunction in RA. Consequently the overall aims of the thesis were 
to carry out a series of experiments in RA patients to comprehensively assess the ANS and to 
explore for relationships between ANS dysfunction and inflammation. Observational case-
control studies were performed to assess sympathetic activity, BRS (Chapter 6) and HRV and 
cardiovascular reactivity to stressors (Chapter 7) in RA patients compared to normotensive 
and hypertensive controls. The rationale behind the inclusion of hypertensive controls was to 
control for the presence of high BP and medications (important confounders) and to 
characterise whether RA patients had similar profiles to hypertensive patients. A longitudinal 
interventional case study was performed assessing the effects of TNF-α-inhibitor therapy on 
sympathetic activity, BRS, HRV and cardiovascular reactivity to mental stress (Chapter 8). 
An explorative observational cohort study of RA patients was performed to assess for 
associations between the corrected QT interval (proxy marker of ANS function) and 
inflammation (Chapter 9). Finally a randomised-controlled cross-over study was performed in 
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healthy individuals to assess the acute effects of an exogenous cortisol surge (mimicking HPA 
axis activation) on autonomic function (Chapter 10).
10.2 General discussion
The systematic literature review (Chapter 4) was the first to be performed and 
demonstrated that autonomic dysfunction was prevalent in RA. The review delineated that the 
pattern of ANS dysfunction from prior studies predominantly included abnormal 
cardiovascular reflex tests and reduced HRV indices of parasympathetic function. The review 
highlighted that there was insufficient evidence to support the presence of sympathetic or 
baroreflex dysfunction in RA. Finally there was insufficient evidence to support the presence 
of associations between inflammation and ANS dysfunction in RA. In the 1980s Ewing and 
colleagues developed a battery of clinical cardiovascular reflex tests that could be performed 
at the bedside (415). These tests were quick, cheap, and reproducible, and allowed 
categorisation of the severity of ANS dysfunction and the system involved (i.e. 
parasympathetic, sympathetic or both). Their work allowed great progress to be made in the in 
recognition of ANS dysfunction particularly in diabetes, a disease characterised by autonomic 
neuropathy (415). However a major limitation of the reflex tests was their inability to 
distinguish the mechanisms underlying ANS dysfunction. The literature review demonstrated 
that cardiovascular reflex tests were impaired in RA although the mechanisms were not 
known. In the mid-1990s a Task Force guideline was developed for the assessment of HRV 
allowing a standardised method for measuring the variability of HR fluctuations detected on 
an ECG recording (196). Following these guidelines a number of studies in RA emerged 
which consistently demonstrated that HRV indices of parasympathetic activity were reduced 
in RA, although the mechanisms still remained unknown. Baroreflex control of HR is an 
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important mechanism however the literature review demonstrated that this was only studied in 
two experiments; cBRS was reported as reduced in one study (447) and normal in another
(446). Using the MOT, which allows BRS to be determined across a wide BP range it was 
demonstrated that reduced cBRS is indeed a pathogenic feature of RA, whilst arterial 
baroreflex of MSNA is unchanged (Experiment 1, Chapter 6). The MOT, a semi-invasive test 
requiring intravenous access that carries inherent risk during infusions of vasoactive drugs
(433), had not been performed in RA and hence this was a novel element to the thesis. The 
experiments in this thesis demonstrated that cBRS (Chapter 6) and HRV (Chapter 7) are
reduced in RA independent of the presence of HTN and furthermore that inverse relationships
exist between cBRS and serum concentrations of inflammatory markers (hs-CRP, IL-6 and 
TNF-α) and between HRV and inflammatory markers (hs-CRP, IL-6). Although confounded
by other factors, these associations are consistent with findings from animal studies that
demonstrated causal relationship. In rats, administration of inflammatory cytokines (IL-6) 
depressed HRV (273) and cBRS (314). The results of Experiment Three (Chapter 8) support a 
causal relationship by demonstrating acute improvements in HRV and cBRS in an RA patient 
following two weeks of TNF-α inhibition. These experiments are novel as it is the first time 
that cBRS was assessed before and after TNF-α inhibition in RA, and collectively provide 
evidence that elevations in circulating cytokines can depress HRV and cBRS. While 
reductions in cBRS and parasympathetic activity contribute to higher resting HR, other 
factors are also involved. In Experiment One (Chapter 6) a higher resting HR was observed in
RA patients compared to controls, which has been reported previously (447, 464, 474). Strong 
independent associations were demonstrated following multivariable adjustment between HR 
and inflammation (hs-CRP, R2 =0.366, F=13.7, p=0.001) and pain (pain VAS, R2=0.526, 
F=36.7, p<0.001, Chapter 6). In addition to inflammation, studies have shown that 
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experimentally evoked pain can also reduce cBRS (519) however another important 
contributory factor is the HPA axis. During stress there is co-activation of the sympathetic 
and HPA systems, resulting in a surge of cortisol and adrenaline released from the adrenal 
glands. The acute effects of cortisol on HR are not clear with two studies showing an acute 
rise in HR in healthy humans, following hydrocortisone (398, 399). Animal studies showed 
that glucocorticoids can induce centrally mediated changes in baroreflex function (406, 407). 
In this thesis an experiment was performed in young healthy male volunteers that 
demonstrated an acute rise in HR, with reductions in HRV and cBRS (Chapter 10). This study 
was the first to demonstrate such an acute effect of cortisol on cBRS in humans. In one other 
recent study one week of prednisolone treatment did not appear to significantly affect cBRS 
(409), although only one spontaneous index of cBRS was assessed. Taken together these 
findings suggest that acute surges in cortisol are required to elicit significant changes in cBRS 
in humans. In summary this thesis demonstrates elevated resting HR, depressed HRV and 
depressed cBRS in RA that are mediated in part by pain and inflammation and provides a 
novel mechanism for the influence of acute cortisol excesses. These findings are relevant as 
they provide novel potential mechanisms for the increased cardiovascular mortality risk seen 
in RA. 
One important finding from the systematic literature review was the insufficient 
evidence for sympathetic dysfunction in RA. This probably relates to the methods employed.
The majority of studies assessed sympathetic activity using clinical cardiovascular reflex tests
and HRV, and reported impaired reflexes but normal HRV (Chapter 4). A major limitation of 
clinical reflexes is that impairments may not just reflect sympathetic dysfunction but also 
impaired baroreflex mechanisms and it is difficult to distinguish between them. Additionally 
subtle impairments will be missed given the way that they are scored (categorically based on 
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Ewing’s criteria). The main limitation of HRV is that there is no parameter that directly and 
solely reflects sympathetic activity. LF power and LF/HF ratio are often purported to indicate 
sympathetic activity however these are heavily influenced by parasympathetic activity (196, 
429). The few studies that assessed catecholamines or sympathetic biomarkers were also 
conflicting. Urinary or plasma catecholamines are not reliable for multiple reasons: difficulty
in measurement, represent global sympathetic activity, cannot delineate regional variances, 
plasma levels reflect uptake, release and clearance whilst urinary levels are dependent on 
renal function, and can be confounded by medications, diurnal variations and concomitant 
diseases (422). In one study pre-ejection period was used as an indirect marker of sympathetic 
activity and reported to be lower in RA patients suggesting increased sympathetic activity
(453). Using the microneurography technique for the first time in RA it was demonstrated that 
resting MSNA was heightened in RA patients, independent of hypertension (Experiment One, 
Chapter 6). In RA patients MSNA burst frequency was significantly increased compared to 
age- sex- and BMI-matched normotensive controls. These results were able to provide direct 
evidence for a heightened sympathetic outflow to the peripheral vasculature in RA that 
supports the findings of Dekkers et al (453). Furthermore this work adds to the literature by 
showing positive associations between MSNA and hs-CRP, although confounded. Given the 
evidence from animals that central administration of inflammatory cytokines increases 
sympathetic activity, a further experiment was performed to assess the effects of TNF-α
inhibition on MSNA (Experiment Three, Chapter 8). It was demonstrated that 3 months of 
TNF-α inhibition resulted in an unexpected rise in MSNA with a fall in BP, whilst arterial 
baroreflex control of MSNA remained unchanged. In light of the fall in BP and unchanged 
sympathetic BRS it may be interpreted that the modest rise in MSNA simply reflects a change 
in the operational point rather than heightened sympathetic outflow, although the latter is 
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possible. The autonomic changes after TNF-α inhibition coincided with satisfactory 
reductions in pain and inflammation (disease activity, serum hs-CRP and cytokines fell 
although inflammatory cytokine concentrations remained relatively high) whilst HR remained 
unchanged. It is not clear whether temporal changes in ANS function following TNF-α
inhibition relate to inflammation, pain or unknown factors. It may also be possible that a 
longer duration of treatment may restore autonomic balance in a more favourable profile, 
particularly as biologic anti-inflammatory agents are associated with improved prognosis
(412). The results of the case study (Chapter 8) are hypothesis generating and require further 
studies to confirm these findings, and delineate the temporal changes in ANS function.
In addition, the systematic review demonstrated that there was insufficient literature 
regarding the cardiovascular responses to CPT and mental stress in RA. Only one study 
assessed CPT responses in RA and reported impaired diastolic BP, however blood flow 
measurements were not made. Similarly data regarding mental stress responses in RA have 
also been conflicting and without limb blood low measurements (Chapter 4). This thesis 
assessed cardiovascular responses to CPT and mental stress in RA with concomitant limb 
blood flow measurements for the first time (Experiment Two, Chapter 7). It was demonstrated 
that HR and BP responses to CPT and mental stress in RA patients were not significantly 
altered compared to normotensive controls. However significant differences in vascular 
responses were seen. In RA leg vasoconstriction during the CPT and forearm vasodilation 
during mental stress were exaggerated compared to normotensive controls. Additionally the 
study showed that forearm vasodilatory responses to mental stress were independently 
associated with inflammation (IL-10). In the case study (Experiment Three, Chapter 8) TNF-α
inhibition altered forearm vasodilatory responses to mental stress, causing an increased 
response at 2 weeks and an attenuated response at 3 months. BP responses to mental stress 
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were blunted prior to starting treatment, and progressively increased at 2 weeks and 3 months 
post treatment. These observations are fascinating and suggest complex mechanisms that may 
involve alterations within the endothelium, circulating factors (e.g. adrenaline, endothelin, 
cortisol), NO bioavailability, central or peripheral sympathetic inhibition, altered α- or β-
adrenergic sensitivity, central dysregulation or a combination of the above. Of course it is also 
possible that the vascular changes may be a direct side-effect of the drug rather that the effects 
of TNF-α cytokine inhibition. One study showed that TNF-α inhibitor infusion acutely 
improved vasodilation during hyperinsulinaemia in patients with metabolic syndrome, 
suggesting a rapid direct mechanism (595).
Finally, this thesis sought to investigate a potential novel mechanism for increased 
cardiovascular risk in RA, QTc interval prolongation (35). The cohort study (Experiment 
Four, Chapter 9) performed in RA patients is the first study to show associations between 
inflammatory cytokines and QTc interval, a surrogate marker of autonomic function and 
independent predictor of mortality risk. In this study undetectable concentrations of IL-10 
were independently associated with shorter QTc interval. Positive associations were 
demonstrated between QTc prolongation and serum concentrations of pro-inflammatory 
cytokines (TNF-α, IL-1β), although confounded by age. These results suggest that low levels 
of inflammation may protect against QTc prolongation, which may theoretically improve 
survival. However further interventional studies are required to confirm whether the mortality 
benefit of anti-inflammatory agents can be attributed to reductions in QTc interval. 
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10.3 Limitations 
The main limitation of the presented studies is that the observational nature of the cross-
sectional studies precludes causality but are hypothesis generating. The interventional study 
was of one individual RA patient and hence should be interpreted with caution. The cohort 
study and case-control studies may be affected by sample bias and hence further studies are 
required to confirm these findings. Another limitation is the relatively small sample size in the 
case-control studies which may introduce type I and type II errors, however the invasive 
nature of the studies makes them less tolerable to diseased groups. The negative findings may 
be due to a lack of statistical power particularly given that cytokine concentrations are highly 
variable, as indeed are HRV parameters. A larger sample size may be necessary to 
demonstrate significant independent relationships between ANS function and inflammatory 
markers. Other limitations include not measuring respiration or cortisol (important potential 
confounders), and limitations inherent to the methods employed. For example, the 
microneurography technique provides a quantitative assessment of sympathetic activity but 
does not provide a qualitative one (i.e. the nature and strength of the signals or indeed whether 
appropriate muscular transduction occurs as a result of nerve firing are not known). Similarly 
given the cyclical nature of inflammatory markers (e.g. hs-CRP and inflammatory cytokines) 
a single laboratory measurement may not necessarily reflect cumulative inflammatory burden. 
10.4 Future directions
Further interventional studies with larger numbers are required to assess the effects of 
cytokine inhibition on ANS function, ideally over several time points. The changes observed 
in ANS function following cytokine inhibition (Chapter 8) suggest that ANS dysfunction in 
RA may be due to functional rather than structural abnormalities. However further studies, 
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including pathological analysis of ANS nerves and associated structures, are required to 
exclude structural aetiologies for the ANS dysfunction observed in RA. Large 
epidemiological studies are required to determine whether ANS dysfunction precedes the 
development of RA, is predictive of the disease’s natural course, and what the prognostic 
significance of these ANS alterations are for patients with RA. Larger case-control studies are 
needed to reproduce the findings from the present studies, ideally with concomitant measures 
of the HPA, respiratory and renin-angiotensin-aldosterone systems to control for their 
influences. Further interventional studies are required to assess whether therapies that target 
the ANS are effective in reducing inflammation in RA (e.g. sympathomimetic agents, β-
adrenergic blockers, vagal nerve stimulation, chronic baroreflex activation therapy). Further 
work is required to investigate the precise mechanisms by which cortisol acutely alters 
baroreflex function in humans. It remains to be determined whether the cortisol-induced ANS 
changes are affected by the dose, type or route of glucocorticoid administration or by the 
presence of pathological diseases (e.g RA). In addition more work is required to determine the 
effect of concomitant sympathetic activation (as occurs during acute stress) on cortisol-
induced ANS changes in health and disease, to further understand the mechanisms underlying 
increased cardiovascular risk associated with acute stress.
10.5 Conclusion
The present work demonstrates that ANS dysfunction is prevalent in RA and 
characterised by depressed HRV indices of parasympathetic function, heightened sympathetic 
outflow to the peripheral vasculature, depressed baroreflex control of HR and heightened 
vascular responses to stressors. These autonomic changes may contribute to the increased 
cardiovascular risk seen in RA, and may well be mediated by inflammation with QTc 
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prolongation as one potential mechanism. Further studies are required to confirm these 
findings, determine whether therapeutic strategies to restore ANS function improve prognosis 
in RA, and to further explore the precise mechanisms by which inflammatory cytokines may 
influence ANS function in health and disease.
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Appendix 1 Quality index score assessment tool criteria
Index Criteria Assessed
High = 2 points Medium = 1 point Low = 0 points
1. Study Design Case-control study with 
appropriate matching (e.g. 
age, sex, body mass index); 
and/or interventional with 
assessment before and after 
biologic agent
Case-control study but 
inappropriately matched
Cohort study or other 
design with 
inappropriate or no 
control group
Rationale A case-control study with appropriate matching is the best study design to answer 
the principle question of the study – is autonomic dysfunction present in 
rheumatoid arthritis?
An interventional study with assessment before and after biologic agent is the best 
study design to answer another principle question – is there a link between 
inflammation and autonomic function in RA?
2. Inclusion/Exclusion 
Criteria
Patients included with a 
formal rheumatoid arthritis 
diagnosis according to 
recognised criteria and 
those with conditions or 
medications that interfere 
with autonomic function 
excluded
Patients included with a 
formal rheumatoid arthritis 
diagnosis according to 
recognised criteria but 
those with conditions or
medications that interfere 
with autonomic function 
not excluded
Criteria for 
rheumatoid arthritis 
diagnosis not 
mentioned
Rationale In order to establish meaningful conclusions from the study patients included must 
have the correct diagnosis according to recognised criteria and to prevent 
confounding factors those with condition or medications affecting autonomic 
function should be excluded
3. Disease characteristics Mentioned in detail (i.e. at 
least 2): disease duration, 
inflammatory marker e.g. 
C-reactive protein or 
erythrocyte sedimentation 
rate, swollen or tender 
joints, medications, 
functional capacity
Mentioned only 1: disease 
duration, inflammatory 
marker e.g. C-reactive 
protein or erythrocyte 
sedimentation, swollen or 
tender joints, medications, 
functional capacity
Not mentioned
Rationale Disease characteristics are necessary to determine the inflammatory status of the 
rheumatoid arthritis patients tested at the time of the study. They allow for 
meaningful interpretation and comparison between different studies.
4. Standardised testing 
condition
Mentioned in detail (i.e. at 
least 2): e.g. testing room 
temperature, time of 
testing, fasting status, 
subject position
Mentioned only 1: e.g. 
testing room temperature, 
time of testing, fasting 
status, subject position
Not mentioned or not 
standardised
Rationale Testing conditions can affect the results of autonomic function assessments and 
hence unwanted bias can be avoided by standardising the testing conditions for 
each subject.
5. Autonomic assessment 
– standardised protocol
Mentioned that the study 
adhered to published 
guidelines or protocols and 
comprehensive details 
Mentioned that the study 
adhered to published 
guidelines and protocols 
but important details 
No mention of 
guidelines or 
protocols
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provided missing; or mentioned that 
study was adapted from 
guidelines or protocols
Rationale Adhering to published guidelines or protocols ensures that testing is performed to 
the highest standard available and allows for meaningful comparison between 
different studies.
6. Autonomic assessment 
– quality of test
Autonomic function 
assessed using a recognised 
and validated tool, and a 
comprehensive assessment 
performed (i.e. more than 
one technique employed)
Gold standard or close to
gold standard assessment 
of autonomic function
Autonomic function 
assessed using a recognised 
tool but a basic assessment 
performed (i.e. only one 
technique)
Reasonable assessment of 
autonomic function
Unrecognised tool to 
measure autonomic 
function such as a 
novel or non-
established method
Unknown or poor 
indicator of 
autonomic function
Rationale A comprehensive assessment of autonomic function involves using the best 
validated tools with numerous aspects of autonomic function tested
7. Statistics –
appropriate sample size
Power calculation 
performed to determine 
sample size and sample 
size achieved
Power calculation 
performed to determine 
sample size but sample size 
not achieved
No mention of power 
calculation
Rationale In order to prevent type 2 errors the correct sample size should be calculated in 
advance and reached.
8. Statistics –
appropriate tests used
Appropriate statistical test 
applied and comprehensive 
details mentioned with 
adjustment made for co-
variables/confounders 
when necessary
Appropriate statistical test 
applied but lacking details 
with no adjustment made 
for co-
variables/confounders 
when necessary
Inappropriate 
statistical test used
Rationale Choosing the most appropriate statistical test ensures accurate results and adjusting 
for co-variables helps to minimise the bias, allowing meaningful and accurate 
interpretation and conclusions.
9. Associations between 
autonomic function and 
inflammation made
Associations made (e.g. 
using regression analysis) 
and adjustments made for 
co-variables/confounders 
(e.g. multiple regression) 
when necessary
Associations made (e.g. 
using regression analysis) 
but no adjustment made for 
co-variables/confounders 
when necessary
Not mentioned or no 
associations made
Rationale To determine whether links between inflammation and autonomic function in RA 
exist associations between indices of inflammation and parameters of autonomic 
function need to be made.
Each index was graded between 0-2, and the total points added to give a final score between 0-18. If an index 
was found to be inappropriate (or irrelevant) to a particular study then the index was omitted and the total score 
reduced to 16. This occurred in studies employing 24-hour home assessments (e.g. 24-hour electrocardiogram 
monitor or urinary testing) where the index “standardised test conditions” did not apply. For all studies a 
percentage was calculated to give a Quality Index Score (QIS). The quality assessment was performed by two 
researchers (Ahmed Adlan and James Fisher) and disagreements were discussed until a consensus was reached. 
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Appendix 2 Characteristics of studies included in the review (cross-sectional, observational, case-control studies)
A. Cross-sectional, observational, case-control studies
Study Year N Characteristics Inclusion
Exclusion
Assessment Key findings QIS
Clinical cardiovascular tests (n=17)
Aydemir et al
(447)
2010 RA 36 30 female, 49 years
Disease duration 11.2 years 
DAS28 4.1
CRP 11mg/L
ESR 33 mm/1st hour
I: ARA 1987 criteria 
E: Condition or 
medication affecting 
ANS
Ewing
HR variation response to 
DB, O, VM 
BP response to HG, O
Abnormal cardiovascular 
tests in 61-75% of RA 
patients
Impaired sympathetic and 
parasympathetic responses
Higher resting HR in RA 
patients
No association between 
inflammation (DAS28, 
CRP, ESR) and ANS 
function
89%
HC 40 31 female, 43 years
Bidikar et al
(450)
2010 RA 50 46 female, 38 years I: ARA 1987 criteria, 
age 20-60 yrs
E: Condition or 
medication affecting 
ANS
Ewing
BP response to CP, HG, 
O
Higher resting HR and 
SBP in RA patients
Abnormal cardiovascular 
tests in RA
Impaired sympathetic 
responses
56%
HC 50 46 female, 38 years
Milovanovic et al
(473)
2010 RA 38 32 female, 56 years
25 RF positive
ESR 14.3 mm/1st hour
I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Ewing
HR variation response to 
DB, O, VM
Abnormal cardiovascular 
tests more prevalent in RA 
than controls
67%
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HC 41 17 female, 37 years
BP response to O
Impaired sympathetic and 
parasympathetic responses
Stojanovich et al
(477)
2007 RA 39 33 female, 58 years
Disease duration 9.5years
64% RF positive
ESR 14.3 mm/1st hour
I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Ewing
HR variation response to 
DB, O, VM
BP response to HG, O
Abnormal cardiovascular 
tests more prevalent in RA
Impaired sympathetic and 
parasympathetic responses 
in RA patients
No correlation between 
inflammation (CRP, ESR, 
Ritchie score) and ANS 
function
78%
HC 35 19 female, 52 years
Veldhuijzen van 
Zanten et al (481)
2005 RA 21 18 females, 57 years
Disease duration 12 years
CRP 10.4 mg/L 
ESR 27.5 mm/1st hour
DAS28 4.57
I: ARA 1987 criteria, 
able to stand for 15 
minutes
E: Previous acute 
coronary syndrome, 
diabetes mellitus, 
serious psychiatric 
disease
HR and BP (sympathetic) 
responses to mental stress
Normal sympathetic 
responses to mental stress 
seen in RA compared to 
osteoarthritis controls
61%
DC 10 6 females, 47 years 
(osteoarthritis)
Sandhu et al
(475)
2004 RA 62 39 female, median 63 years
Steinbrocker’s class 1 or 2
76% RF positive
None had evidence of current 
flare in joint
7 had peripheral nerve damage
I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Ewing
HR variation response to 
DB, O, VM
BP response to HG, O
Abnormal cardiovascular 
tests in RA – worse in 
patients with peripheral 
neuropathy or RF positive
Impaired parasympathetic 
and sympathetic (only 
83%
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HC 41 21 females, median 50 years DBP response to HG) 
responses in RA patients
No correlation between 
inflammation (CRP, ESR) 
and ANS function
Gozke et al (458) 2003 RA 10 10 females, 49 years I: ARA 1987  criteria
E: Symptoms of 
clinical ANS 
dysfunction
RR interval  variation at 
rest and in response to 
DB
Abnormal cardiovascular 
tests in RA
Impaired parasympathetic 
responses in RA patients
39%
HC 14 14 females, 45 years
Johannes et al
(465)
2003 RA 13 No females, 64 years I: RA (no criteria), 
male
E: None reported
HR and BP (sympathetic) 
responses to mental stress
Higher resting HR in RA 
patients and hypertensive 
controls, compared to 
healthy
Lower resting DBP in RA 
patients compared to 
hypertensive and healthy 
controls
Higher BP (sympathetic) 
response to mental stress 
in RA patients compared 
to hypertensive and 
healthy controls
50%
HC 30 No females, 39 years
DC 53 No females, 49 years 
(Hypertensive)
Louthrenoo et al
(471)
1999 RA 34 30 females, 47 years
Disease duration 5.1years
15.5 swollen joints
Ritchie articular index 11.6
56% RF positive
ESR 35.2 mm/1st hour
I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Ewing
HR variation in response 
to DB, O
SBP response to O
Abnormal cardiovascular 
tests in RA
Parasympathetic 
dysfunction in RA 
patients. 
61%
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HC 62 50 females, 47 years
34 age and gender match controls 
used in analysis
No correlation between 
inflammation (ESR, 
number of swollen joints) 
and ANS function
Bekkelund et al
(449)
1997 RA 43 43 females, 44 years
Disease duration 13.6 years
24.1 arthritic joints
Ritchie articular index 22.6
CRP 10.8mg/L
ESR 23.2 mm/1st hour
I: ARA 1987 criteria, 
females, aged 16-55 
years
E: Known somatic or 
psychiatric disease, 
concomitant systemic 
connective tissue 
disease or primary 
neurological disease, 
alcoholism, 
atlantodental 
space>5mm
Ewing
HR variation in response 
to DB, O, VM
BP response to O
Normal cardiovascular 
tests in RA
78%
HC 61 61 females, 42 years
Maule et al (472) 1997 RA 17 17 females, 37 years
Disease duration 9.3 years
I: ARA 1987 criteria
E: Diabetes, obesity, 
renal failure, chronic 
liver disease, 
arrhythmia, anaemia, 
anti-hypertensive 
therapy
Ewing
HR variation in response 
to DB, O, VM
BP response to O
Normal cardiovascular 
tests in RA
44%
HC 25 25 females, 32 years
Geenen et al
(456)
1996 RA 21 17 females, 56 years
Disease duration 4-12months, 
VAS pain 26mm
ESR 23 mm/1st hour
I: ARA 1987 criteria
E: Any other serious 
disease. Controls were 
free from chronic pain, 
cardiovascular 
complaints or disease.
HR and BP (sympathetic) 
responses to mental stress
Abnormal cardiovascular 
tests in RA
Impaired HR and BP 
(sympathetic) responses in 
RA patients
No correlation between 
inflammation (ESR) and 
ANS function
67%
HC 20 16 females, 53 years
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Piha et al (474) 1993 RA 34 34 females, 49 years
Disease duration 15 years
ARA functional class: I = 6, II = 
20, III = 8
28 had arthritis in 3 or more joint 
areas and positive findings on 
hand radiographs
ESR 23 mm/1st hour
I: ARA 1987 criteria, 
females 
E: Condition or 
medication affecting 
ANS.
HR variation response to 
DB, O, VM
Higher resting HR in RA
Impaired HR variation 
(parasympathetic) 
responses to O and VM 
(which were statistically 
insignificant when age and 
HR used as co-variants)
No correlation between 
inflammation (ESR) and 
ANS function
78%
HC 69 69 females, 43 years
DC 76 76 females, 43 years (diabetic)
Tan et al (478) 1993 RA 30 27 females, 51 years
Disease duration 90.2months
Steinbrocker function class: II = 
25, III = 5 
CRP 380 mg/L
ESR 61 mm/1st hour
I: ARA 1987 criteria
E: Control subjects 
were healthy with no 
symptoms or signs of 
neurological disease
RR interval variation at 
rest and in response to 
DB
Abnormal cardiovascular 
tests in 27% of RA 
patients
Impaired parasympathetic 
activity (RR interval 
variation in response to 
DB)
56%
HC 30 26 females, 50 years
Toussirot et al
(479)
1993 RA 50 31 females, 56 years
Disease duration 6 years
52% RF positive
52% inflammatory syndrome (not 
clearly defined)
I: ARA 1987 criteria, 
patients hospitalized 
with a flare or for 
therapeutic adjustment
E: Condition or 
medication affecting 
ANS
HR response to DB, O, 
VM
Abnormal cardiovascular 
tests in 60% of RA 
patients
Impaired parasympathetic 
responses (HR response to 
VM only) in RA patients
No correlation between 
56%
HC 82 53 females, 47 years
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inflammation 
(inflammatory syndrome, 
articular damage on 
radiograph) and ANS 
function
Leden et al (470) 1983 RA 17 12 females, 56 years
Disease duration 20 years
14 seropositive
Steinbrocker’s function class: II = 
6, III = 8, IV = 2. 
All had erosions
I: ARA 1987 criteria 
admitted for 
reconstruction joint 
surgery
E: Respiratory disease, 
abnormal creatinine or 
proteinuria
BP response to O
HR variation response to 
DB, O
Normal cardiovascular 
tests in RA patients 
overall
Sub-group showed 
significant impairment in 
cardiovascular tests in RA 
patients with a high v low 
(7 v 10) disease severity 
score
Impaired parasympathetic 
(HR variation response to 
DB and O) and 
sympathetic responses (BP 
response to O) found in 
RA patients with high 
disease severity score v 
controls
44%
HC 24 8 females, 53 years
Edmonds et al
(454)
1979 RA 27 55 years I: Ropes et al 1958 
criteria, normotensive
E: Cardiac failure, 
anaemia, medications 
affecting cardiac 
rhythm
Ewing
HR variation response to 
DB, O, VM
Higher proportion of 
abnormal cardiovascular 
tests in RA
Impaired parasympathetic 
responses in RA patients
Mean ESR higher in RA 
patients with abnormal 
HR variation response to 
O
39%
HC 13 51 years (old healthy)
HC 15 25 years (young healthy)
DC 13 54 years (osteoarthritis)
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HRV tests (n=13)
Janse van 
Rensburg et al
(464)
2012 RA  45 45 females, 47 years
Disease duration 4.3 years
DAS28 3.3
CRP 8.6 mg/L
I: ARA 1987 criteria, 
classification of global 
functional status = 
class I or II, female, 
aged 30-60 years, 
controlled disease
E: Condition or 
medication affecting 
ANS.
Short term HRV
Parasympathetic 
(pNN50%, SDNN, 
rMSSD, HF, SD1), 
sympathetic (LF, LF/HF 
ratio) balance at rest and 
in response to O
Higher resting HR in RA
Lower HRV in RA
Increased sympathetic 
tone and decreased 
parasympathetic activity
Reduced response to O in 
RA
78%
HC 39 39 females, 45 years
Vlcek et al (483) 2012 RA 22 22 females, 31 years
Disease duration 7.4 years
DAS28-CRP 3.4
CRP 7.5 mg/L
I: ARA 1987 criteria, 
female, age<40years, 
normal BMI
E: Any disease
Short term HRV
Parasympathetic (HF), 
sympathetic (LF, LF/HF 
ratio) balance at rest and 
in response to O
Normal HRV at rest and 
in response to O in RA
78%
HC 15 15 females, 30 years
Yadav et al (484) 2012 RA 45 39 females, 41 years I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Short term HRV
Parasympathetic (SDNN, 
SDSD, rMSSD, NN50, 
HF), sympathetic (LF, 
LF/HF) balance
Lower HRV in RA
Reduced parasympathetic 
activity
Positive correlation 
between inflammation 
(DAS28) and 
parasympathetic tone 
(SDSD only)
72%
HC 45 39 females, 37 years
Avsar et al (446) 2011 RA 26 18 females, 56 years I: ARA 1987 criteria
E: Condition or 
medication affecting 
Heart rate turbulence 
from 24 hour holter ECG 
monitor at home.
Normal heart rate 
turbulence 
(parasympathetic activity 
56%
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HC 26 18 females, 55 years ANS Parasympathetic and 
arterial baroreflex 
sensitivity
and arterial baroreflex 
sensitivity) in RA patients
Aydemir et al
(447)
2010 RA 36 30 females, 49 years I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Short term HRV
Parasympathetic (HF), 
sympathetic (LF, LF/HF 
ratio) balance at rest and 
in response to O
Reduced sympathetic 
activity (LF) in RA
89%
HC 40 31 females, 43 years
Bruchfeld et al
(451)
2010 RA 13 9 females, 52 years
Disease duration 13.2years
11 RF positive
DAS28-CRP 3.9
I: ARA 1987 criteria
E: Smoking, diabetes 
mellitus
Short term HRV
Parasympathetic (HF) 
and sympathetic (LF, 
LF/HF ratio) balance
Reduced parasympathetic
activity (HF) in RA
61%
HC 10 3 females, 32 years
Milovanovic et al
(473)
2010 RA 38 32 females, 56 years
25 RF positive
ESR 14.3 mm/1st hour
I: ARA 1987 criteria, 
stable condition
E: Condition or 
medication affecting 
ANS
Short term HRV
Parasympathetic 
(pNN50%, SDRR, 
rMSSD, HF), 
sympathetic (LF, LF/HF 
ratio) balance
Long term HRV
Parasympathetic, 
sympathetic activity
Lower HRV in RA
Reduced parasympathetic 
(SDNN, pNN50%, 
rMSSD) activity in RA
67%
HC 41 17 females, 37 years
Vlcek et al (482) 2008 RA 8 8 females, 31 years I: ARA 1987 criteria
E: None reported
Short term HRV
Parasympathetic (HF) 
and sympathetic (LF, 
LF/HF) balance at rest 
and in response to O
Normal HRV at rest and 
in response to O in RA 
patients
61%
HC 8 8 females, 31 years
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Anichkov et al
(445)
2007 RA 23 23 females, 48 years
Disease duration 4 years
19 RF positive
DAS 4.2
ESR 24mm/1st hour
Ritchie articular index 16
I: ARA 1987 criteria, 
female, aged 18-65 yrs, 
disease duration ≥12 
months
E: Condition or 
medication affecting 
ANS
Long term HRV
Parasympathetic (SDNN, 
SDANN, rMSSD, SD1) 
activity
Lower HRV in RA 
patients
Reduced parasympathetic 
activity (SDNN, SDANN, 
rMSSD, SD1)
Negative correlation 
between inflammation 
(number of swollen joints, 
Ritchie articular index, 
DAS, leucocyte count) 
and HRV, 
parasympathetic activity 
(SDNN, SDANN)
88%
HC 23 23 females, 47 years
Goldstein et al
(457)
2007 RA 13 9 females, median 52 years
Disease duration 13 years,
11 RF positive
DAS28 4.5
CRP 14.5mg/L
I: ARA 1987 criteria
E: None reported
Short term HRV
Parasympathetic 
(rMSSD, HF) and 
sympathetic balance (LF, 
LF/HF ratio)
Lower HRV in RA 
patients
Reduced parasympathetic 
activity (rMSSD, HF) in 
RA patients
72%
HC 11 6 females, median 38 years
Kamal(467) 2007 RA 52 49 years
Disease duration 8.4 years 
CRP 51.4 mg/L
ESR 42.6 mm/1st hour
I: RA (no criteria)
E: Condition or 
medication affecting 
ANS
Short term HRV.
Parasympathetic activity 
(SDNN).
Low HRV in RA patients
Reduced parasympathetic 
activity (SDNN) in RA 
patients
33%
HC 51 46 years
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Dekkers et al
(453)
2004 RA 25 19 females, 55 years
Disease duration <2years
Thompson joint score 31
ESR 15 mm/1st hour
I: ARA 1987 criteria, 
minimum age 18 yrs
E: Any other serious 
disease. For healthy 
controls: chronic 
disease, chronic pain, 
hypertension or heart 
problems
ECG, impedence 
cardiogram
Parasympathetic 
(respiratory sinus 
arrhythmia), sympathetic 
(pre-ejection period) 
activity.
Lower pre-ejection period 
found in RA patients 
(indicating higher 
sympathetic activity)
Normal respiratory sinus 
arrhythmia 
(parasympathetic activity) 
in RA patients
Association between 
inflammation (ESR, 
Thompson joint score) and 
increased sympathetic 
activity
72%
HC 28 20 females, 56 years
Evrengul et al
(455)
2004 RA 42 31 females, 48 years
Disease duration 6.5 years
35 RF positive
Steinbrocker’s function class: I = 
16, II = 18, III = 8
CRP 50.3 mg/L
ESR 41.7 mm/1st hour
I: ARA 1987 criteria, 
stages I-IV of 
Steinbrocker’s 
functional 
classification
E: Condition or 
medication affecting 
ANS
Short term HRV
Parasympathetic (SDNN, 
pNN50%, rMSSD, HF), 
sympathetic (LF, LF/HF 
ratio) balance
Low HRV in RA patients
Reduced parasympathetic 
activity (SDNN) in RA 
patients
No correlation between 
inflammation (ESR) and 
HRV parameters
89%
HC 44 31 females, 45 years
Biomarkers (n=5)
Kopec-Medrek et 
al (468)
2012 RA 16 16 females, post-menopausal I: RA (no criteria) 
treated with infliximab 
(TNF alpha inhibitor), 
post menopausal 
females, active disease 
and not received 
Plasma NPY 
(sympathetic activity)
Plasma NPY (sympathetic 
activity) was higher in RA 
patients
Positive correlation 
between inflammation 
67%
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HC 16 16 females, post-menopausal
Age and BMI matched
remission after 
treatment with at least 
two DMARDs
E: HRT, smoking, 
conditions known to 
affect ANS
(CRP, DAS28) and 
plasma NPY (sympathetic 
activity)
Capellino et al
(452)
2008 RA 24 14 females, 58 years I: ARA 1987 criteria
E: None reported
Serum chromogranin A 
(sympathetic activity)
Serum chromogranin A 
(sympathetic activity) was 
higher in RA patients
50%
HC 37 26 females, 38 years
Vlcek et al (482) 2008 RA 8 8 females, 31 years I: ARA 1987 criteria
E: None reported
Plasma NPY 
(sympathetic activity) at 
rest and in response to O.
Normal plasma NPY 
(sympathetic activity) in 
RA patients
61%
HC 8 8 females, 31 years
Harle et al (460) 2006 RA 62 52 females, 58 years
Disease duration 9.7 years
9 tender joints
7.5 swollen joints
ESR 27.7 mm/1st hour.
I: ARA 1987 criteria, 
fertile women were not 
taking contraceptives 
and tested in the early 
to mid-follicular phase 
of the menstrual cycle
E: None reported
Serum NPY (sympathetic 
activity)
Higher NPY found only in 
RA patients with previous 
prednisolone use
67%
HC 23 12 females, 52 years
Grimsholm et al
(459)
2005 RA 7 51 years (early RA)
Disease duration <1 year
I: ARA 1987 criteria
E: None reported
Serum NPY (sympathetic 
activity)
NPY higher in long-
standing RA patients but 
not statistically significant
NPY in early RA patients 
comparable to healthy 
controls
28%
RA 28 59 years (long-standing RA)
Disease duration >1year
HC 11 39 years
Note: 25/35 female RA patients
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Skin sympathetic responses (n=5)
Gozke et al (458) 2003 RA 10 10 females, 49 years I: ARA 1987 criteria
E: Symptoms of 
clinical ANS 
dysfunction
Sympathetic skin 
responses to nerve 
stimulation
Normal sympathetic skin 
responses in RA
39%
HC 14 14 females, 45 years
Johannes et al
(465)
2003 RA 13 No females, 64 years I: RA (clinical 
diagnosis), male
E: None reported
Skin temperature and 
conductance responses to 
mental stress
Sympathetic skin 
responses to mental stress 
higher in RA patients
50%
HC 30 No females, 39 years
DC 53 No females, 49 years 
(hypertensive)
Geenen et al
(456)
1996 RA 21 17 females, 56 years
Disease duration 4-12months
VAS pain 26mm
ESR 23 mm/1st hour
I: ARA 1987 criteria
E: Any other serious 
disease. Controls were 
free from chronic pain, 
cardiovascular 
complaints or disease
Sympathetic skin 
conductance to mental 
stress
Normal resting skin 
conductance in RA 
patients
Reduced sympathetic skin 
responses to mental stress
67%
HC 20 16 females, 53 years
Jolliffe et al (466) 1995 RA 40 57 years I: ARA 1987 criteria
E: Diabetes mellitus, 
vasoactive medication, 
skin conditions 
affecting the wrist
Sympathetic skin 
responses to intra-dermal 
nicotine
Normal sympathetic skin 
responses in RA patients
44%
HC 46 57 years
Tan et al (478) 1993 RA 30 27 females, 51 years
Disease duration 90.2months
Steinbrocker function class: II = 
25, III = 5 
ESR 61 mm/1st hour
CRP 380 mg/L
I: ARA 1987 criteria
E: Control subjects 
were healthy with no 
symptoms or signs of 
neurological disease
Sympathetic skin 
responses to nerve 
stimulation
Normal sympathetic skin 
responses in RA
56%
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HC 30 26 females, 50 yrs
Catecholamines (n=4)
Vlcek et al (483) 2012 RA 22 22 females, 31 years
Disease duration 7.4 years
DAS28-CRP 3.4
CRP 7.5 mg/L
I: ARA 1987 criteria, 
female, age<40yrs, 
normal BMI
E: Any disease
Plasma EPI and NE 
(sympathetic activity) at 
rest and in response to O
Normal EPI and NE 
(sympathetic activity) at 
rest and in response to O 
in RA
78%
HC 15 15 females, 30 years
Vlcek et al (482) 2008 RA 8 8 females, 31 years I: ARA 1987 criteria
E: None reported
Plasma EPI and NE 
(sympathetic activity) at 
rest and in response to O
Baseline plasma NE 
(sympathetic activity) was 
higher in RA patients
There was a trend for 
reduced plasma NE 
(sympathetic activity) in 
RA patients
61%
HC 8 8 females, 31 years
Imrich et al (463) 2005 RA 15 15 females, 41 years
Disease duration 8.2 years
CRP 15.4mg/L
ESR 20.3 mm/1st hour
I: ARA 1987 criteria, 
female
E: Diabetes, impaired 
glucose tolerance
Serum EPI and NE 
(sympathetic activity) at 
rest and in response to 
insulin-induced 
hypoglycaemia
Basal and cumulative 
levels of EPI were reduced 
(but not statistically 
significantly) in RA 
patients
Basal levels of NE were 
normal in RA patients, but 
cumulative levels were 
67%
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HC 14 14 females, 44 years reduced (reduced basal 
sympathetic activity).
Serum EPI response to 
insulin-induced 
hypoglycaemia was 
normal in RA however 
serum NE response was 
reduced in RA (impaired 
sympathetic response)
Igari et al (462) 1977 RA 22 20 females, 45 yrs
ESR 44.8mm/1st hr, Steinbrocker 
class 2.5
I: Ropes et al 1958 
criteria for classical or 
definite RA
E: None reported
24 hour urinary 
adrenaline and 
noradrenaline 
(sympathetic activity)
Baseline 24 hour urinary 
adrenaline was reduced in 
RA patients
44%
HC 6 2 females, 33 years
Arterial baroreflex sensitivity  (n=2)
Avsar et al (446) 2011 RA 26 18 females, 56 years I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Heart rate turbulence 
from 24 hour holter ECG 
monitor at home
Parasympathetic and 
arterial baroreflex 
sensitivity
Normal heart rate 
turbulence 
(parasympathetic activity 
and arterial baroreflex 
sensitivity) in RA patients
56%
HC 26 18 females, 55 years
Aydemir et al
(447)
2010 RA 36 30 females, 49 years I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Sequence method 
(arterial baroreflex 
sensitivity) at rest and in 
response to O
Reduced arterial 
baroreflex sensitivity at 
rest in RA patients
89%
HC 40 31 females, 43 years
Pupillary light reflex (n=1)
Barendregt et al
(448)
1996 RA 18 18 females, 64 years (with ocular 
dryness)
I: ARA 1987 criteria, 
with or without dryness 
of eyes or mouth 
Pupillary light reflexes: 
constriction latency and 
maximum constriction 
Parasympathetic 
dysfunction (prolonged 
constriction latency and 
61%
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RA 18 18 females, 59 years (without 
ocular dryness)
E: Condition or 
medication known to 
affect ANS
velocity (parasympathetic 
activity)
elevated maximum 
constriction velocity) 
found in RA patients with 
ocular drynessHC 33 33 females, 56 years
Mean values given unless otherwise indicated.
ANS = autonomic nervous system, ARA 1987 criteria = American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,(8) BP = 
blood pressure, BMI = body mass index, CP = cold pressor test, CRP = C reactive protein, DAS28 = disease activity score 28, DB = deep breathing, DBP = diastolic 
blood pressure, DC = disease controls, DMARD = disease modifying anti-rheumatic drug, E = exclusion, ECG = electrocardiogram, EPI = epinephrine, ESR = 
erythrocyte sedimentation rate, HC = healthy controls, HF = high frequency power in the range 0.15-0.40 Hz, HG = handgrip, HR = heart rate, HRT = hormone 
replacement therapy,  HRV = heart rate variability, I = inclusion, LF = low frequency power in the range 0.04-0.15Hz, LF/HF ratio = low frequency to high frequency 
ratio, N = number of subjects, NE = norepinephrine, NN = inter-beat interval, NN50 = number of pairs of adjacent NN intervals differing by more than 50 milliseconds 
in the entire recording, NPY = neuropetide Y, O = orthostasis, pNN50% = NN50 as a percentage of the total number of all NN intervals, QIS = quality index score (%), 
RA = rheumatoid arthritis, RF = rheumatoid factor antibody, rMSSD = square root of the mean of the sum of the squares of difference between adjacent NN intervals, 
Ropes et al 1958 criteria = 1958 Revision of diagnostic criteria for rheumatoid arthritis,(596) SBP = systolic blood pressure, SD1 = standard deviation of the Poincare 
plot, SDANN = standard deviation of the averages of NN intervals in all 5 minute segments of the entire recording, SDNN = standard deviation of all NN intervals, 
SDSD = standard deviation of differences between adjacent NN intervals, TNF = tumour necrosis factor, VAS = Visual Analogue score, VM = Valsalva’s manoeuvre
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Appendix 3 Characteristics of studies included in the review (cohort and interventional studies)
B. Cohort and interventional studies
Study Year N Characteristics Inclusion Exclusion Assessment Key findings QIS
Interventional studies (n=3)
Kopec-Medrek et 
al (468)
2012 RA 16 16 females, post-menopausal I: RA (no criteria) 
treated with infliximab 
(TNF alpha inhibitor), 
post menopausal 
females, active disease 
and not received 
remission after 
treatment with at least 
two DMARDs
E: HRT, smoking, 
conditions known to 
affect ANS
Plasma NPY 
(sympathetic activity) at 
week 0, 2, 14, 54 and 62.
Plasma NPY (sympathetic 
activity) was higher in RA 
patients at baseline and 
with infliximab infusion.
Positive correlation 
between inflammation 
(CRP, DAS28) and 
plasma NPY (sympathetic 
activity)
67%
HC 16 16 females, post-menopausal 
Age and BMI matched
Cross-sectional, case-control, 
observational study with 
longitudinal interventional 
component.
Intervention: TNF alpha inhibitor 
therapy (infliximab) in 16 RA 
patients.
1 year follow up
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Harle et al (460) 2006 RA 62 52 females, 58 years
Disease duration 9.7 years
9 tender joints
7.5 swollen joints
ESR 27.7 mm/1st hour
I: ARA 1987 criteria, 
fertile women were not 
taking contraceptives 
and tested in the early 
to mid-follicular phase 
of the menstrual cycle
E: None reported
Serum NPY (sympathetic 
activity) at week 0 and 12
Higher serum NPY found 
only in RA patients with 
previous prednisolone use
TNF alpha inhibitor 
therapy had no effect on 
serum NPY levels, despite 
a good clinical response
67%
HC 23 12 females, 52 years
Cross-sectional, case-control, 
observational study with 
longitudinal interventional 
component
Intervention: TNF alpha inhibitor 
therapy (adalimumab) in 32 RA 
patients
Follow up 12 weeks post therapy
Igari et al (462) 1977 RA 22 20 females, 45 years
ESR 44.8 mm/1st hour
Steinbrocker class 2.5
I: ARA 1987 criteria 
for classical or definite 
RA
E: None reported
24 hour urinary 
adrenaline and 
noradrenaline 
(sympathetic activity) 
before and after 
synovectomy
Baseline 24 hour urinary 
adrenaline was reduced in 
RA patients
24 hour urinary adrenaline 
and noradrenaline 
significantly decreased 
two weeks after 
synovectomy in RA 
patients
44%
HC 6 2 females, 33 years
Cross-sectional, case-control, 
observational study with 
longitudinal interventional 
component
Intervention: synovectomy 
performed in 6 RA patients
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Cohort studies (n=3)
Holman et al (461) 2008 ALL 
33
RA 25, Psoriatic arthritis 8
Disease duration 7.6 years
14 RF positive
Baseline DAS28 4.9
Remission DAS28 2.0
I: Inflammatory 
arthritis including 25 
RA (no criteria) 
undergoing TNF alpha 
inhibitor therapy.
Short term HRV. 
Parasympathetic (HF), 
sympathetic (LF) and 
overall HRV (total 
power).
Low HRV (total power), 
low parasympathetic (HF) 
and high sympathetic 
function (LF) was 
predictive of poor 
response to TNF alpha 
inhibitor therapy.
No correlation between 
baseline autonomic 
function (HRV 
parameters) and change in 
DAS28 score.
56%
RA 25 Prospective, double-blind, 
exploratory study to investigate 
HRV as a predictor of TNF alpha 
inhibitor therapy in patients with 
inflammatory arthritis.
Schwemmer et al
(476)
2006 RA 30 17 females, 52 years
Disease duration 6.7 years
9 swollen joints
9 tender joints
63% RF positive
CRP 31 mg/L
ESR 30.2 mm/1st hour
Prospective, cohort study with 
longitudinal survival
Follow-up: 8 years
I: ARA 1987 criteria
E: Condition or 
medication affecting 
ANS
Clinical cardiovascular 
tests (Ziegler et al 1992) 
HR variation at rest and 
responses to DB, O, VM
SBP responses to O
Pupillary light reflex: 
latency time, area in 
darkness
Cardiac and pupillary 
ANS dysfunction in 60% 
of RA patients
3 of 4 deaths were due to 
cardiac causes
Non-survivors had higher 
HR variation response to 
DB, but lower HR 
variation to O
61%
van Middendorp et 
al (480)
2005 RA 60 38 females, 59 years
Disease duration 13 years
Thompson joint score 21
ESR 16 mm/1st hour
Cross-sectional, cohort, 
observational  study
I: RA (no criteria)
E: Receiving 
glucocorticoid therapy
24 hour urinary 
noradrenaline excretion 
(sympathetic activity)
No correlation found 
between sympathetic 
activity and inflammation 
(ESR or IL-6)
56%
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Other studies (n=1)
Lazzerini et al
(469)
2008 RA 20 Disease duration 10.4 years
16 erosive disease
CRP 4.8 mg/L
ESR 22.9 mm/1st hour
Randomized, placebo-controlled, 
single-blind cross-over to 
investigate the arrhythmia risk 
during acute infliximab therapy in 
patients with chronic arthritis
I: RA (ARA 1987 
criteria) or 
Spondyloarthritis
E: coronary artery 
disease, no alterations 
in cardiac enzymes or 
serum electrolytes, 
ECG or 
echocardiographic 
abnormalities
Short and long term HRV
Parasympathetic (rMSSD, 
pNN50%, SDNN, 
SDANN, HF power), 
sympathetic (LF, LF/HF 
ratio) activity and overall 
HRV (total power) during 
infliximab and placebo 
infusions (2 hour 
recordings)
TNF alpha inhibitor 
therapy (infliximab) 
acutely reduced HRV 
(total power) and 
sympathetic activity (LF, 
LF/HF)
Patients who developed 
new-onset arrhythmia had 
reduced HRV (total 
power) and 
parasympathetic activity 
(rMSSD, pNN50%, HF), 
reduced sympathetic
activity (LF) and tended 
to have a higher CRP
61%
Mean values given unless otherwise indicated.
ANS = autonomic nervous system, ARA 1987 criteria = American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,(8) BMI 
= body mass index, CRP = C reactive protein, DAS28 = disease activity score 28, DB = deep breathing, DMARD = disease modifying anti-rheumatic drug, E = 
exclusion, ESR = erythrocyte sedimentation rate, HC = healthy controls, HF = high frequency power in the range 0.15-0.40 Hz, HR = heart rate, HRT = hormone 
replacement therapy,  HRV = heart rate variability, I = inclusion, IL-6 = interleukin-6, LF = low frequency power in the range 0.04-0.15Hz, LF/HF ratio = low 
frequency to high frequency ratio, N = number of subjects, NN= inter-beat interval, NPY = neuropetide Y, O = orthostasis, pNN50% = NN50 as a percentage of the 
total number of all NN intervals, QIS = quality index score (%), RA = rheumatoid arthritis, RF = rheumatoid factor antibody, rMSSD = square root of the mean of the 
sum of the squares of difference between adjacent NN intervals, SBP = systolic blood pressure, SDANN = standard deviation of the averages of NN intervals in all 5 
minute segments of the entire recording, SDNN = standard deviation of all NN intervals, TNF = tumour necrosis factor, VM = Valsalva’s manoeuvre
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Appendix 4 Prevalence of ANS dysfunction in RA
Study N Criteria for ANS dysfunction Prevalence 
(%)
Aydemir et al.
2010
36 Ewing test.(415) Two of five abnormal tests from: 
HR response to Valsalva’s manoeuvre (Valsalva ratio≤1.1)
HR variation during deep breathing (inter-beat interval maximum-
minimum ≤10)
HR response to standing (30:15 ratio≤1.0) 
BP response to standing (fall in systolic BP≥20)
BP response to handgrip (diastolic BP rise ≤10mmHg)
61
Modified (by authors) Ewing test.(447) Two abnormal and one 
borderline from: 
Ewing test + inspiration/expiration heart rate ratio ≤1
BP response to orthostasis (fall in diastolic BP≥10mmHg) 
75
Bidikar et al.
2010
50 Fall in systolic BP in response to orthostasis ≥10mmHg 44
Milovanovic et 
al. 2010
50 Two of three positive tests from: 
BP response to orthostasis
HR response to deep breathing
HR response to orthostasis
86
Stojanovic et al.
2007
39 Two of three positive tests from: 
BP response to orthostasis
BP response to handgrip
HR response to deep breathing
HR response to orthostasis
HR response to Valsava’s manoeuvre
Moderate to severe autonomic nervous system (ANS) dysfunction:
Ewing score≥4
74
Schwemmer et 
al. 2006
30 Ewing test (result below 5th percentile) 43
Two of five abnormal (below 5th centile from normal healthy control 
subjects) tests from: 
RRI variation at rest
RRI variation difference between deep breathing and rest
RRI variation difference between deep breathing and rest
Valsalva’s manoeuvre (RRI maximum/RRI minimum)
HR response to orthostasis, BP fall ≥25mmHg
20
One of two abnormal (below 5th centile from normal healthy control 
subjects) tests from: 
Latency time of pupillary reflex
Maximal pupillary area
50
Cardiovascular and pupillary dysfunction (both of the above abnormal) 60
Gozke et al.
2003
10 Inter-beat interval (RRI) variation difference between deep breathing 
and rest
50
RRI variation ratio of deep breathing to rest 80
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Geenen et al.
1996
13 Lower mean response to cognitive discrimination than the least 
responding control
38
Tousirrot et al.
1993
50 Two of three abnormal tests from: 
HR response to deep breathing
HR response to orthostasis
HR response to Valsalva’s manoeuvre
60
Edmonds et al.
1979
27 HR response to orthostasis, RRI ratio<1 33
N = number of RA patients. Prevalence (%) values given are means either quoted or calculated from the study. 
ANS = autonomic nervous system
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Appendix 5 Associations between inflammation and autonomic function
Pain VAS hs-CRP IL-6 TNF-α IL-10
hs-CRP 0.586 *
<0.001
57
- - - -
IL-6 0.519 *
<0.001
62
0.339 *
0.010
57
- - -
TNF-α 0.306 *
0.016
62
0.010
0.939
57
0.753 *
<0.001
62
- -
IL-10 0.114
0.378
62
-0.068
0.616
57
0.537 *
<0.001
62
0.612 *
<0.001
62
-
HR 0.464 *
<0.001
63
0.362 *
0.006
57
0.339 *
0.010
57
0.059
0.646
57
-0.068
0.616
57
Mean BP 0.224
0.077
63
0.253
0.057
57
0.073
0.572
62
0.025
0.844
62
-0.138
0.286
62
MSNA burst 
frequency
0.238
0.150
38
0.418 *
0.011
36
0.266
0.107
38
0.039
0.816
38
-0.044
0.794
38
MSNA burst 
incidence
-0.032
0.849
38
0.193
0.260
36
0.039
0.815
38
-0.033
0.844
38
-0.109
0.516
38
GMOT
-0.506 *
<0.001
55
-0.332 *
0.019
50
-0.408 *
0.002
55
-0.322 *
0.016
55
-0.080
0.561
55
GSEQ -0.318 *
0.011
63
-0.338 *
0.010
57
-0.132
0.306
62
-0.024
0.853
62
-0.087
0.500
62
258
Pain VAS hs-CRP IL-6 TNF-α IL-10
rMSSD -0.437 *
<0.001
63
-0.420 *
0.001
57
-0.258 *
0.043
62
-0.137
0.289
62
0.018
0.891
62
pNN50 -0.419 *
0.001
63
-0.430 *
0.001
57
-0.226
0.077
62
-0.074
0.568
62
0.040
0.759
62
LF power -0.367 *
0.003
63
-0.371 *
0.004
57
-0.270 *
0.034
62
-0.224
0.080
62
-0.098
0.451
62
HF power -0.371 *
0.003
63
-0.348 *
0.008
57
-0.205
0.110
62
-0.138
0.285
62
-0.098
0.451
62
LF/HF ratio 0.126
0.325
63
0.112
0.407
57
-0.060
0.643
62
-0.168
0.192
62
-0.262 *
0.040
62
SD1 -0.437 *
<0.001
63
-0.420 *
0.001
57
-0.258 *
0.043
62
-0.137
0.289
62
0.018
0.891
62
SD2 -0.390 *
0.002
63
-0.344 *
0.009
57
-0.313 *
0.013
62
-0.192
0.134
62
-0.055
0.670
62
Systolic BP 
response to 
CPT
-0.057
0.664
60
-0.036
0.793
55
0.081
0.536
60
0.185
0.156
60
0.112
0.395
60
Diastolic BP 
response to 
CPT
-0.103
0.432
60
-0.023
0.865
55
0.143
0.277
60
0.245
0.059 (trend)
60
0.212
0.103
60
Mean BP 
response to 
CPT
-0.093
0.479
60
0.017
0.900
55
0.139
0.289
60
0.232
0.074 (trend)
53
0.179
0.171
60
HR response 
to CPT
-0.100
0.447
60
-0.147
0.285
55
0.113
0.388
60
0.254 *
0.050
60
0.299 *
0.020
60
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Pain VAS hs-CRP IL-6 TNF-α IL-10
Leg blood 
flow response 
to CPT
-0.202
0.129
58
-0.022
0.874
55
-0.086
0.520
60
-0.0574
0.670
58
-0.118
0.380
58
LVC response 
to CPT
-0.100
0.447
60
-0.086
0.543
55
-0.082
0.543
60
-0.040
0.765
58
-0.142
0.287
58
Systolic BP 
response to 
PASAT
-0.120
0.408
50
0.018
0.905
46
-0.287 *
0.044
50
-0.107
0.461
50
-0.141
0.328
50
Diastolic BP 
response to 
PASAT
-0.120
0.408
50
0.017
0.912
46
-0.177
0.220
50
-0.056
0.699
50
-0.145
0.315
50
Mean BP 
response to 
PASAT
-0.084
0.561
50
0.010
0.949
46
-0.151
0.296
50
-0.017
0.909
50
-0.088
0.541
50
HR response 
to PASAT
-0.244 
0.088 (trend)
50
-0.195
0.193
46
-0.133
0.355
50
-0.009
0.950
50
0.187
0.194
50
Leg blood 
flow response 
to PASAT
0.171
0.240
49
0.287
0.056 (trend)
45
0.161
0.268
49
0.104
0.475
49
0.061
0.678
49
LVC response 
to PASAT
0.179
0.218
49
0.246
0.103 (trend)
45
0.237
0.101 (trend)
49
0.159
0.274
49
0.121
0.406
50
Forearm 
blood flow 
response to 
PASAT
-0.113
0.435
50
0.035
0.816
46
0.081
0.577
50
0.148
0.305
50
0.198
0.168
50
FVC response 
to PASAT
-0.124
0.392
50
0.002
0.991
46
0.104
0.473
50
0.160
0.267
50
0.250
0.080 (trend)
50
Spearman’s correlation. Values expressed are Spearman’s rho, P value and N. * Significance P≤0.05.
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Appendix 6 Scatter plots demonstrating significant associations between inflammation and 
autonomic function
Scatter plots demonstrating significant associations between ANS function and inflammatory markers including: 
hs-CRP and resting HR (Panel A); TNF- α and HR response to CPT (Panel B); and IL-10 and HR response to 
CPT (Panel C), HR response to PASAT (Panel D), forearm blood flow response to CPT (Panel E) and FVC 
response to PASAT (Panel F).  
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Appendix 7 Correlations between QT, QTc, HR, age, CRP, ESR and cytokines
HR * Age CRP ESR IL-6 TNF-α IL-1α IL-1β IL-10
QT -0.807
<0.001
112
0.038
0.694
112
-0.126
0.185
112
-0.205
0.030
112
-0.057
0.552
112
0.099
0.299
112
0.113
0.235
112
0.132
0.165
112
0.108
0.257
112
QTBAZ 0.517
<0.001
112
0.293
0.002
112
0.202
0.033
112
0.134
0.158
112
0.222
0.016
112
0.199
0.036
112
0.158
0.097
112
0.210
0.026
112
0.333
<0.001
112
QTFHS -0.041
0.668
112
0.244
0.009
112
0.088
0.356
112
-0.010
0.917
112
0.129
0.175
112
0.180
0.057
112
0.180
0.058
112
0.220
0.020
112
0.294
0.002
112
HR 0.251
0.008
112
0.248
0.008
112
0.175
0.064
112
0.034
0.724
112
-0.031
0.744
112
0.004
0.744
112
0.109
0.251
112
CRP 0.568
<0.001
112
0.185
0.0051
112
0.021
0.830
112
-0.004
0.965
112
0.088
0.356
112
0.0083
0.387
112
ESR 0.323
0.001
112
0.153
0.106
112
0.144
0.129
112
0.196*
0.038
112
0.121
0.203
112
262
IL-6 0.300
0.001
112
0.497
<0.001
112
0.511
<0.001
112
0.205
0.030
112
TNF-α 0.784
<0.001
112
0.767
<0.001
112
0.775
<0.001
112
IL-1α 0.917
<0.001
112
0.853
<0.001
112
IL-1β 0.902
<0.001
112
Values reported are correlation coefficient (Spearman’s rank rho or * Pearson product r), P Value and N. Significance = P<0.05, P<0.01, P<0.001 shown in bold. 
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, HR = heart rate, IL=interleukin, QTBAZ = QT corrected using Bazett’s formula, QTFHS = QT corrected 
using Framingham Heart Study formula, TNF=tumour necrosis factor.
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